<SEC-DOCUMENT>0001047469-20-002644.txt : 20200428
<SEC-HEADER>0001047469-20-002644.hdr.sgml : 20200428
<ACCEPTANCE-DATETIME>20200428160926
ACCESSION NUMBER:		0001047469-20-002644
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200618
FILED AS OF DATE:		20200428
DATE AS OF CHANGE:		20200428
EFFECTIVENESS DATE:		20200428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		20825071

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2241464zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#20ZAD19501_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Celldex Therapeutics,&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=444810,FOLIO='blank',FILE='DISK123:[20ZAD1.20ZAD19501]BA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>Perryville III Building<BR>
53 Frontage Road, Suite&nbsp;220<BR>
Hampton, NJ 08827  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> To be held on June&nbsp;18, 2020  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To the Stockholders of<BR>
Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOTICE IS HEREBY GIVEN</B></FONT><FONT SIZE=2> that the Annual Meeting of Stockholders of Celldex Therapeutics,&nbsp;Inc. (the "Company" or "we" or "us") will
be held on June&nbsp;18, 2020 beginning at 9:00&nbsp;a.m. Eastern Time. In light of the coronavirus/COVID-19 outbreak and governmental decrees that in-person gatherings be postponed or canceled,
and in the best interests of public health and the health and safety of our stockholders, employees and Board of Directors, we are planning to hold the Annual Meeting virtually via the Internet at
www.virtualshareholdermeeting.com/CLDX2020. Unless we publicly announce a change in our plans in the manner described in the attached proxy statement, you will not be able to attend the Annual Meeting
in person. If we elect to hold a physical meeting, it will be held at the offices of Lowenstein Sandler&nbsp;LLP, One Lowenstein Drive Roseland, NJ&nbsp;07068. At the meeting, stockholders will
act on the following matters to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected
and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the year ending
December&nbsp;31, 2020; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares reserved for issuance
thereunder by 1,900,000 shares to 4,133,333 shares and certain other administrative changes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
stockholders of record at the close of business on April&nbsp;21, 2020 are entitled to receive notice of and to vote at the Annual Meeting or any postponement or adjournment
thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. Whether you plan to attend the meeting or not, you may vote your shares by marking, signing, dating and mailing the enclosed proxy card in the envelope provided.
If you attend the meeting and prefer to vote in person, you may do so even if you have already voted your shares. You may revoke your proxy in the manner described in the proxy statement at any time
before it has been voted at the meeting. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>Sam Martin<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer and Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:times;"><FONT SIZE=2>May&nbsp;4,
2020<BR>
Hampton, NJ </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=536111,FOLIO='blank',FILE='DISK123:[20ZAD1.20ZAD19501]BC19501A.;5',USER='CHE109864',CD='27-APR-2020;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="page_ca19501_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>Perryville III Building<BR>
53 Frontage Road, Suite&nbsp;220<BR>
Hampton, NJ 08827  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement contains information related to the Annual Meeting of Stockholders to be held on June&nbsp;18, 2020 at 9:00&nbsp;a.m.
Eastern Time. In light of the coronavirus/COVID-19 outbreak and governmental decrees that in-person gatherings be postponed or canceled, and in the best interests of public health and the health and
safety of our stockholders, employees and Board of Directors, we are planning to hold the Annual Meeting virtually via the Internet. Unless we publicly announce a change in our plans, in order to
attend our Annual Meeting, you must log in to www.virtualshareholdermeeting.com/CLDX2020 using the 16-digit control number on the notice, proxy card or voting instruction form that accompanied the
proxy materials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Meeting could be adjourned or postponed to another date and/or time. If the pandemic abates to the extent that the Company believes that it will be safe for all constituencies
to attend in person, we may also determine to revert to our original plans to hold the Annual Meeting in person. If we make any such determination, we will announce plans for an in-person meeting in a
press release that we will disseminate and file with the SEC and on the investor relations page of our website at www.celldex.com. In such event, our meeting would be held at the offices of Lowenstein
Sandler&nbsp;LLP, One Lowenstein Drive, Roseland, NJ 07068 or at such other time and place to which the Annual Meeting may be adjourned or postponed. At this point, however, we expect to hold the
Annual Meeting virtually via the Internet. A list of record holders of the Company's common stock entitled to vote at the Annual Meeting will be available for examination by any stockholder, for any
purpose germane to the Annual Meeting, at our principal offices at Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, New Jersey 08827, during normal business hours for ten days
prior to the Annual Meeting. A list will also be available on the virtual meeting platform during the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enclosed proxy is solicited by the Board of Directors of Celldex Therapeutics,&nbsp;Inc. The proxy materials relating to the Annual Meeting are being mailed to stockholders
entitled to vote at the meeting on or about May&nbsp;4, 2020. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Important Notice of Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June&nbsp;18, 2020.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Our proxy materials, including our Proxy Statement for the 2020 Annual Meeting, 2019 Annual Report to Stockholders (which contains our Annual Report on
Form&nbsp;10-K) and proxy card, are available on the Internet at www.proxyvote.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca19501_about_the_meeting"> </A>
<A NAME="toc_ca19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THE MEETING    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why are we calling this Annual Meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are calling the Annual Meeting to seek the approval of our stockholders to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected
and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the year ending
December&nbsp;31, 2020; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=218010,FOLIO='1',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ca19501_1_2"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares reserved for issuance
thereunder by 1,900,000 shares to 4,133,333 shares and other administrative changes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the Board's recommendations?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors recommends that you vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the election of each of the six director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the ratification of the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent
registered public accounting firm for the year ending December&nbsp;31, 2020; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the approval of an amendment to our 2008 Stock Option and Incentive Plan including an
increase in the number of the shares reserved for issuance thereunder by 1,900,000 shares to 4,133,333 shares and certain other administrative changes; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> an advisory vote on the compensation of the Named Executive Officers as described in this
proxy statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who is entitled to vote at the meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date, April&nbsp;21, 2020, are entitled to receive notice of the Annual
Meeting and to vote the shares of common stock that they held on that date at the meeting, or any postponement or adjournment of the meeting. Holders of our common stock are entitled to one vote per
share on each matter to be voted upon. As of the record date, we had 18,082,050 outstanding shares of common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who can attend the meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All stockholders as of the record date, or their duly appointed proxies, may attend the Annual Meeting. If, as we expect, the Annual Meeting is
held virtually, attendance shall solely be via the Internet at www.virtualshareholdermeeting.com/CLDX2020 using the 16-digit control number on the notice, proxy card or voting instruction form that
accompanied the proxy materials. In that event, stockholders will not be able to attend the Annual Meeting in person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
live webcast of the Annual Meeting will begin promptly at 9:00 am Eastern Time. Online access to the audio webcast will open approximately 10 minutes prior to the start of the Annual
Meeting to allow time for our stockholders to log in and test their devices' audio system. We encourage our stockholders to access the meeting in advance of the designated start time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
may also vote, and submit written questions, during the Annual Meeting on www.virtualshareholdermeeting.com/CLDX2020. To demonstrate proof of stock ownership, you will need
to enter the 16-digit control number received with your notice, proxy card or voting instruction form to submit questions and vote at our Annual Meeting. If you hold your shares in "street name" (that
is, through a broker or other nominee), you will need authorization from your broker or nominee in order to vote. We intend to answer questions submitted during the meeting that are pertinent to the
Company and the items being brought for stockholder vote at the Annual Meeting, as time permits, and in accordance with the Rules of Conduct for the Annual Meeting. To promote fairness, efficiently
use the Company's resources and ensure all stockholder questions are able to be addressed, we will respond to no more than one question from a single stockholder. Questions and answers will be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=434167,FOLIO='2',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ca19501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>grouped
by topic and substantially similar questions will be grouped and answered once. We have retained Broadridge Financial Solutions to host our virtual annual meeting and to distribute, receive,
count and tabulate proxies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following instructions apply in the event that we announce that we have changed our plans and intend to hold the meeting in person at the offices of Lowenstein Sandler&nbsp;LLP in
Roseland, New Jersey: Please note that if you hold your shares in "street name" (that is, through a broker or other nominee), you will need to bring a copy of your proxy card delivered to you by your
broker or a legal proxy given to you by your broker and check in at the registration desk at the meeting. For security reasons, you must comply with our pre-registration requirements, you must present
a form of government issued photograph identification on the day of the Annual Meeting, and you must arrive at least thirty minutes prior to the meeting in order to attend the Annual Meeting. If you
are a stockholder of record and plan to attend the Annual Meeting, please contact Kathy Reamer by email at kreamer@celldex.com or by phone at 908-200-7500 ext. 7508 to register to attend the Annual
Meeting. If you hold shares through an intermediary, such as a bank or broker, and you plan to attend, you must send a written request to attend either by regular mail or email, along with proof of
share ownership, such as a bank or brokerage firm account statement, confirming ownership to: Celldex Therapeutics,&nbsp;Inc., Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton,
NJ 08827, Attn: Kathy Reamer or kreamer@celldex.com. Attendance at the Annual Meeting will be limited to persons who pre-registered on or before June&nbsp;12, 2020, who present a form of
government-issued photograph identification on the day of the Annual Meeting and who arrive by 8:30&nbsp;a.m. local time. The Rules of Conduct for the Annual Meeting would also apply, to the extent
relevant, at an in-person meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What constitutes a quorum?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of our common stock outstanding on the record date will
constitute a quorum for our meeting. Signed proxies received but not voted and broker non-votes will be included in the calculation of the number of shares considered to be present at the meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do I vote?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You can vote on matters that come before the Annual Meeting by completing, dating and signing the enclosed proxy card and returning it in the
enclosed postage-paid envelope. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
shares will be voted as you indicate on your proxy card. If you vote the enclosed proxy but you do not indicate your voting preferences, and with respect to any other matter that
properly comes before the meeting, the individuals named on the proxy card will vote your shares FOR the matters submitted at the meeting, or if no recommendation is given, in their own discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a stockholder of record, to submit your proxy by telephone or via the Internet, follow the instructions on the proxy card. If you hold your shares in street name, you may vote
by telephone or via the Internet as instructed by your broker, bank or other nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
will have the right to vote at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as we expect, we hold the Annual Meeting remotely via the Internet, you will have the right to vote on the day of, or during, the Annual Meeting on
www.virtualshareholdermeeting.com/CLDX2020. To demonstrate proof of stock ownership, you will need to enter the 16-digit control number received with your notice, proxy card or voting instruction form
to vote at our Annual Meeting if it is held remotely. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we change our plans, hold the meeting in person and you attend the Annual Meeting, you may vote in person. However, if your shares are held in the name of a bank, broker or other
nominee, you must obtain a legal proxy, executed in your favor, from the holder of record to be able to vote in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=903169,FOLIO='3',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ca19501_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2>person
at the Annual Meeting. In that case, you should allow yourself enough time prior to the Annual Meeting to obtain this proxy from the holder of record. If you attend the Annual Meeting and
prefer to vote in person, you may do so even if you have already voted your shares by proxy. Even if you plan to attend our Annual Meeting, we recommend that you also submit your proxy as described
above so that your vote will be counted if you later decide not to attend our Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I vote and then change my mind?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may revoke your proxy at any time before it is exercised by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> filing with the Secretary of the Company a notice of revocation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sending in another duly executed proxy bearing a later date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attending the meeting and casting your vote in person. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
latest vote will be the vote that is counted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What is the difference between holding shares as a stockholder of record and as a beneficial owner?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our stockholders hold their shares through a stockbroker, bank or other nominee rather than directly in their own name. As summarized
below, there are some distinctions between shares held of record and those owned beneficially. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder of Record  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name with our transfer agent, Computershare Trust Company,&nbsp;N.A., you are considered, with
respect to those shares, the stockholder of record. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote in person at the Annual Meeting. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial Owner  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in
street name, and these proxy materials are being forwarded to you by your broker, bank or nominee which is considered, with respect to those shares, the stockholder of record. As the beneficial owner,
you have the right to direct your broker as to how to vote and are also invited to attend the Annual Meeting. However, because you are not the stockholder of record, you may not vote these shares in
person at the Annual Meeting unless you obtain a signed proxy from the record holder giving you the right to vote the shares. If you do not vote your shares or otherwise provide the stockholder of
record with voting instructions, your shares may constitute broker non-votes. The effect of broker non-votes is more specifically described in "What vote is required to approve each proposal?" below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are "broker non-votes"?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Banks and brokers acting as nominees are permitted to use discretionary voting authority to vote proxies for proposals that are deemed "routine"
by the New York Stock Exchange, but are not permitted to use discretionary voting authority to vote proxies for proposals that are deemed "non-routine" by the New York Stock Exchange. The
determination of which proposals are deemed "routine" versus "non-routine" may not be made by the New York Stock Exchange until after the date on which this proxy statement has been mailed to you. As
such, it is important that you provide voting instructions to your bank, broker or other nominee, if you wish to determine the voting of your shares. If the New York Stock Exchange determines a
proposal to be "non-routine," failure to vote, or to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=88215,FOLIO='4',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ca19501_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>instruct
your broker how to vote any shares held for you in your broker's names will have the same effect as a vote against such proposal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
broker "non-vote" occurs when a proposal is deemed "non-routine" and a nominee holding shares for a beneficial owner does not have discretionary voting authority with respect to the
matter being considered and has not received instructions from the beneficial owner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
election of directors (Proposal No.&nbsp;1), the approval of an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares reserved for
issuance thereunder by 1,900,000 shares to 4,133,333 shares (Proposal No.&nbsp;3) and the advisory vote on the compensation of our Named Executive Officers (Proposal No.&nbsp;4) are generally not
considered to be "routine" matters, and brokers are not permitted to vote on those matters if the broker has not received instructions from the beneficial owner. Accordingly, it is particularly
important that beneficial owners instruct their brokers how they wish to vote their shares. The ratification of our independent registered public accounting firm (Proposal No.&nbsp;2) is generally
considered to be a "routine" matter, and hence your brokerage firm will be able to vote on Proposal No.&nbsp;2 even if it does not receive instructions from you, so long as it holds your shares in
its name. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What vote is required to approve each proposal?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of a majority of the outstanding shares entitled to vote must be present, in person or by proxy, at the Annual Meeting in order to have
the required quorum for the transaction of business. Pursuant to Delaware corporate law, abstentions and broker non-votes will be counted for the purpose of determining whether a quorum is present.
Abstentions and broker non-votes are not counted for the purpose of determining the number of votes cast and will therefore not have any effect with respect to any of the proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that a quorum is present, the following votes will be required:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the election of directors (Proposal No.&nbsp;1), each nominee presented in Proposal 1 must be elected by a majority of the
votes cast in person or by proxy at the Annual Meeting. Nominees are elected by a majority vote for non-contested director elections. Because the number of nominees properly nominated for the Annual
Meeting is the same as the number of directors to be elected, the election of directors at this Annual Meeting is non-contested. If the number of votes "For" a nominee exceeds the number of votes
"Withheld" (among votes properly cast in person or by proxy), then the nominee will be elected. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the ratification of the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm
(Proposal No.&nbsp;2), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the approval of an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares
reserved for issuance thereunder by 1,900,000 shares to 4,133,333 shares and certain other administrative changes; (Proposal No.&nbsp;3), approval will require the affirmative vote of the holders of
a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the advisory vote on the compensation of our Named Executive Officers as disclosed in this proxy statement (Proposal
No.&nbsp;4), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of the common stock will not have any dissenters' rights of appraisal in connection with any of the matters to be voted on at the meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=276912,FOLIO='5',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ca19501_1_6"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are we soliciting this proxy</I></B></FONT><FONT SIZE=2>? </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are soliciting this proxy on behalf of our Board of Directors by mail and will pay all expenses associated therewith. Some of our officers and other employees also
may, but without compensation other than their regular compensation, solicit proxies by further mailing or personal conversations, or by telephone, facsimile or other electronic means. We will also,
upon request, reimburse brokers and other persons holding stock in their names, or in the names of nominees, for their reasonable out-of-pocket expenses for forwarding proxy materials to the
beneficial owners of the capital stock and to obtain proxies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=223748,FOLIO='6',FILE='DISK123:[20ZAD1.20ZAD19501]CA19501A.;4',USER='CHE109864',CD='27-APR-2020;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce19501_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce19501_proposal_1__to_elect_six_direc__pro05521"> </A>
<A NAME="toc_ce19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1: TO ELECT SIX DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING<BR>  AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY<BR>  ELECTED AND QUALIFIED    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ce19501_(proposal_no._1)"> </A>
<A NAME="toc_ce19501_2"> </A></FONT> <FONT SIZE=2><B>  (Proposal No.&nbsp;1)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, six directors are to be elected. All directors of the Company hold office until the next Annual Meeting of Stockholders
or until their respective successors are duly elected and qualified or their earlier resignation or removal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is the intention of the persons named in the proxies for the holders of common stock to vote the proxies for the election of the nominees named below, unless otherwise specified in
any particular proxy. Our management does not contemplate that the nominees will become unavailable for any reason, but if that should occur before the meeting, proxies will be voted for another
nominee, or other nominees, to be selected by our Board of Directors. In accordance with our by-laws and Delaware law, a stockholder entitled to vote for the election of directors may withhold
authority to vote for certain nominees for directors or may withhold authority to vote for all nominees for directors. Each director
nominee must be elected by a majority of the votes cast in person or by proxy at the Annual Meeting. Nominees are elected by a majority vote for non-contested director elections. Because the number of
nominees properly nominated for the Annual Meeting is the same as the number of directors to be elected, the election of directors at this Annual Meeting is non-contested. Broker non-votes will not be
treated as a vote for or against any particular director nominee and will not affect the outcome of the election. Stockholders may not vote, or submit a proxy, for a greater number of nominees than
the six nominees named below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees for Election  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The persons listed below are our current directors and have been nominated for re-election (the "Director Nominees") to fill the six director
positions to be elected by the holders of the common stock. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Directors

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year First<BR>
Became<BR>
Director </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos (Chair of the Board)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci (Chief Executive Officer)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith L. Brownlie</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James J. Marino</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following biographical descriptions set forth certain information with respect to the Director Nominees, based on information furnished to Celldex by each Director Nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nominees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Karen L. Shoos</B></FONT><FONT SIZE=2> was appointed Chair of the Board of Directors in June 2019 and has been a
director of Celldex since May 2001. Ms.&nbsp;Shoos is currently a consultant in international blood safety and since November 2015, Ms.&nbsp;Shoos has been the Director of Operations for the
Maryland Tech Council Venture Mentoring Services Program. From May 2013 to September 2016, Ms.&nbsp;Shoos was Principal Investigator, AABB International Technical Assistance. From October 1994 to
May 2013, Ms.&nbsp;Shoos was Chief Executive Officer of AABB. AABB is a professional standards setting
and accrediting organization in the fields of blood and cellular therapies. Prior to AABB, from 1984 to 1994, Ms.&nbsp;Shoos held senior positions at the American Red Cross, including Acting Senior
Vice </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=741359,FOLIO='7',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2>President,
Biomedical Services (1993-1994) and Secretary and General Counsel (1990-1993). Prior to the American Red Cross, Ms.&nbsp;Shoos was a lawyer in private practice. Ms.&nbsp;Shoos earned
her B.A. from Yale University and her J.D. from Case Western Reserve University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed President and Chief Executive Officer of Celldex in September 2008 and as a director of Celldex in
December 2008. Since May 2003, Mr.&nbsp;Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In addition, he was
Treasurer of Medarex,&nbsp;Inc. (now a part of Bristol-Myers Squibb&nbsp;Co.) from December 1998 to March 2004. Mr.&nbsp;Marucci held a series of senior financial positions at Medarex from
December 1998 to May 2003. Mr.&nbsp;Marucci is a member of the Board of Trustees of BioNJ&nbsp;Inc. and also served as its Treasurer through 2010. Mr.&nbsp;Marucci is a member of the Board of
the College of Business and Public Management at Kean University. Mr.&nbsp;Marucci received his M.B.A. from Columbia University and his M.H.L. from Brown University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Keith L. Brownlie</B></FONT><FONT SIZE=2> became a director of Celldex in June 2017. Mr.&nbsp;Brownlie was employed by the accounting firm Ernst&nbsp;&amp;
Young&nbsp;LLP from 1974 to 2010. At Ernst&nbsp;&amp; Young, he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York Metro Area. From 2010
until 2019, Mr.&nbsp;Brownlie served as a member of the board of directors and chairman of the audit committee of Soligenix,&nbsp;Inc., a publicly held biopharmaceutical company. From 2012 until
2019, Mr.&nbsp;Brownlie served as a member of the board of directors and served as the chairman of the audit committee of Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation), a
publicly held biopharmaceutical company. From 2011 to 2013, Mr.&nbsp;Brownlie also served as a member of the board of directors and served as the chairman of the audit committee of EpiCept
Corporation, a publicly held biopharmaceutical company. From 2013 to 2014, Mr.&nbsp;Brownlie was a member of the board of directors and served as the chairman of the audit committee of Cancer
Genetics,&nbsp;Inc., a publicly held biopharmaceutical company. Mr.&nbsp;Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Herbert J. Conrad</B></FONT><FONT SIZE=2> became a director of Celldex in March 2008 upon consummation of the AVANT Merger. Mr.&nbsp;Conrad had been a director
of Celldex Research since March 2004. Mr.&nbsp;Conrad was President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche,&nbsp;Inc., a pharmaceutical company, from 1982 until his retirement
in 1993. Mr.&nbsp;Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings,&nbsp;Inc., a publicly held biopharmaceutical company. Mr.&nbsp;Conrad serves as an Advisor to
the Seaver Autism Center at Mount Sinai Hospital. In addition to serving on the board of directors of privately held biotechnology companies, Mr.&nbsp;Conrad has served as Chairman of the Board of
Directors of Pharmasset,&nbsp;Inc., GenVec,&nbsp;Inc. and Bone Care International,&nbsp;Inc. Mr.&nbsp;Conrad has also served as director of Arbutus Biopharma Corporation and was a director and
co-founder of Reliant
Pharmaceuticals,&nbsp;Inc. He received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>James J. Marino</B></FONT><FONT SIZE=2> became a director of Celldex in March 2017. Mr.&nbsp;Marino has served as a member of the board of directors of Onconova
Therapeutics,&nbsp;Inc., a publicly held biopharmaceutical company, since July 2015 and is currently a member of their Audit Committee and Chair of their Compensation Committee. Prior to July 2015,
Mr.&nbsp;Marino was a Partner at the global law firm of Dechert&nbsp;LLP for 28&nbsp;years, where he served as Managing Partner of the Princeton Office. Previously, he served on the board of
directors of Pharmacopeia&nbsp;Inc. and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. He currently
serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center. Mr.&nbsp;Marino received his B.A., M.B.A., and J.D. from Rutgers University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Harry H. Penner, Jr.</B></FONT><FONT SIZE=2> has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT
Merger. Mr.&nbsp;Penner has served as Chairman and Chief Executive Officer of Nascent BioScience,&nbsp;LLC, a firm engaged in the creation and development </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=230751,FOLIO='8',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
new life science companies since 2001. From 1993 to 2001, Mr.&nbsp;Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, Mr.&nbsp;Penner
was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the
company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chairman of BioCT (formerly Connecticut
United for Research Excellence), and as Chairman of the Connecticut Board of Governors of Higher Education and the Connecticut Technology Council. Mr.&nbsp;Penner is currently Chairman of the Board
of CaroGen Corporation. Mr.&nbsp;Penner is also Chairman of the Board of Affinimark Technologies,&nbsp;Inc., NeuroCyte Therapeutics,&nbsp;Inc. and QCDx&nbsp;LLC, and a board member of
OmaxHealth,&nbsp;Inc., all of which he is a founder. Mr.&nbsp;Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New
York University. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Family Relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no family relationships among our Director Nominees, management and other key personnel. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board of Directors and Its Committees  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently managed by a six member Board of Directors, a majority of whom are "independent" as that term is defined in the applicable
NASDAQ listing standards. Other than Mr.&nbsp;Marucci, each of our directors is deemed "independent" as that term is defined in the applicable NASDAQ listing standards. Our Board of Directors met
five times in 2019. Each of the directors attended at least 75% of the aggregate of (i)&nbsp;the total number of meetings of our Board of Directors and (ii)&nbsp;the total number of meetings of
all committees of our Board of Directors on which the Director served. Our annual meeting of stockholders is generally held to coincide with one of the Board's regularly scheduled meetings. We do not
have a formal policy requiring members of the Board of Directors to attend our annual meetings, although our directors typically attend the annual meeting. Each of the then current directors attended
the 2019 Annual Meeting of Stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established an Audit Committee currently consisting of Keith L. Brownlie, Chair, James J. Marino and Harry H. Penner,
Jr. The Audit Committee makes recommendations concerning the engagement of independent public accountants, reviews with the independent public accountants the scope and results of the audit
engagement, approves professional services provided by the independent public accountants, reviews the independence of the independent public accountants, considers the range of audit and non-audit
fees, and reviews the adequacy of our internal accounting controls. Each member of the Audit Committee is "independent" as that term is defined in the rules of the SEC and the applicable NASDAQ
listing standards. The Board has determined that each Audit Committee member has sufficient knowledge in financial and auditing matters to serve on the Committee. The Board has designated
Mr.&nbsp;Brownlie as an "audit committee financial expert," as defined under the applicable rules of the SEC and the applicable NASDAQ listing standards. The Audit Committee met five times during
2019. Our Board has adopted an Audit Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=60821,FOLIO='9',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_10"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Compensation Committee currently consisting of James&nbsp;J. Marino, Chair, Herbert&nbsp;J. Conrad
and Harry&nbsp;H. Penner,&nbsp;Jr. The primary function of the Compensation Committee is to assist the Board in the establishment of compensation for the Chief Executive Officer, to approve the
compensation of other officers and senior employees and to approve certain other personnel and employee benefit matters. Each member of the Compensation Committee is "independent" as that term is
defined in the rules of the SEC and the applicable NASDAQ listing standards. In 2019, the Compensation Committee engaged Radford, a part of Aon&nbsp;plc, to provide guidance on various aspects of
the Company's board and executive compensation programs. The Compensation Committee has assessed the independence of Radford and concluded that no conflict of interests exists under applicable SEC
rules. The Compensation Committee met nine times during 2019. Our Board has adopted a Compensation Committee Charter, which is available for viewing at </FONT> <FONT SIZE=2><I>www.celldex.com.</I></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Herbert&nbsp;J. Conrad, Chair,
Keith&nbsp;L. Brownlie and Karen&nbsp;L. Shoos. The primary function of the Nominating and Corporate Governance Committee is to assist the Board in reviewing, investigating and addressing issues
regarding Board composition, policy and structure; membership on Board committees; and other matters regarding our governance. Each member of the Nominating and Corporate Governance Committee is
"independent" as that term is defined in the rules of the SEC and the applicable NASDAQ listing standards. The Nominating and Corporate Governance Committee met six times during 2019. Our Board has
adopted a Nominating and Corporate Governance Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director selection criteria  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee is responsible for reviewing, on an annual basis, the appropriate mix of professional
competencies, key attributes, skills and experiences required of board members to work together as a team to properly oversee our strategies and operations. The process followed by the Nominating and
Corporate Governance Committee to evaluate any candidates whether identified or recommended by board members, management, members of the Nominating and Corporate Governance Committee, stockholders or
other external sources, includes meeting from time to time to evaluate biographical information and background material relating to potential candidates to the Board and interviews of selected
candidates by members of the Committee and the Board. All nominees must have, at a minimum, high personal and professional integrity, exceptional ability and judgment, and be effective in collectively
serving the long-term interests of all stockholders, all as described above. Other qualifications that may be considered by the Committee are described in the Nominating and Corporate Governance
Committee Charter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
board members are expected to possess certain key attributes necessary to creating a functional board: high personal and professional ethics, integrity and values; practical wisdom
and mature judgment; an inquisitive and objective perspective; professional experience at a policy-making level in business, government, education or medicine; time availability for in-person
participation at board and committee meetings; and a commitment to representing the long-term interests of our stockholders. We look for directors with professional competencies that include senior
management operational experience, accounting and finance capabilities, deep industry-related experience, biologic development and manufacturing expertise, business development leadership, medical and
scientific proficiencies, and government and public policy experience. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=857348,FOLIO='10',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of our directors brings unique perspectives and experiences to the Board of Directors and contributes in guiding and directing our strategies to meet our business objectives and to
provide value to our stockholders. For example, Mr.&nbsp;Conrad, Mr.&nbsp;Marucci and Mr.&nbsp;Penner have all either currently or formerly been chief executive officers of life sciences
companies and have experienced the challenges of such a position and completed a significant number of financing and business development transactions. Ms.&nbsp;Shoos has also formerly been chief
executive officer of a healthcare-related company and has experienced the challenges of such a position in the highly regulated blood supply and cellular therapies sectors, which are similar to our
regulated biologics industry. Mr.&nbsp;Marino, as partner at a large law firm, focused his practice on representing public and private life sciences companies and has extensive experience advising
his clients in the full range of corporate, transactional, finance, compliance and governance matters. Mr.&nbsp;Brownlie, as partner at an international public accounting firm and leader of the
firm's regional life sciences industry practice, and as chairman of the audit
committees of other publicly traded biopharmaceutical companies, has developed a deep knowledge of the life sciences industry and the relevant public company accounting standards and regulations and
is deemed a "Financial Expert" under the Sarbanes-Oxley Act as that term is defined by the SEC. Messrs.&nbsp;Brownlie and Conrad have many years of experience on the boards of directors of larger
public pharmaceutical and life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independence
is also an important selection criterion for nomination to our Board. Independent directors should be free of any relationship with us, our management, other directors or
other parties that may impair, or appear to impair, the director's ability to make independent judgments. Independent directors must satisfy the criteria for independence established by NASDAQ.
Currently all of our directors are independent except for our Chief Executive Officer, Mr.&nbsp;Marucci. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
all board members are expected to act in our best interests and the best interests of our stockholders and to avoid any conflicts of interest in accordance with our Code of
Business Conduct and Ethics. In selecting director nominees, the Nominating and Corporate Governance Committee seeks individuals who are free from conflicts of interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
candidates should be enthusiastic and excited about their service on our Board and working collaboratively with existing board members to create value for all of our
stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder nominations for directorships  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders may propose a potential director candidate for consideration by the Nominating and Corporate Governance Committee by submitting
their names and background to the Secretary of Celldex at Perryville&nbsp;III Building, 53&nbsp;Frontage Road, Suite&nbsp;220, Hampton, NJ&nbsp;08827. All such recommendations will be
forwarded to the Nominating and Corporate Governance Committee, which will review and consider only such recommendations if appropriate biographical and other information is provided, as described
below, on a timely basis. All security holder recommendations for director candidates must be submitted to us not less than 120 calendar days prior to the date on which our proxy statement is released
to stockholders in connection with our annual meeting, and must include the following information:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name and address of record of the security holder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a representation that the security holder is a record holder of our securities, or if the security holder is not a record holder, evidence of
ownership in accordance with Rule&nbsp;14a-8(b)(2) of the Securities Exchange Act of 1934; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name, age, business and residential address, educational background, current principal occupation or employment, and principal occupation
or employment for the preceding five&nbsp;(5)&nbsp;full fiscal years of the proposed director candidate; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=13,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=539410,FOLIO='11',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_12"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of the qualifications and background of the proposed director candidate which addresses the minimum qualifications and other
criteria for Board membership approved by the Board from time to time and set forth in the Nominating and Corporate Governance Committee Charter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of any arrangements or understandings between the security holder and the proposed director candidate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the consent of the proposed director candidate to be named in the proxy statement relating to our annual meeting of stockholders and to serve
as a director if elected at such annual meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that appropriate information is provided for candidates recommended by stockholders, the Nominating and Corporate Governance Committee will evaluate those candidates by
following substantially the same process, and applying substantially the same criteria, as for candidates submitted by Board members or other persons, as described above and as set forth in its
written charter. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide
independent oversight of management. The Board understands that there is no single, generally accepted approach to providing Board leadership and that given the dynamic and competitive environment in
which we operate, the right Board leadership structure may vary as circumstances warrant. Consistent with this understanding, the Nominating and Corporate Governance Committee considers the Board's
leadership structure on an annual basis. This consideration includes the pros and cons of alternative leadership structures in light of the Company's operating and governance environment at the time,
with the goal of achieving the optimal model for effective oversight of management by the Board. Currently, the roles of Chief Executive Officer and Chair of the Board are separate.
Mr.&nbsp;Marucci, our Chief Executive Officer, is a member of our Board. Ms.&nbsp;Shoos, an independent director, serves as Chair of the Board. The Board believes that its current leadership
structure provides independent board leadership, engagement and oversight. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our independent committee chairs are responsible for leading committee meetings, determining committee meeting schedules, agenda and information flow, and reporting to the
full Board on the committee's actions and areas of responsibilities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Oversight  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for assessing and managing risk and the Board of Directors oversees and reviews certain aspects of our risk
management processes. The Board of Directors is involved in risk oversight through direct decision-making authority with respect to significant matters and the oversight of management and its
committees. The Board is responsible for overseeing risks related to our overall operations and strategy, including, among others, product development, potential asset acquisitions, financial
reporting, business continuity (including succession planning) and reputational risks faced by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
committees of the Board execute their oversight responsibility for risk management as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Audit Committee is responsible for overseeing our internal financial and accounting controls and the work performed by the independent
registered public accounting firm. As part of its oversight function, the Audit Committee regularly discusses with management and the independent registered public accounting firm our major financial
and controls-related risk exposures and steps that management has taken to monitor and control such exposures. The Audit Committee also reviews our risk management insurance programs. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=14,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=719019,FOLIO='12',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_13"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Compensation Committee is responsible for overseeing risks related to our cash and equity-based compensation programs and practices. As
part of its oversight function, the Compensation Committee periodically discusses with the President and Chief Executive Officer as well as the Board of Directors, as necessary, the compensation plan
for both executive officers and the independent directors, performance goals and objectives for the period and related achievement, peer group and other relevant compensation benchmarks and practices
and other matters to ensure our compensation practices are in our best interest and that of our shareholders. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Nominating and Corporate Governance Committee is responsible for overseeing risks related to the composition and structure of the Board of
Directors and its committees and our corporate governance. In this regard, the Nominating and Corporate Governance Committee assesses the qualifications and independence of members of the Board, makes
annual recommendations regarding Board and committee membership, and reviews any transactions between us and our officers, directors, affiliates of officers and directors or other related parties for
conflicts of interest. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Matters  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a majority voting standard for uncontested elections of directors and eliminated the mandatory retirement age for directors.
Since it is an uncontested election at this Annual Meeting, all director nominees are required to receive a number of "FOR" votes representing at least a majority of votes cast in the election. If
such a director nominee fails to receive "FOR" votes
representing at least a majority of votes cast and is an incumbent director, the by-laws require the director to promptly tender his or her resignation to the Board, subject to acceptance by the
Board. The Nominating and Corporate Governance Committee of the Board would then be charged with making a recommendation to the Board as to whether to accept or reject the tendered resignation, or
whether other action should be taken. In contested elections, where the number of nominees exceeds the number of directors to be elected, the plurality voting standard would continue to apply. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, upon the recommendation of our Nominating and Corporate Governance Committee, we adopted corporate governance guidelines which are available for viewing at </FONT> <FONT SIZE=2><I>www.celldex.com.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as
appropriate. Absent unusual circumstances or as contemplated by committee charters, and subject to advice from legal counsel, the Secretary of Celldex is primarily responsible for monitoring
communications from stockholders and for providing copies or summaries of such communications to the Board of Directors as he considers appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
from stockholders will be forwarded to all directors if they relate to important substantive matters or if they include suggestions or comments that the Secretary
considers to be important for the Board of Directors to know. Communication relating to corporate governance and corporate strategy are more likely to be forwarded to the Board of Directors than
communications regarding personal grievances, ordinary business matters and matters as to which Celldex tends to receive repetitive or duplicative communications. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
who wish to send communications to the Board of Directors should address such communications to: The Board of Directors, Celldex Therapeutics,&nbsp;Inc.,
Perryville&nbsp;III Building, 53&nbsp;Frontage Road, Suite&nbsp;220, Hampton, NJ&nbsp;08827, Attention:&nbsp;Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=15,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=105916,FOLIO='13',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_14"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics that applies to our directors, officers and employees. The purpose of the Code of Business
Conduct and Ethics is to deter wrongdoing and to promote, among other things, honest and ethical conduct and to ensure to the extent possible that our business is conducted in a consistently legal and
ethical manner. Our Code of Business Conduct and Ethics is publicly available on our website at www.celldex.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or
grant any waiver, including any implicit waiver from a provision of the Code of Business Conduct and Ethics to our Directors or Executive Officers, we will disclose the nature of such amendments or
waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding our current executive officers: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="351pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Individual

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position and Office </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Executive Vice President and Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Sarah Cavanaugh</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, Corporate Affairs and Administration</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Product Development Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Margo Heath-Chiozzi, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Regulatory Affairs</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Richard Wright, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Commercial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Diane C. Young, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Medical Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed President and Chief Executive Officer of Celldex in September 2008 and as a director of the Company in
December 2008. See Mr.&nbsp;Marucci's biography under </FONT><FONT SIZE=2><I>Director Nominees</I></FONT><FONT SIZE=2> above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Tibor Keler, Ph.D.</B></FONT><FONT SIZE=2> became Executive Vice President and Chief Scientific Officer of Celldex in July 2014. Since May 2003, Dr.&nbsp;Keler
has held a number of positions with Celldex, including as a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and
Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March
2004. Dr.&nbsp;Keler received his Ph.D. in Microbiology from the University of Pennsylvania. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Sarah Cavanaugh</B></FONT><FONT SIZE=2> became Senior Vice President, Corporate Affairs and Administration in June 2017. Ms.&nbsp;Cavanaugh served as Vice
President, Investor Relations and Corporate Communications of Celldex from August 2012 to June 2017. Prior to Celldex, she served from 2007 to 2012 as a Vice President at MacDougall Biomedical
Communications, a strategic communications and investor relations firm for the life sciences industry. Ms.&nbsp;Cavanaugh previously served as Director of Corporate Communications for Point
Therapeutics,&nbsp;Inc., an oncology-focused biotech company, and Director of Corporate Communications for Fallon Community Health Plan, a leading Massachusetts managed care organization. She began
her health care career at the American Cancer Society, holding various positions prior to completing her tenure there as Division Communications and Marketing Director for the Mid-South Division.
Ms.&nbsp;Cavanaugh received her B.A. from the University of New Hampshire. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Elizabeth Crowley</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Product Development Officer in August 2016. Ms.&nbsp;Crowley served as Senior
Vice President, Product Development of Celldex from July 2014 to August 2016. Ms.&nbsp;Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior
level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations. Ms.&nbsp;Crowley started her career at Bayer Corporation in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=16,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=635164,FOLIO='14',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2>1992,
holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management.
Ms.&nbsp;Crowley received her B.S. in Chemistry with a concentration in Business from Boston College. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Margo Heath-Chiozzi, M.D.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;became Senior Vice President, Regulatory Affairs in October 2017. Previously from 2003 until September 2017,
Dr.&nbsp;Heath-Chiozzi served in roles of increasing responsibility at Bristol-Myers Squibb Company including Executive Director, Global Regulatory Sciences; Vice President, Global Regulatory
Strategy; and Vice President, Global Submissions and Regulatory Policy. Prior to that, from 1995 to 2003, Dr.&nbsp;Heath-Chiozzi served in roles of increasing responsibility at Abbott Laboratories,
including Medical Director, Pharmacogenetics; Senior Director, Global Marketed Product Development and Outcomes Research; and Global Project Head, Abbott/Millennium Obesity/Diabetes Alliance. Before
joining Abbott, she was appointed to the University of Hawaii John A. Burns School of Medicine, where she served as Assistant Professor, and was concurrently Director of the HIV Research Clinical at
the Queen's Medical Center as well as Director of the Women's Immunology Clinical at the Kapiolani Medical Center for Women and Children, in Honolulu. Dr.&nbsp;Heath-Chiozzi received her B.S. and
M.D. from the University of Utah. She received further medical training in internal medicine at Duke University and completed fellowships in infectious disease at Brigham&nbsp;&amp; Women's Hospital and
Dana-Farber Cancer Institute in Boston. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Sam Martin</B></FONT><FONT SIZE=2> became Senior Vice President, Chief Financial Officer and Secretary in July 2017. Mr.&nbsp;Martin served as Vice President,
Finance of Celldex from January 2015 to July 2017 and Senior Director, Finance of Celldex from August 2011 to January 2015. Mr.&nbsp;Martin joined Celldex as the Director of Financial Reporting,
Planning and Analysis in 2009. Prior to joining Celldex, from 2000 to 2009, Mr.&nbsp;Martin served in roles of increasing responsibility at Alseres Pharmaceuticals,&nbsp;Inc., most recently
serving as the Director of Finance and Corporate Compliance. Mr.&nbsp;Martin began his career at Ernst&nbsp;&amp; Young&nbsp;LLP, holding various positions prior to completing his tenure as Audit
Manager. Mr.&nbsp;Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Ronald Pepin, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Business Officer of Celldex in July 2011. From June 2010 to April 2011,
Dr.&nbsp;Pepin served as Vice President at Shire Pharmaceuticals. From August 2000 to December 2009, Dr.&nbsp;Pepin was Senior Vice President, Business Development at Medarex. Earlier in his
career, Dr.&nbsp;Pepin was Executive Director of External Science and Technology at Bristol-Myers Squibb Company. Dr.&nbsp;Pepin received his B.A. from Tufts University and his Ph.D. in Genetics
from Georgetown University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Richard Wright, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Commercial Officer of Celldex in July 2015. Dr.&nbsp;Wright served as Vice
President of Commercial Operations of Celldex from April 2012 to July 2015. From November 2010 to April 2012, Dr.&nbsp;Wright was Managing Director of Navigant Consulting, a global life sciences
consulting practice. From September 2003 to October 2010, Dr.&nbsp;Wright held several senior leadership roles at Bristol-Myers Squibb including Senior Vice President of the U.S. ImmunoScience
Division. Dr.&nbsp;Wright currently serves on the Scientific Advisory Board for the Seaver Foundation, a nonprofit organization supporting the Center for Autism Treatment and Research at Mount Sinai
Hospital. Dr.&nbsp;Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry
of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Diane C. Young, M.D.</B></FONT><FONT SIZE=2> became Senior Vice President, Chief Medical Officer of Celldex in June 2019. Previously, from July 2015 until
February 2019, Dr.&nbsp;Young served as Vice President, Chief Medical Officer of GTx,&nbsp;Inc. Prior to that, from 2002 to June 2015, Dr.&nbsp;Young served in roles of increasing responsibility
at Novartis Oncology including Vice President, Head of Oncology Clinical Development and Medical Affairs, Latin America and Canada; Vice President, Global Head of Medical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=17,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=989269,FOLIO='15',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_ce19501_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2>Affairs,
Oncology Business Unit; and Vice President, Global Head of Clinical Development Phase&nbsp;2/3, Oncology Business Unit. Prior to that, from 1993 to 2002, Dr.&nbsp;Young served in roles of
increasing responsibility at R.W. Johnson Pharmaceutical Research Institute including Vice President for Global Development and Senior Director, Clinical Research and Development. She also held roles
at Sandoz Research Institute from 1991 to 1993 including Director of Clinical Research, Cytokine Development
Unit and Associate Medical Director. From 1988 to 1990, she was Assistant Director, Clinical Investigation II at Hoffman-LaRoche,&nbsp;Inc. She received her A.B. in Biochemical Sciences from Harvard
University and her M.D. from Harvard Medical School. She received further medical training in internal medicine at Johns Hopkins Hospital and Vanderbilt University Hospital and completed a fellowship
in medical oncology at Dana-Farber Cancer Institute. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=18,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=543778,FOLIO='16',FILE='DISK123:[20ZAD1.20ZAD19501]CE19501A.;9',USER='CHE109864',CD='27-APR-2020;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da19501_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


EXECUTIVE COMPENSATION  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da19501_compensation_discussion_and_analysis"> </A>
<A NAME="toc_da19501_1"> </A></FONT> <FONT SIZE=2><B>  Compensation Discussion and Analysis    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Introduction  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee oversees and administers our executive compensation programs. The Committee's complete roles and responsibilities are
set forth in the written charter of the Compensation Committee adopted by our Board of Directors, which can be found at our website, </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation programs are designed to deliver compensation that is competitive with our peer group and that allows us to attract
and retain superior talent who can perform effectively and succeed in a demanding business environment. Our compensation programs are also designed to reward performance against pre-established goals
and align the interests of our executives with our stockholders. We believe that the compensation of our executive officers should focus executive behavior on the achievement of near-term corporate
targets as well as long-term business objectives and strategies. We believe that pay-for-performance compensation programs, which reward our executives when they achieve individual and/or corporate
goals, create stockholder value and thus have emphasized company and individual performance in setting compensation. We use a combination of base salary, annual cash incentive compensation programs, a
long-term equity incentive compensation program and a broad-based benefits program to create a competitive compensation package for our executive management team. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
describe below our compensation philosophy, policies and practices with respect to our (i)&nbsp;Chief Executive Officer, (ii)&nbsp;Chief Financial Officer, and (iii)&nbsp;three
most highly compensated executive officers, other than the Chief Executive Officer and Chief Financial Officer, who were serving as executive officers as of December&nbsp;31, 2019, collectively
referred to as our Named Executive Officers. In 2019, our Named Executive Officers were Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi, and Mr.&nbsp;Martin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a biopharmaceutical company focusing on the development of a pipeline of drug candidates to treat cancer and other difficult-to-treat diseases and several immunotherapy technologies,
we establish corporate goals that are designed to contribute to the development of our lead programs, ensure that we manage our cash effectively and have sufficient funding to complete near-term
development activities for our lead drug candidates and, where appropriate, to pursue partnerships and collaborations through which we can leverage the value of our drug candidates. We seek to link
the financial interests of our Named Executive Officers to those of our stockholders by tying compensation to the achievement of these strategic corporate goals, which we believe will drive long-term
stockholder value. Each year we establish corporate goals, the achievement of which we believe are essential to the long-term success of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee has adopted a compensation philosophy of targeting our executive compensation to the 50<SUP>th</SUP>&nbsp;percentile of executive compensation of our peer
group and the Radford Global Life Sciences Survey results. Executive compensation may be above or below the 50<SUP>th</SUP>&nbsp;percentile based on an executive's experience, scope of position,
individual performance and company constraints. The Compensation Committee increased the annual base salary for Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi and
Mr.&nbsp;Martin by 4.0% to 5.5% in mid-2019, depending on the position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2019 and January 2020, our Compensation Committee reviewed our performance relative to our 2019 corporate goals and concluded that we had achieved 75% of our pipeline
development, business and financial operations goals, particularly with respect to the progress made in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=93392,FOLIO='17',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2>advancing
our clinical programs. Our Compensation Committee approved annual bonus payments of 75% to 83% of the 2019 bonus target for Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley,
Dr.&nbsp;Heath-Chiozzi and Mr.&nbsp;Martin, depending on the position. Further, stock options granted to our executive officers in 2019 have exercise prices equal to 100% of the fair value on the
date of grant and vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter based on continued service. We believe that stock
options structured in this manner encourage our executive officers to focus on increasing stockholder value and stock price appreciation over the long term and limit unnecessary risk taking behavior,
while promoting retention. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2019, we accomplished the following significant milestones during the year: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Continued progress in Phase&nbsp;1 study of
CDX-1140:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Dose-escalation in both the monotherapy and combination with CDX-301 cohorts were completed with an identified maximum tolerated dose
and recommended Phase&nbsp;2 dose of CDX-1140 at 1.5 mg/kg&#151;one of the highest systemic dose levels in the CD40 agonist class. Interim data from this ongoing study presented in November
2019 demonstrated that CDX-1140 has the potential to successfully balance systemic doses for good tissue and tumor penetration with an acceptable safety profile and that the candidate has promising
biological and clinical activity. The study was expanded to explore additional combination cohorts with mechanisms that we believe could be complementary or synergistic with CDX-1140, including a
combination with KEYTRUDA&reg; (pembrolizumab).  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Continued progress in Phase&nbsp;2 study of
CDX-3379:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In June of 2019, data were presented that suggested that observed antitumor activity with CDX-3379 might be associated with somatic
mutations in the FAT1 and NOTCH1, NOTCH2 or NOTCH3 (NOTCH1-3) genes&#151;genes associated with tumor suppression. Based on these biomarker observations and the clinical activity observed in the
ongoing Phase&nbsp;2 study, the study was expanded to allow for an evaluation of the utility of biomarkers for patient selection. Enrollment is ongoing.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Initiated Phase&nbsp;1 study of
CDX-0159:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In 2019, we completed all activities to support the filing of an Investigational New Drug (IND) application for CDX-0159 and, in
November 2019, the Phase&nbsp;1a study was initiated in healthy volunteers.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Cash runway through 2021:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We
ended 2019 with cash, cash equivalents and marketable securities of $64.4&nbsp;million which we believe will enable us to fund our operating expenses and capital expenditure requirements into the
first quarter of 2021. This guidance excludes anticipated proceeds from future sales of common stock under the Cantor agreement or other potential fundraising. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Independent Compensation Consultants  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that independent advice is important in developing Celldex's director and executive compensation programs
and engages Radford, which is part of the Rewards Solutions practice at Aon&nbsp;plc, as its independent compensation consultant. In 2019, Radford provided advisory services in connection with the
amendment and restatement of our 2008 Stock Option and Incentive Plan and 2004 Employee Stock Purchase Plan (the "Plans"), including an increase in the number of shares reserved for issuance under the
Plans. Radford reports directly to the Committee and provides guidance on trends in executive and non-employee director compensation, the development of specific executive compensation programs, the
composition of the Company's compensation peer group and other matters as directed by the Committee. The Company also participated in various Radford surveys in 2019. In 2019, Radford did not provide
any other services to Celldex. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=605952,FOLIO='18',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_19"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Data Used to Make Compensation Determinations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In making decisions regarding the compensation of our executive officers, the Compensation Committee generally considers compensation and survey
data for similarly situated
executives at a comparison group of companies it considers our peer group. These comparison data are primarily used to gauge the reasonableness and competitiveness of executive compensation decisions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
draw upon a pool of talent that is highly sought after by large and established pharmaceutical and biotechnology companies as well as other development-stage life science companies,
both within and outside our geographic areas. We believe that the compensation practices of our industry in general and of our select peer group in particular provide useful information to help us
establish compensation practices that allow us to attract, retain, and motivate a highly talented executive team. We believe we must offer a compensation package to all of our officers and our other
employees that is competitive with our peer group, as well as larger pharmaceutical and biotechnology companies from whom we frequently recruit. In addition, the comparator companies should be aligned
with our current stage of development and have similar short and long-term growth objectives. In 2019, the Compensation Committee set the target level of total executive compensation, as well as the
key elements of compensation, at the 50<SUP>th</SUP>&nbsp;percentile of our peer group, but then adjusted each of the elements based on an individual's performance and contribution to our
strategic objectives. The Committee may need to adjust these levels in the future to attract or retain specific individuals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
review the levels of cash, equity and total compensation for all comparable officers in our peer group relative to the elements of compensation paid to our officers. In considering
how these data relate to our existing compensation structure, we take into account our size, stage of development, performance and geographic location as compared to these peer companies, as well as
what we know about the comparable scope of responsibilities of our officers versus those of comparable executives at such peer group companies. We used two primary market frames of reference (which we
refer to as the "market") against which to compare our total executive compensation practices and levels and inform our decisions regarding compensation of our officers as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Select Peer Group&#151;A select group of national biotechnology companies at a similar stage of development as our company with similar
headcount, R&amp;D expense, market capitalization and in most cases, similar therapeutic targets, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Radford Global Life Sciences Survey&#151;A national survey of executive compensation levels and practices that covers approximately
sixty executive positions in over 600 multinational life sciences organizations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not apply a specific weighting to either data source when making compensation comparisons. Instead, we develop competitive market guidelines using these data sources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
review our peer group each year to ensure continued relevance as we grow and develop, and the Compensation Committee approves our peer group prior to its adoption. In May 2018, the
following peer group was approved by the Compensation Committee and used to inform our decisions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=574933,FOLIO='19',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2>affecting
executive compensation in 2018. In 2019, the Compensation Committee reviewed the peer group and determined that the peer group remained an appropriate comparison for the Company.: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Achillion Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Merrimack Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Advaxis,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>NewLink Genetics Corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Agenus&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>OncoMed Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ardelyx,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Protagonist Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ra Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Calithera Biosciences,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Selecta Biosciences,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cidara Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Seres Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cytokinetics, Incorporated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Syndax Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Idera Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Tocagen&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Inovio Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2018, this peer group consisted of public companies in the biopharmaceutical industry with product candidates generally in mid-stage development, with employee headcount average
of 97 (range of 44 to 278), R&amp;D expense average of $63&nbsp;million and market capitalization average of $242&nbsp;million. We believe that, as of May 2019, this list was representative of the
companies with whom we generally compete for talent. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration and Objectives of Our Executive Compensation Program  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors, which comprises independent, non-employee directors, is responsible for establishing and
administering the policies governing the compensation of our employees, including salary, bonus and stock option grants. The policy of the Compensation Committee is to compensate our employees with
competitive salaries based on their level of experience and job performance. All permanent employees, including executive officers, are eligible for annual bonus awards based on achievement of our
strategic corporate goals and participation in our stock option program. The stock option grants are made in accordance with our 2008 Stock Option and Incentive Plan, as amended (the "2008 Plan"). The
Compensation Committee is also responsible for the administration of our 2004 Employee Stock Purchase Plan, as amended (the "2004 Plan"), in which employees participate on a voluntary basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee has designed our overall executive compensation program to achieve the following objectives:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attract and retain talented and experienced executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> motivate and reward executives whose knowledge, skills and performance are critical to our success; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide a competitive compensation package that aligns the interests of our executive officers and stockholders by including a significant
variable component which is weighted heavily towards performance-based rewards, based upon achievement of predetermined goals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> foster a shared commitment among executives by aligning our and their individual goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compensate our executives to manage our business to meet our near-term and long-term objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use a mix of short-term compensation (base salaries and cash incentive bonuses) and long-term compensation (equity incentive compensation) to provide a total compensation structure
that is designed to achieve these objectives. We determine the percentage mix of compensation structures that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=712359,FOLIO='20',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2>we
think is appropriate for each of our executive officers. In general, the Compensation Committee believes that a substantial percentage of the compensation of our executive officers should be
performance based. The Compensation Committee uses its judgment, experience and the recommendations of the chief executive officer (except for his own compensation) to determine the appropriate mix of
compensation for each executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining whether to adjust the compensation of any of our Named Executive Officers, we annually take into account the changes, if any, in the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market compensation levels; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the contributions made by each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the increases or decreases in responsibilities and roles of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the business needs of the Company with respect to each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the relevance of each executive officer's experience to other potential employers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the readiness of each executive officer to assume a more significant role within the organization. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, with respect to new executive officers, we take into account their prior base salary and annual cash incentives, their expected contribution and our business needs. We
believe that our executive officers should be fairly compensated each year relative to market pay levels within our industry. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Components  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to both attract and retain experienced and qualified executives to manage us, the Compensation Committee's policy on executive
compensation is to (i)&nbsp;pay salaries which are competitive with the salaries of executives in comparable positions in the biotechnology industry, and (ii)&nbsp;allow for additional
incentive-based compensation through the payment of annual cash bonuses and the grant of stock-based incentive awards. This policy is designed to have a significant portion of each executive's total
compensation be tied to our progress in order to incentivize the executive to fully dedicate himself or herself to achievement of corporate goals, and to align the executive's interest with those of
our stockholders through equity incentive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program is primarily composed of base salary, incentive cash compensation payable on an annual basis and equity compensation. In addition, we provide our
executives with benefits that are generally available to our salaried employees, including medical, dental, group life and accidental death and dismemberment insurance, short- and long-term disability
coverage and our 401(k) plan. Within the context of the overall objectives of our compensation programs, we determined the specific amounts of compensation to be paid to each of our executives in 2019
based on a number of factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our understanding of the amount of compensation generally paid by similarly situated companies to their executives with similar roles and
responsibilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the roles and responsibilities of our executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the individual experience and skills of, and expected contributions from, our executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts of compensation being paid to our other executives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our executives' historical compensation. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=185548,FOLIO='21',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
discuss each of the primary elements of our executive compensation in detail below. While we have identified particular compensation objectives that each element of executive
compensation serves, our compensation programs complement each other and collectively serve all of our executive compensation objectives described above. Accordingly, whether or not specifically
mentioned below, we believe that, as a part of our overall executive compensation, each element to a greater or lesser extent serves each of our objectives. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each executive officer (except the chief executive officer whose performance is reviewed by the Compensation Committee) has an annual
performance review with the chief executive officer who makes recommendations on salary increases, promotions and stock option grants to the
Compensation Committee. We have historically established base salaries for each of our executives based on many factors, including average salary increases expected in the biotechnology industry in
the Boston, Massachusetts, New Haven, Connecticut and central New Jersey areas, competition in the marketplace to hire and retain executives, experiences of our Board members and leadership team with
respect to salaries and compensation of executives in similarly situated companies in our industry and other similar industries, as well as additional factors which we believe enable us to hire and
retain our leadership team in an extremely competitive environment. Our Compensation Committee annually reviews salary ranges and individual salaries for our executive officers and approved the
following annual salaries for our Named Executive Officers: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase $ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Increase % </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>632,579</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>608,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>451,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>434,453</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,378</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>343,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margo Heath-Chiozzi, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>386,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>370,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sam Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>385,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>365,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Performance-Based Cash Bonus  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designed our annual cash bonuses to reward our executive officers for their individual performance and their actual performance and
contributions to our corporate goals for each year, as approved in advance by our Compensation Committee and Board of Directors. The corporate goals are allocated between specific product and
financial performance targets. Achievement of our corporate goals was, in 2019, the primary factor considered by our Compensation Committee in determining the annual bonuses for our executive
officers. However, the Compensation Committee retains discretion to adjust any individual bonus based on assessment of such individual's performance. Our performance-based bonus plan emphasizes the
contributions of each of our executive officers to the achievement of our corporate goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the beginning of each calendar year, the Compensation Committee establishes annual corporate performance goals and target bonuses. In 2019, the Compensation Committee established
target bonuses for each of our Named Executive Officers including 60% of base salary for Mr.&nbsp;Marucci, 40% of base salary for Dr.&nbsp;Keler, and 35% of base salary for Ms.&nbsp;Crowley,
Dr.&nbsp;Heath-Chiozzi, and Mr.&nbsp;Martin. These target bonuses were consistent with the 2018 targets. Corporate goals are proposed by management, reviewed and approved by the Compensation
Committee and also approved by the Board of Directors on an annual basis. The Compensation Committee considers and assigns a relative weight to appropriately focus efforts on corporate goals that are
intended to enhance shareholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=140225,FOLIO='22',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee reviewed the 2019 corporate goals at meetings held in April, June and September 2019 to gauge our levels of achievement and to assess whether the corporate
goals approved earlier in the year remained relevant and complete. In November 2019 and January 2020, prior to approving 2019 incentive bonuses, the Compensation Committee evaluated our 2019
performance by assessing if, and the extent to which, we achieved or failed to achieve the corporate goals approved by the Board of Directors for 2019. The Compensation Committee considered the 2019
performance and determined that we met 75% of our 2019 corporate goals for pipeline development and business and financial operations. Our corporate goals for 2019 and the level at which the
Compensation Committee determined they were achieved are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=3 ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>2019 Corporate Goals

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Relative<BR>
Weight </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019<BR>
Achievement </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> Pipeline Development:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>CDX-1140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Complete monotherapy and CDX-301 combination dose escalation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Initiate enrollment in expansion cohorts and/or a new combination cohort</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Present emerging data</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>CDX-3379</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Deliver stage&nbsp;1 results in Phase&nbsp;2 Erbitux combination study in advanced head and neck squamous cell carcinoma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>If data supports further development, initiate stage&nbsp;2 enrollment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>CDX-0159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Complete IND enabling activities and file an IND</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Initiate Phase&nbsp;1 healthy volunteer study</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>Earlier stage pipeline assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Complete manufacturing and IND enabling activities for CDX-527 (bispecific) to support an IND filing in Q1-2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Complete cell line development and proof of concept activities for the TAM program to support an IND filing in Q4-2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> Business and Financial Operations:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Provide sufficient cash to extend runway through 2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Bring in approved or clinical stage asset, as appropriate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#149;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Complete an out-licensing transaction, as acceptable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> Totals:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Compensation Committee's January 2020 meeting, Mr.&nbsp;Marucci reviewed in detail the performance of each executive officer, excluding himself, and considered such individual's
contributions to our success in 2019. Mr.&nbsp;Marucci's bonus recommendations were based on such individual performance assessments and the fact that the Company achieved 75% of its predetermined
corporate goals in 2019 and each employee, including the executive officers, contributed to our success in achieving the 2019 corporate goals. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee discussed Mr.&nbsp;Marucci's recommendations for the Named Executive Officers and reviewed Mr.&nbsp;Marucci's performance for fiscal 2019. Based on
Mr.&nbsp;Marucci's recommendations for each of the Named Executive Officers, the Compensation Committee's review of
Mr.&nbsp;Marucci's performance and the Compensation Committee's determination that 75% achievement of the corporate goals for 2019, the Compensation Committee approved annual bonus payments of 75%
to 83% of the 2019 bonus target for Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi and Mr.&nbsp;Martin, depending on the position </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=25,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=38546,FOLIO='23',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determined that annual incentive bonuses paid to the Named Executive Officers for 2019, were fair, reasonable and appropriate based on the factors described
above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also use stock options and equity-based incentive programs to attract, retain, motivate and reward our executive officers. Through our
equity-based grants, we seek to align the interests of our executive officers with our stockholders, reward and motivate both near-term and long-term executive performance and provide an incentive for
retention. Our decisions regarding the amount and type of equity incentive compensation and relative weighting of these awards among total executive compensation have been based on our understanding
of market practices of similarly situated companies and our negotiations with our executives in connection with their initial employment or promotion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have adopted an equity grant policy that formalizes how we grant equity awards by setting a regular schedule for granting equity awards in connection with the hiring or promotion of
any of our employees, granting annual equity awards and granting equity awards to non-employee directors. Such policy also outlines grant approval requirements and specifies the vesting schedule and
exercise prices for restricted stock units and stock option awards. We believe that this policy will mitigate the risk that issues or concerns would be raised in the future regarding the timing of
grants of equity awards to our officers, directors and employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such grants to our Named Executive Officers are subject to prior approval by the Compensation Committee at a regularly scheduled meeting during the year. The date of grant and the
fair market value of the award are based upon the date of the Compensation Committee meeting approving such grant. When granting equity-based awards, the Compensation Committee considers a number of
factors in determining the amount of equity incentive awards, if any, to grant to our executives, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the existing levels of stock ownership among the executive officers relative to each other and to our employees as a whole; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> previous grants of stock options to such executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> vesting schedules of previously granted options; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of the executives and their contributions to our overall performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an outside survey of stock option grants and restricted common stock awards in the biotechnology industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an internally prepared survey of similarly situated biotechnology companies' proxy statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> personal knowledge of the Compensation Committee members regarding executive stock options and restricted common stock awards at comparable
companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the financial statement impact of stock option awards on our results of operations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount and percentage of our total equity on a diluted basis held by our executives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
compensation awards to our Named Executive Officers consist of stock option awards. Stock option awards provide our executive officers with the right to purchase shares of our
common stock at a fixed exercise price typically for a period of up to ten years, subject to continued employment with us. Stock options are earned on the basis of continued service to us and
generally vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter. All historical option grants were made at what our Compensation
Committee and Board of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=26,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1029902,FOLIO='24',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2>Directors
determined to be the fair market value of our shares of our common stock on the respective grant dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;19, 2019, the Compensation Committee awarded stock options to all qualified employees, including stock options to purchase 100,000 shares, 60,000 shares, 43,000 shares,
43,000 shares, and 43,000 shares of our common stock to each of Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi and Mr.&nbsp;Martin, respectively. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that establishing competitive benefit packages for our employees is an important factor in attracting and retaining highly qualified
personnel. Executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, group life and accidental death and dismemberment insurance, short- and
long-term disability coverage and our 401(k) plan, in each case on the same basis as other employees. We provide a matching contribution under our 401(k) plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements and Post-Termination Compensation and Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We depend greatly on the intellectual capabilities and experience of our key executives. Our success is dependent on our ability to attract and
retain highly skilled executives with significant experience in the biotechnology industry, particularly as we expand our activities in clinical trials, the regulatory approval process and sales and
manufacturing. Therefore we enter into employment agreements with each of our Named Executive Officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, each employment arrangement provides for cash severance, 100% acceleration of any unvested options, restricted stock and/or other equity awards and continuation of certain
employee benefits in the event that an executive's employment is terminated within a one year period immediately following a change of control either without cause or by the executive for good reason.
The cash severance consists of a single lump sum payment equal to (i)&nbsp;twenty-four (24)&nbsp;times the executive's highest monthly base compensation paid hereunder during the preceding
twenty-four month period, plus (ii)&nbsp;150% (200%, in the case of Mr.&nbsp;Marucci) of the highest one-year annual bonus actually received by the executive during the preceding two full fiscal
years prior to the date of termination. We use a "double trigger" with respect to benefits that are to be provided in connection with a change of control. A change of control does not itself trigger
benefits; rather, benefits are paid only if the employment of the executive is terminated by us other than for cause, death or disability or by the executive for good reason during the one year period
immediately following the change of control. We believe a "double trigger" benefit maximizes shareholder value because it prevents a windfall to executives in the event of a change of control in which
the executive retains significant responsibility as defined in his or her individual agreement, while still providing our executives appropriate incentives to cooperate in negotiating any change of
control that may put their jobs at risk. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the benefits that only accrue in connection with a change of control, our agreements with the Named Executive Officers provide for cash severance, 25% acceleration of
unvested options (in the case of Mr.&nbsp;Marucci, Dr.&nbsp;Keler and Ms.&nbsp;Crowley), restricted stock and/or other equity awards and continuation of certain employee benefits if we terminate
their employment with us without cause or they terminate their employment with us for good reason, as such terms are defined in the applicable agreement with the executive officer. The cash severance
consists of a lump sum cash payment equal to 100% (200% in the case of Mr.&nbsp;Marucci) of the executive's then existing base salary. A further discussion of the terms and projected payments under
each of these agreements is set forth below under the heading </FONT><FONT SIZE=2><I>Potential Payments upon Termination of Employment or Change in Control.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=27,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1028155,FOLIO='25',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<A NAME="page_da19501_1_26"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committee Consideration of the Company's 2019 Shareholder Advisory Vote on Executive Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our 2019 Annual Meeting of Shareholders, approximately 83% of the shares voted at the meeting approved, on an advisory basis, the
compensation of the Named Executive Officers. Given that a majority of the shares voted approved the 'say on pay' advisory proposal, the Committee did not implement specific changes and continued with
its performance-based compensation philosophy and its balanced approach to various components of its compensation program. However, the Compensation Committee does monitor the results of the annual
advisory 'say-on-pay' proposal and refers to such results as one of many factors considered in connection with the discharge of its responsibilities, although the Committee does not assign a
quantitative weighting to any such factors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=28,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=274027,FOLIO='26',FILE='DISK123:[20ZAD1.20ZAD19501]DA19501A.;8',USER='CHE109864',CD='27-APR-2020;14:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc19501_1_27"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_summary_compensation_table"> </A>
<A NAME="toc_dc19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary compensation table reflects certain information concerning compensation for services in all capacities awarded to, earned
by or paid during the years ended December&nbsp;31, 2019, 2018 and 2017 to (i)&nbsp;our Chief Executive Officer, (ii)&nbsp;our Chief Financial Officer, and (iii)&nbsp;our three most highly
compensated executive officers, other than the Chief Executive Officer and Chief Financial Officer, who were serving as executive officers as of December&nbsp;31, 2019 (collectively, the "Named
Executive Officers"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive<BR>
Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>619,478</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>284,661</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>208,580</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,128,320</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>President and Chief</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>608,249</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>291,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>468,811</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,331</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,385,351</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Executive Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>597,569</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>310,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>739,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,005</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,664,024</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
442,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
135,549</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
125,148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
4,182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
707,353</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Executive Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>434,453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>140,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>170,078</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>748,713</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>426,825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>147,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>252,121</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>830,729</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
350,484</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
104,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
3,481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
547,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>343,330</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>107,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>130,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>585,708</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Chief Product Development</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>337,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>105,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>127,617</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>574,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Margo Heath-Chiozzi, M.D.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
377,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
107,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
6,017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
580,206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Senior Vice President, Regulatory</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>370,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>107,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>119,922</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,832</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>602,754</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Affairs</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Sam Martin(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
374,231</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
103,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
8,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
575,017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>327,615</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>172,256</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>622,246</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>262,054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>96,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>101,160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,081</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>465,295</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Bonus column include annual bonus amounts earned by each of our Named Executive Officers in 2019, 2018 and 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Option Awards column reflect the dollar amounts for the aggregate grant date fair value in accordance with accounting principles generally
accepted in the United States of America (U.S.&nbsp;GAAP) of stock option awards made in fiscal years ended December&nbsp;31, 2019, 2018 and 2017 for annual awards pursuant to the 2008 Plan. For a
discussion regarding the valuation of our stock option awards for financial statement reporting purposes, please refer to Note&nbsp;2 in the Notes to the Financial Statements contained in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019. These amounts do not represent the actual amounts paid to the Named Executive Officers or the actual value that may be realized
by the Named Executive Officers upon exercise of such stock options.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts listed in the All Other Compensation column includes our matching contribution to the 401(k) Savings Plan of each Named Executive Officer and premiums
paid for life insurance under our nondiscriminatory group plan for each Named Executive Officer. In addition, Mr.&nbsp;Marucci's compensation includes (i)&nbsp;the annual premium of $2,550 in
2019, 2018 and 2017 for a $1,000,000 term life insurance policy and (ii)&nbsp;$3,721, $4,668 and $5,485 for the personal use of a Company car in 2019, 2018 and 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Dr.&nbsp;Heath-Chiozzi
joined us on October&nbsp;3, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>On
July&nbsp;1, 2017, Mr.&nbsp;Martin was promoted to Senior Vice President and Chief Financial Officer. The amounts included above are for the full year ended
December&nbsp;31, 2017. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=918788,FOLIO='27',FILE='DISK123:[20ZAD1.20ZAD19501]DC19501A.;12',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dc19501_1_28"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_grants_of_plan-based_awards"> </A>
<A NAME="toc_dc19501_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Grants of Plan-Based Awards    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information on stock options and stock awards granted in 2019 to each of our Named Executive Officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=4 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares of<BR>
Stock or<BR>
Units<BR>
(#) </B></FONT></TH>
<TH ROWSPAN=4 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Future<BR>
Payouts Under<BR>
Equity Incentive Plan Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair Value of<BR>
Stock and<BR>
Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base Price of<BR>
Option<BR>
Awards<BR>
($/Sh)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6/19/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>208,580</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6/19/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6/19/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margo Heath-Chiozzi, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6/19/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6/19/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>89,689</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
exercise prices reflect the closing price of our common stock on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
grant date fair values are generally the amount we would expense in our financial statements over the award's service period, but does not include a reduction
for estimated forfeitures. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=787960,FOLIO='28',FILE='DISK123:[20ZAD1.20ZAD19501]DC19501A.;12',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dc19501_1_29"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_outstanding_equity_awards_at_fiscal_year-end"> </A>
<A NAME="toc_dc19501_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Outstanding Equity Awards at Fiscal Year-End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the stock option grants and stock awards to our Named Executive Officers at
December&nbsp;31, 2019. All share and per share amounts reflect the one for fifteen reverse stock split which became effective February&nbsp;8, 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Market or<BR>
Payout<BR>
Value of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/19/29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>26,874</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>44,791</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/13/28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,789</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/15/27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,959</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>381.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>201.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>245.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>85.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12,025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>42.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>67.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/19/29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,251</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/13/28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/15/27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,448</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,351</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,766</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>381.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,766</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>201.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>245.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>85.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,599</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>42.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>67.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/19/29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/13/28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/15/27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,723</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>676</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>381.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,065</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>201.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>245.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/20/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>42.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>67.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Margo Heath-Chiozzi, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/19/29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Margo Heath-Chiozzi, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/13/28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Margo Heath-Chiozzi, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>45.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10/3/27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/19/29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/13/28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,707</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/15/27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>176</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,399</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>381.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>799</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>201.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>245.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/20/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>42.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>25%
of the options vest on the first anniversary of the grant date and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=911593,FOLIO='29',FILE='DISK123:[20ZAD1.20ZAD19501]DC19501A.;12',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dc19501_1_30"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_option_exercises_and_stock_vested"> </A>
<A NAME="toc_dc19501_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Option Exercises and Stock Vested    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the number of option exercises in fiscal 2019 and the number of shares of stock
issued under the 2008 Plan that vested in fiscal 2019 and the corresponding amounts realized by our Named Executive Officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Exercise<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Exercise<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Vesting<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Vesting<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margo Heath-Chiozzi, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sam Martin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_employment_agreements"> </A>
<A NAME="toc_dc19501_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Employment Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and conditions of the employment agreements of Mr.&nbsp;Marucci, Dr.&nbsp;Keler, Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi and
Mr.&nbsp;Martin are governed by written employment contracts which became effective on January&nbsp;1, 2018. The employment agreements provide, among other things,
for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> current annual base salary ($632,579 in the case of Mr.&nbsp;Marucci, $451,831 in the case of Dr.&nbsp;Keler, $358,830 in the case of
Ms.&nbsp;Crowley, $386,250 in the case of Dr.&nbsp;Heath-Chiozzi and $385,000 in the case of Mr.&nbsp;Martin) or such greater amount as may from time to time be determined by the Board of
Directors or the Compensation Committee thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> eligibility for an annual bonus with a current bonus target (60% of base salary in the case of Mr.&nbsp;Marucci, 40% of base salary in the
case of Dr.&nbsp;Keler and 35% of base salary in the case of Ms.&nbsp;Crowley, Dr.&nbsp;Heath-Chiozzi and Mr.&nbsp;Martin); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a lump sum severance payment equal to 100% (200% in the case of Mr.&nbsp;Marucci only) of the executive's then-existing annual base salary in
the event that the executive's employment is terminated without cause or the executive resigns "for good reason" (as defined in the employment agreement) and 25% accelerated vesting of any unvested
equity awards (in the case of Mr.&nbsp;Marucci, Dr.&nbsp;Keler and Ms.&nbsp;Crowley); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment equal to twenty-four
(24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month period preceding the date of termination plus 150% (200% in the case of
Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal years preceding the date of termination in the event of termination without
cause or resignation "for good reason" by the executive within one year immediately following a change in control (as defined in the employment agreement). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
employment agreements had an initial term through December&nbsp;31, 2018 and shall automatically renew for additional one year terms unless either party gives ninety
(90)&nbsp;days prior written notice of its intent not to renew. The Company may terminate the employment agreements without cause, on 90-days' prior notice, or for cause, subject to a 30-day cure
period in certain circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=260938,FOLIO='30',FILE='DISK123:[20ZAD1.20ZAD19501]DC19501A.;12',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dc19501_1_31"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_pension_benefits"> </A>
<A NAME="toc_dc19501_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Pension Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers participate in qualified or nonqualified defined benefit plans sponsored by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc19501_nonqualified_deferred_compensation"> </A>
<A NAME="toc_dc19501_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Nonqualified Deferred Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers are covered by a defined contribution or other plan that provides for the deferral of compensation on a
basis that is not tax-qualified. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=344329,FOLIO='31',FILE='DISK123:[20ZAD1.20ZAD19501]DC19501A.;12',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de19501_1_32"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de19501_potential_payments_upon_termin__pot02940"> </A>
<A NAME="toc_de19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Potential Payments Upon Termination of Employment or Change in Control    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Named Executive Officers have provisions in their employment agreements regarding severance upon certain termination events or acceleration
of stock options in the event of our change of control or termination following a change of control. These severance and acceleration provisions are described in "Employment Agreements," and certain
estimates of these change of control benefits are provided in the tables below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table describes the potential payments and benefits upon employment termination for our Named Executive Officers as if their employment had terminated as of
December&nbsp;31, 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Executive benefits and payments<BR>
upon termination

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for no good<BR>
reason </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for good<BR>
reason(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
without<BR>
cause(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
for cause </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary termination<BR>
by the executive<BR>
for good reason<BR>
or termination by<BR>
Celldex without<BR>
cause in connection<BR>
with or following<BR>
change of control(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Anthony S. Marucci</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,265,158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,265,158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,265,158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>583,920</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,301,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,301,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,885,366 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Tibor Keler, Ph.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>451,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>451,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>903,662</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>210,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>488,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>488,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,149,950 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Elizabeth Crowley</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>717,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>160,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>878,160 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Margo Heath-Chiozzi, M.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>386,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>386,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>772,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>160,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>422,538</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>422,538</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,288 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=34,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=600484,FOLIO='32',FILE='DISK123:[20ZAD1.20ZAD19501]DE19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_de19501_1_33"> </A>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Executive benefits and payments<BR>
upon termination

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for no good<BR>
reason </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for good<BR>
reason(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
without<BR>
cause(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
for cause </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary termination<BR>
by the executive<BR>
for good reason<BR>
or termination by<BR>
Celldex without<BR>
cause in connection<BR>
with or following<BR>
change of control(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Sam Martin</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>385,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>385,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>770,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>172,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,288 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>421,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>421,288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>978,788 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
termination without cause or resignation for good reason, the employee is generally entitled to a lump sum payment equal to 100% (200% in the case of
Mr.&nbsp;Marucci only) of the employee's then annual base salary, continuation of certain employee benefits and 25% accelerated vesting of any unvested equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
employee is generally entitled to accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment equal to
twenty-four (24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month period preceding the date of termination plus 150% (200% in the case
of Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal years preceding the date of termination in the event of termination
without cause or resignation "for good reason" by the executive within one year immediately following a change in control (as defined in the employment agreement).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
exercise price of each unvested option outstanding was greater than $2.23 per share (the closing price on the last trading day of 2019).  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de19501_ceo_pay_ratio"> </A>
<A NAME="toc_de19501_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CEO Pay Ratio    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As required by Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item&nbsp;402(u) of
Regulation&nbsp;S-K, we are required to disclose the ratio of our median employee's annual total compensation to the annual total compensation of our principal executive officer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of this disclosure is to provide a measure of the equitability of pay within our company. We believe our compensation philosophy and process yield an equitable result for all
of our employees. During fiscal 2019, the principal executive officer of Celldex was our Chief Executive Officer, Anthony S. Marucci. For 2019, the annual total compensation, using the same
methodology we use for our named executive officers as set forth in the summary compensation table, for Mr.&nbsp;Marucci was $1,128,320, and for our median employee was $115,473, resulting in an
estimated pay ratio of 10 to 1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with Item&nbsp;402(u) of Regulation&nbsp;S-K, we identified the median employee by (i)&nbsp;determining our employee population as of December&nbsp;31, 2018
(including all full-time, part-time, salaried, hourly, and seasonal employees, but excluding Mr.&nbsp;Marucci), (ii)&nbsp;calculating the total compensation for each employee for fiscal 2018 by
aggregating (A)&nbsp;annual base salary for salaried employees (or hourly rate multiplied by expected annual work schedule, for hourly employees), (B)&nbsp;the bonus for 2018, and (C)&nbsp;the
estimated accounting value of any equity awards granted during 2018, and (iii)&nbsp;ranking this compensation measure for our employees from lowest to highest. We do not believe that there has been
any change in our employee population or employee compensation arrangements for fiscal 2019 that would result in a significant change to our pay ratio disclosure. As such, and as permitted by
Item&nbsp;402(u) of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=35,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=322180,FOLIO='33',FILE='DISK123:[20ZAD1.20ZAD19501]DE19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_de19501_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2>Regulation&nbsp;S-K,
we are using the same median employee for our pay ratio disclosure that we identified for our pay ratio disclosure for fiscal 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. Because the SEC
rules for identifying the median compensated employee and calculating the pay ratio based on that employee's annual total compensation allow companies to adopt a variety of methodologies, to apply
certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices, the pay ratio reported by other companies may not be comparable
to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in
calculating their own pay ratios. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de19501_director_compensation"> </A>
<A NAME="toc_de19501_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Director Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June 2018, Directors who are not our employees are each entitled to receive a retainer fee of $40,000 each fiscal year ("Annual
Retainer"). The Chair of the Board is entitled to receive an annual retainer fee of $30,000 in addition to his or her Annual Retainer and any retainer for committee service. The Chairperson of the
Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board of Directors is entitled to receive an annual retainer fee of $15,000, $12,500 and $8,000,
respectively, in addition to his or her Annual Retainer. Each committee member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee (other than the
Chairperson of a committee) will receive an annual retainer of $7,500, $6,250 and $4,000, respectively, in addition to his or her Annual Retainer. Stipends and retainers are paid in advance on a
quarterly basis. The Directors shall be reimbursed for necessary travel and business expenses as incurred but will not receive any additional fees for attending meetings or calls of the Board of
Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2019, all non-employee directors received an annual stock option grant to purchase 4,500 shares of the Company's common stock following the Annual Meeting of Stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the annual compensation for our non-employee directors during 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned or<BR>
Paid in Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,614</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith L. Brownlie</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,804</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,190</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,054</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James J. Marino</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,758</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63,136</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in the Option Awards column reflect the grant date fair value in accordance with U.S.&nbsp;GAAP of stock option awards made in 2019 to each of our
non-employee directors for awards pursuant to the 2008 Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of
forfeiture (so long as the director remains a member of the Board as of such date). As of December&nbsp;31, 2019, our non employee directors had the following stock options outstanding: Karen L.
Shoos&#151;11,918, Keith L. Brownlie&#151;10,499, Herbert J. Conrad&#151;11,918, James J. Marino&#151;10,499 and Harry H. Penner, Jr.&#151;11,918. For a discussion
regarding the valuation of our stock option awards for </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=36,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=447490,FOLIO='34',FILE='DISK123:[20ZAD1.20ZAD19501]DE19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_de19501_1_35"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>financial
statement reporting purposes, please refer to Note&nbsp;2 in the Notes to the Financial Statements contained in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2019. These amounts do not represent the actual amounts paid to the directors or the actual value that may be realized by the directors upon exercise of such stock options.  </FONT></P>

</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de19501_compensation_committee__de102477"> </A>
<A NAME="toc_de19501_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors is currently composed of the following three non-employee directors: James J. Marino,
Chair, Herbert J. Conrad and Harry H. Penner, Jr. None of these Compensation Committee members was an officer or employee of us during the year. No Compensation Committee interlocks between us and
another entity existed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de19501_risk_considerations"> </A>
<A NAME="toc_de19501_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Risk Considerations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not believe that our compensation practices and policies for our employees, including our executive officers, create risks or are likely
to create risks that are reasonably likely to have a material adverse effect on our results of operations or financial condition. The Compensation Committee considered our strategic goals and
operational practices and evaluated our incentive program design to assess whether these programs foster a business environment that might drive inappropriate decision-making or behavior. We are a
biopharmaceutical company that is generating a pipeline of drug candidates to treat cancer and other difficult-to-treat diseases and do not yet generate earnings. While a significant portion of our
executives' compensation is performance-based, we believe several features of our program mitigate inappropriate or excessive risk-taking that could harm shareholder value: we set performance goals
that we believe are reasonable and set targets with payouts at multiple levels of performance, rather than an "all or nothing" approach. As discussed above in our Compensation Discussion and Analysis
section we use a mix of performance goals in our annual and long-term incentive programs to align incentive compensation with a broad set of measures important to the creation of shareholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=37,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=280792,FOLIO='35',FILE='DISK123:[20ZAD1.20ZAD19501]DE19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg19501_1_36"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg19501_compensation_committee_report"> </A>
<A NAME="toc_dg19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT*    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis with management and based on such review and
discussion of the Compensation Discussion and Analysis, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Compensation Committee:<BR>
James J. Marino, Chair<BR>
Herbert J. Conrad<BR>
Harry H. Penner, Jr.<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Compensation Committee is not to be deemed "filed" with the SEC (irrespective of any general incorporation language in any document filed
with the SEC) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended, or to the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934, except to the
extent we specifically incorporate it by reference into a document filed with the SEC. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=616590,FOLIO='36',FILE='DISK123:[20ZAD1.20ZAD19501]DG19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di19501_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di19501_report_of_the_audit_committee"> </A>
<A NAME="toc_di19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE*    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned members of the Audit Committee of the Board of Directors of Celldex submit this report in connection with the committee's review
of the financial reports for the fiscal year ended December&nbsp;31, 2019 as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has reviewed and discussed with management the audited financial statements for Celldex for the fiscal year ended December&nbsp;31, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with representatives of PricewaterhouseCoopers&nbsp;LLP the matters which are required to be discussed with them under the
provisions of Auditing Standard No.&nbsp;61, as amended, </FONT><FONT SIZE=2><I>Communications with Audit Committees</I></FONT><FONT SIZE=2>. That Auditing Standard requires the auditors to ensure
that the Audit Committee received information regarding the scope and results of the audit.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with PricewaterhouseCoopers&nbsp;LLP, the independent registered public accounting firm, the auditors' independence from
management and Celldex including the matters in the written disclosures and the letter from the independent auditors required by PCAOB Rule&nbsp;3526. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Audit Committee considered whether the provision of tax or other non-audit services by PricewaterhouseCoopers&nbsp;LLP is compatible with maintaining its independence.
In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the Board of Directors has approved) that the audited financial statements
be included in Celldex's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2019 for filing with the Securities and Exchange Commission. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Audit Committee:<BR>
Keith L. Brownlie, Chair<BR>
James J. Marino<BR>
Harry H. Penner, Jr.<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Audit Committee is not to be deemed "soliciting material" or deemed to be "filed" with the Securities and Exchange Commission (irrespective
of any general incorporation language in any document filed with the Securities and Exchange Commission) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended, or to
the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into a document filed with the Securities and Exchange
Commission. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=39,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=221927,FOLIO='37',FILE='DISK123:[20ZAD1.20ZAD19501]DI19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk19501_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Security Ownership of Certain Beneficial Owners and Management  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information as of April&nbsp;8, 2020 with respect to the beneficial ownership of common stock of the
Company by the following: (i)&nbsp;each of the Company's current directors; (ii)&nbsp;each of the Named Executive Officers; (iii)&nbsp;the current executive officers; (iv)&nbsp;all of the
executive officers and directors as a group; and (v)&nbsp;each person known by the Company to own beneficially more than five percent (5%) of the outstanding shares of the Company's common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the following table, beneficial ownership is determined in accordance with the applicable SEC rules and the information is not necessarily indicative of beneficial
ownership for any other purpose. Except as otherwise noted in the footnotes to the table, we believe that each person or entity named in the table has sole voting and investment power with respect to
all shares of the Company's common stock shown as beneficially owned by that person or entity (or shares such power with his or her spouse). Under the SEC's rules, shares of the Company's common stock
issuable under options that are exercisable on or within 60&nbsp;days after April&nbsp;8, 2020 ("Presently Exercisable Options") are deemed outstanding and therefore included in the number of
shares reported as beneficially owned by a person or entity named in the table and are used to compute the percentage of the common stock beneficially owned by that person or entity. These shares are
not, however, deemed outstanding for computing the percentage of the common stock beneficially owned by any other person or entity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of the common stock beneficially owned by each person or entity named in the following table is based on 17,857,589 shares of common stock outstanding as of
April&nbsp;8, 2020 plus any shares issuable upon exercise of Presently Exercisable Options held by such person or entity. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="111pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Business Address of Beneficial Owners*

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount and Nature of<BR>
Beneficial Ownership(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Common Stock(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>5% Holders</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Renaissance Technologies&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,115,368</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>800 Third Avenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10022</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Directors and Executive Officers</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith L. Brownlie</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Sarah Cavanaugh</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,186</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,426</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,118</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margo Heath-Chiozzi, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,739</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James J. Marino</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,843</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Sam Martin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,907</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>173,932</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,653</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Karen L. Shoos</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,648</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard Wright, Ph.D</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Diane C. Young, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Directors and Executive Officers as a group (14 persons)</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>435,902</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(17)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the address is c/o Celldex Therapeutics,&nbsp;Inc., Perryville&nbsp;III Building, 53&nbsp;Frontage Road, Suite&nbsp;220, Hampton,
NJ&nbsp;08827.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the persons shown have sole voting and investment power over the shares listed. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=971567,FOLIO='38',FILE='DISK123:[20ZAD1.20ZAD19501]DK19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dk19501_1_39"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Common
stock includes all outstanding common stock plus, as required for the purpose of determining beneficial ownership (in accordance with Rule&nbsp;13d-3(d)(1)
of the Securities Exchange Act of 1934, as amended), all common stock subject to any right of acquisition, through exercise or conversion of any security, within 60&nbsp;days of the record date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G filed with the SEC by Renaissance Technologies&nbsp;LLC on February&nbsp;12, 2020
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
5,666 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
17,869 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
7,085 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,630 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
11,143 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
66,382 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
5,666 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
18,922 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
169,494 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
7,085 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
44,017 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
7,085 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
24,972 shares of common stock underlying options which are or may be exercisable as of April&nbsp;8, 2020 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Please
refer to footnotes 4&nbsp;-&nbsp;16.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Section&nbsp;16(a) Beneficial Ownership Reporting Compliance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, requires Celldex's directors and executive officers, and persons who
are beneficial owners of more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (the "SEC").
These persons are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. To our knowledge, based solely on a review of the copies of such reports furnished
to us and written representations that no other reports were required during the fiscal year ended December&nbsp;31, 2019, all reports required to be filed under Section&nbsp;16(a) were filed on a
timely basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=557541,FOLIO='39',FILE='DISK123:[20ZAD1.20ZAD19501]DK19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dk19501_1_40"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with Related Persons  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is our policy that all employees and directors, as well as their family members, must avoid any activity that is or has the appearance of
conflicting with Celldex's business interest. This policy is included in our Code of Business Conduct and Ethics. All directors and officers of Celldex complete a directors and officers questionnaire
at the beginning of each year, in which they are asked to disclose family relationships and other related party transactions. Our Audit Committee must review and approve all related party
transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K. Our Audit Committee's procedures for reviewing related party transactions are not in writing. Other than compensation arrangements
for our Named Executive Officers and directors, which are described in the section entitled "Executive Compensation," since January&nbsp;1, 2019, there have been no transactions or series of similar
transactions to which we were a party or will be a party, in which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts involved exceeded or will exceed $120,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the
foregoing persons, had or will have a direct or indirect material interest. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk19501_the_board_of_directors_recomme__the04190"> </A>
<A NAME="toc_dk19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>  "FOR" THE ELECTION OF THE DIRECTOR NOMINEES.    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=968394,FOLIO='40',FILE='DISK123:[20ZAD1.20ZAD19501]DK19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm19501_1_41"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm19501_proposal_2__ratify_the_appoint__pro06307"> </A>
<A NAME="toc_dm19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 2: RATIFY THE APPOINTMENT OF<BR>  PRICEWATERHOUSECOOPERS&nbsp;LLP AS OUR INDEPENDENT REGISTERED<BR>  PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2020<BR>  <BR>    (Proposal No.&nbsp;2)    <BR>
</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has reappointed PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm to audit the
financial statements of the Company for the fiscal year ending December&nbsp;31, 2020, and has further directed that management submit their selection of independent registered public accounting
firm for ratification by our stockholders at the Annual Meeting of Stockholders. A representative of PricewaterhouseCoopers&nbsp;LLP is expected to attend the Annual Meeting and will have an
opportunity to make a statement, if he or she desires, and will be available to respond to appropriate questions. Neither the accounting firm nor any of its members have any direct or indirect
financial interest in or any connection with us in any capacity other than as public registered accounting firm. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principal Accountant Fees and Services  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the fees for professional services rendered by PricewaterhouseCoopers&nbsp;LLP, our independent registered
public accounting firm, for each of the last two fiscal years: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Fee Category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>644</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>827</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>866 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents fees, including out of pocket expenses, for professional services provided in connection with the audit of our annual audited
financial statements, our 2018 audit of internal control over financial reporting, the review of our quarterly financial statements included in our Forms&nbsp;10-Q, accounting consultations or
advice on accounting matters necessary for the rendering of an opinion on our financial statements, services provided in connection with the offerings of our common stock and audit services provided
in connection with other statutory or regulatory filings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit-Related Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit-related fees in 2018 consist of fees for services performed related to our adoption of the new lease standard in the first quarter of
2019. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax fees in 2018 are associated with tax planning and research related activities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


All Other Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All other fees consist of fees relating to an accounting research tool and disclosures database. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for appointing, setting compensation and overseeing the work of the independent auditors. The Audit Committee has established a policy regarding
pre-approval of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=870959,FOLIO='41',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2>all
auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section&nbsp;10A(g) of the Exchange Act or the applicable rules of the SEC or the
Public Company Accounting Oversight Board) to be provided to Celldex by the independent auditor. However, the pre-approval requirement may be waived with respect to the provision of non-audit services
for Celldex if the "de minimis" provisions of Section&nbsp;10A(i)(1)(B) of the Exchange Act are satisfied. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has considered whether the provision of Audit-Related Fees, Tax Fees, and All Other Fees as described above is compatible with maintaining
PricewaterhouseCoopers&nbsp;LLP's independence and has determined that such services for fiscal years 2019 and 2018 were compatible. All such services were approved by the Audit Committee pursuant
to Rule&nbsp;2-01 of Regulation&nbsp;S-X under the Exchange Act to the extent that rule was applicable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for reviewing and discussing the audited financial statements with management, discussing with the independent registered public accountants the
matters required in Auditing Standards No.&nbsp;1301, receiving written disclosures from the independent registered public
accountants required by the applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accountants' communications with the Audit Committee
concerning independence and discussing with the independent registered public accountants their independence, and recommending to the Board of Directors that the audit financial statements be included
in our annual report on Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm19501_the_board_of_directors_recomme__the05471"> </A>
<A NAME="toc_dm19501_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>  "FOR" THE RATIFICATION OF THE INDEPENDENT REGISTERED PUBLIC<BR>  ACCOUNTING FIRM.    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=617408,FOLIO='42',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_43"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm19501_proposal_3__approve_the_amendm__pro03321"> </A>
<A NAME="toc_dm19501_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 3: APPROVE THE AMENDMENT TO THE<BR>  2008 STOCK OPTION AND INCENTIVE PLAN<BR>  <BR>    (Proposal No.&nbsp;3)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders are requested in this Proposal 3 to approve an amendment to our 2008 Stock Option and Incentive Plan as amended and restated
effective as of June&nbsp;19, 2019 (the "2008 Plan"). The general purpose of our 2008 Plan is to provide a means whereby eligible employees, officers, non-employee directors and other individual
service providers develop a sense of proprietorship and personal involvement in the development and financial success of the Company and to encourage them to devote their best efforts to the business
of the Company, thereby advancing the interests of the Company and its stockholders. Our Board believes that the 2008 Plan advances our interests by enhancing our ability to (i)&nbsp;attract and
retain employees, officers, non-employee directors and other individual service providers, (ii)&nbsp;provide incentives for such persons to exert maximum efforts for the success of the Company and
its subsidiaries, and (iii)&nbsp;reward such persons for these efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed below, approval of the amendment of our 2008 Plan is intended, among other things, to ensure that we have sufficient shares reserved for issuance under the 2008 Plan to
provide incentives to
new and existing employees and independent contractors for the next year. We are asking to increase the number of shares reserved for issuance thereunder by 1,900,000 to 4,133,333 shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;19, 2020, the Board of Directors approved an amendment to the 2008 Plan, subject to approval at this Annual Meeting by our stockholders, to increase the number of shares
reserved for issuance thereunder by 1,900,000 to 4,133,333 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our stockholders do not approve the amendment of the 2008 Plan, we will continue to operate the 2008 Plan under its current provisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
below is a summary of the 2008 Plan and a discussion of the federal income tax consequences of the issuance and exercise of incentives under the 2008 Plan to recipients and
to us. This summary of the 2008 Plan is qualified entirely by reference to the complete text of the 2008 Plan, a copy of which is attached to this proxy statement as </FONT> <FONT SIZE=2><B><I>Appendix&nbsp;A</I></B></FONT><FONT SIZE=2> and the
complete text of the amendment to the 2008 Plan, a copy of which is attached to this proxy statement as
</FONT><FONT SIZE=2><B><I>Appendix&nbsp;B</I></B></FONT><FONT SIZE=2><I>.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the 2008 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan may be administered by the Board of Directors, or the compensation committee or similar committee of the Board of Directors (the
"administrator"). The administrator, at its discretion, may grant a variety of stock incentive awards based on our Common Stock. Awards under the 2008 Plan include stock options (both incentive
options and non-qualified options), stock appreciation rights, restricted stock, deferred stock, cash-based awards, performance shares, unrestricted stock and dividend equivalent rights. These awards
are described in greater detail below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
maximum number of shares of Common Stock that can be issued under the 2008 Plan is 2,233,333 shares. Based solely upon the closing price of the Common Stock as reported by NASDAQ on
April&nbsp;8, 2020, the maximum aggregate market value of the securities to be issued under the 2008 Plan would be $4.0&nbsp;million. If this amendment is approved, the maximum number of shares of
Common Stock issuable under the 2008 Plan will increase from 2,233,333 shares to 4,133,333 shares. For years, we have successfully used stock options to attract, retain and motivate employees in a
highly competitive marketplace. Option grants have been given to a broad base of employees and Named Executive Officers. We believe that our stock option program has been very successful over the
years in motivating our employees while enhancing shareholder value and therefore it is very valuable to us that we be able to continue offering option grants. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=292229,FOLIO='43',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares issued by Celldex under the 2008 Plan may be authorized but unissued shares, or shares reacquired by Celldex (subject to the limitation set forth below). For purposes of
determining the aggregate number of shares of common stock that may be issued under the 2008 Plan, the following shares will be counted as issued and, therefore, may not be made subject to new awards
under the 2008 Plan:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock repurchased by us with option proceeds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock that are tendered (by either actual delivery or attestation) or withheld to either pay the exercise price of a stock
option granted under the 2008 Plan or to satisfy tax withholding obligations associated with an award granted under the 2008 Plan; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock that are covered by stock appreciation rights to the extent that such stock appreciation rights are exercised and
settled in shares of common stock, whether or not shares of common stock are actually issued to the grantee upon such exercise. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2008 Plan provides that the administrator may require that vesting or grants of certain awards be conditioned on the satisfaction of performance criteria that may include any of the
following: (i)&nbsp;our return on equity, assets, capital or investment, (ii)&nbsp;our pre-tax or after-tax profit levels or that of any subsidiary, division, operating unit or business segment,
or any combination of the foregoing; (iii)&nbsp;cash flow, funds from operations, year-end cash and equivalents balance or similar measure; (iv)&nbsp;total shareholder return; (v)&nbsp;changes
in the market price of our stock; (vi)&nbsp;sales or market share; (vii)&nbsp;earnings per share; (viii)&nbsp;partnerships, collaborations, joint ventures, alliances and similar arrangements
involving us; (ix)&nbsp;mergers, acquisitions and business combinations of or by us; or (x)&nbsp;our rights to intellectual property and scientific discoveries. The 2008 Plan continues to include
certain provisions addressing awards intended to qualify for the exception for "qualified performance-based compensation" under Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended
(the "Code"). Section&nbsp;162(m) of the Internal Revenue Code denies a tax deduction to any publicly held corporation for compensation paid to certain "covered employees" in a taxable year to the
extent that compensation exceeds $1,000,000
for a covered employee. Effective for taxable years beginning prior to January&nbsp;1, 2018, an exception to this deduction limit applied to "performance-based compensation," such as stock options
and other equity awards, that satisfies certain criteria. Under the Tax Cuts and Jobs Act of 2017, the performance-based pay exception to Section&nbsp;162(m) was eliminated, but a transition rule
may allow the exception to continue to apply to certain performance-based compensation payable under written binding contracts that were in effect on November&nbsp;2, 2017. As a result, certain of
the provisions of the 2008 Plan with respect to performance-based awards may no longer be applicable with respect to new awards. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan is administered by our Board of Directors or by the compensation committee or a similar committee of
the Board of
Directors. The administrator of the 2008 Plan has full power and authority to select the participants to whom awards will be granted, to make any combination of awards to participants, to accelerate
the exercisability or vesting of an award only upon a grantee's death, a grantee's "disability" (as defined in the 2008 Plan) or a "change of control" (as defined in the 2008 Plan) or "sale event" (as
defined in the 2008 Plan) and to determine the specific terms and conditions of each award, subject to the provisions of the 2008 Plan. The administrator may delegate to the Chief Executive Officer
the authority to grant awards to individuals who are not subject to the reporting and other provisions of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended, and are not Covered
Employees, provided that the administrator fixes the maximum number of shares that may be awarded and provides specific guidelines regarding such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility and Limitations on Grants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Persons eligible to receive awards under the 2008 Plan are all full-time and part-time employees,
 officers,
non-employee directors, consultants, advisors or other individual service providers of the Company. As of April&nbsp;8, 2020, the Company had a total of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=625633,FOLIO='44',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2>approximately
133 full-time and part-time employees, including seven officers and nine executive officers (who are not included in the number of officers) and five non-employee directors. None of our
subsidiaries has any employees, and none of the officers and directors of our subsidiaries are eligible for awards under the 2008 Plan other than those who are eligible as officers or directors of the
Company. As of that date, we had approximately five consultants who we have historically granted options to, and no one in the categories of other advisors or other individual service providers. As
awards under the 2008 Plan are within the discretion of the administrator, the Company cannot determine how many individuals in each of the categories described above will receive awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of stock options awarded under the 2008 Plan may not be less than the fair market value of the Common
Stock on the
date of the option grant, except that for a grant of an incentive stock option to any employee who is an owner of more than 10&nbsp;percent of the voting power of Celldex, the exercise price of
stock options awarded under the 2008 Plan may not be less than 110% of the fair market value of the Common Stock on the date of the option grant. The term of each stock option may not exceed
10&nbsp;years from the date of grant, except that for a grant of an incentive stock option to any employee who is an owner of more than 10&nbsp;percent of the voting power of Celldex the term of
each stock option may not exceed 5&nbsp;years from the date of grant. The administrator will determine at what time or times each option may be exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award a stock appreciation right either as a freestanding award or in tandem with a
stock option.
The administrator may award stock appreciation rights subject to such conditions and restrictions as the administrator may determine. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award shares to participants subject to such conditions and restrictions as the administrator
may determine.
These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with Celldex through a specified restricted period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award deferred stock units to participants subject to such conditions and restrictions as the
administrator may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with Celldex through a specified restricted period. At the end of the
deferral period, the participants shall be paid, to the extent vested, in shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrestricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may grant (or sell at par value or for a higher purchase price determined by the Administrator)
shares that are
free from any restrictions under the 2008 Plan. Unrestricted stock may be issued to participants in recognition of past services or other valid consideration, and may be issued in lieu of cash
compensation to be paid to such individuals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may in its discretion grant awards entitling the grantee to receive cash-denominated payments and
determine the
terms and conditions of the cash-based award. Each cash-based award will specify a cash-denominated payment amount, formula or payment ranges as
determined by the administrator. Payment with respect to a cash-based award may be made in cash or stock, as the administrator determines. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may grant performance share awards that entitle the recipient to acquire shares of Common Stock
upon the
attainment of specified performance goals. The administrator determines the performance goals, performance periods and other terms of any such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend Equivalent Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award a dividend equivalent right either as a freestanding award or in tandem with
another award
under the 2008 Plan. The administrator may award dividend equivalent rights subject to such conditions and restrictions as the administrator may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=937270,FOLIO='45',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2>determine.
Dividend equivalents credited to the holder may be paid currently or may be deemed to be reinvested in additional shares of stock, which may thereafter accrue additional equivalents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Participants in the 2008 Plan are responsible for the payment of any federal, state or local taxes that the Company is
required by
law to withhold upon any option exercise or vesting of other awards. Subject to approval by the administrator, participants may elect to have the minimum tax withholding obligations satisfied either
by authorizing the Company to withhold shares to be issued pursuant to an option exercise or other award, or by transferring to the Company shares having a value equal to the amount of such taxes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control Provisions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of a "change in control" (as defined in the 2008 Plan), all outstanding stock options,
 stock
appreciation rights and dividend equivalent rights will not automatically become fully exercisable and all other outstanding awards with conditions and restrictions relating solely to the passage of
time and continued employment or service will not be fully vested, if provision is made in connection with the change of control for the assumption or continuation by the successor entity of such
outstanding equity awards, or the substitution of such outstanding awards with new awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares
and, if appropriate, the per share exercise prices, as such parties shall agree. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments and Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan is available for the grant of new awards until June&nbsp;15, 2027 (or March&nbsp;1, 2027 with
respect
to incentive stock options). In addition, the board of directors may amend or discontinue the 2008 Plan at any time, and the administrator may amend or cancel any outstanding award for the purpose of
satisfying changes in law or for any other lawful purpose. No such amendment may adversely affect the rights under any outstanding award without the holder's consent. Except in connection with a
merger, consolidation, reorganization, recapitalization, reclassification, stock dividend, stock split or other similar transaction or change in our capital stock, the administrator may not, without
obtaining stockholder approval, reprice or otherwise reduce the exercise price of outstanding stock options or stock appreciation rights or cancel outstanding options with an exercise price above the
current stock price in exchange for cash or securities. Additionally, stockholder approval will be required to amend the 2008 Plan if the administrator determines that this approval is required to
ensure that incentive stock options qualify as such under the Code, or that compensation earned under awards qualifies as performance-based compensation under the Code or as required under the
applicable securities exchange or market system rules. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Aspects Under the Code  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the principal federal income tax consequences of certain transactions under the 2008 Plan. It does not describe
all federal tax consequences under the 2008 Plan, nor does it describe state or local tax consequences. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No taxable income is generally realized by the optionee upon the grant or exercise of an incentive option. If shares
issued to an
optionee pursuant to the exercise of an incentive option are sold or transferred after two years from the date of grant and after one year from the date of exercise, then (i)&nbsp;upon sale of such
shares, any amount realized in excess of the option price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital
loss, and (ii)&nbsp;there will be no deduction for the Company for federal income tax purposes. The exercise of an incentive option will give rise to an item of tax preference that may result in
alternative minimum tax liability for the optionee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired upon the exercise of an incentive option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a "disqualifying
disposition"), generally (i)&nbsp;the optionee will realize ordinary income in the year of disposition in an amount equal to the excess </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=48,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=634942,FOLIO='46',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2>(if
any) of the fair market value of the shares at exercise (or, if less, the amount realized on a sale of such shares) over the option price thereof, and (ii)&nbsp;the Company will be entitled to
deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive option is paid by tendering shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an incentive option is exercised at a time when it no longer qualifies for the tax treatment described above (e.g.,&nbsp;if the holding periods described above are not satisfied),
the option is treated as a non-qualified option. In addition, an incentive option will not be eligible for the tax treatment described above if it is exercised more than three months following
termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule does not
apply. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Qualified Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No income is realized by the optionee at the time the option is granted. Generally (i)&nbsp;at exercise,
ordinary income is
realized by the optionee in an amount equal to the difference between the option price and the fair market value of the shares on the date of exercise, and the Company receives a tax deduction for the
same amount, and (ii)&nbsp;at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares
have been held. Special rules will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares. Upon exercise, the optionee will also be subject to
Social Security taxes on the excess of the fair market value over the exercise price of the option. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Parachute Payments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The vesting of any portion of an option or other award that is accelerated due to the occurrence of a change in control may cause a portion of
the payments with respect to such accelerated awards to be treated as "parachute payments" as defined in Section&nbsp;280G of the Code. Any such parachute payments may be non-deductible to the
Company, in whole or in part, and may subject the recipient to a non-deductible 20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on the Company's Deductions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of Section&nbsp;162(m) of the Code, the Company's deduction for certain awards under the 2008 Plan may be limited to the extent
that the Chief Executive Officer or other executive officer whose compensation is required to be reported in the summary compensation table receives compensation in excess of $1&nbsp;million a year
(other than performance-based compensation that otherwise meets the requirements of Section&nbsp;162(m) of the Code, to the extent an exception for performance-based compensation is still
applicable). Effective for taxable years beginning prior to January&nbsp;1, 2018, an exception to this deduction limit applied to "performance-based compensation", such as stock options and other
equity awards, that satisfies certain criteria. Under the Tax Cuts and Jobs Act of 2017, the performance-based pay exception to Section&nbsp;162(m) was eliminated, but a transition rule may allow
the exception to continue to apply to certain performance-based compensation payable under written binding contracts that were in effect on November&nbsp;2, 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2019 regarding shares of our common stock that may be issued under our
existing equity compensation plans, including our 2008 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=49,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=535515,FOLIO='47',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_dm19501_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2>Stock
Option and Incentive Plan (the "2008 Plan") and our 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="108pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="119pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities to<BR>
be issued upon exercise<BR>
of outstanding options<BR>
and rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under<BR>
equity compensation plan<BR>
(excluding securities<BR>
referenced in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,699,202</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44.87</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>674,422</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan and the 2004 ESPP Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not be
determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 ESPP Plan of which 81,288 shares are available for grants in the form of restricted
stock, deferred stock, performance shares or unrestricted stock under the 2008 Plan.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive awards under the 2008 Plan are subject to the discretion of the Compensation Committee. Therefore, it is generally not possible to
determine the incentives awards that will be granted or awarded under the 2008 Plan in the future to any person or the incentive awards that would have been granted or awarded if this amendment to our
2008 Plan had been in effect in the year ended December&nbsp;31, 2019. However, irrespective of whether the amendment to our 2008 Plan is approved, we expect to issue options to each of our
non-employee directors following the Annual Meeting in accordance with our non-employee director compensation policy, which is described in more detail in the section titled "Director Compensation."
Furthermore, information about awards granted in 2019 to our Named Executive Officers can be found in the table under the heading "Grants of Plan-Based Awards" in the section titled "Executive
Compensation." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting will be required to approve the
amendment of our 2008 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm19501_the_board_of_directors_recomme__the05291"> </A>
<A NAME="toc_dm19501_4"> </A>
<BR></FONT><FONT SIZE=2><B>  THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR"<BR>  APPROVAL OF THE AMENDMENT TO OUR 2008 STOCK OPTION AND INCENTIVE PLAN.    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=50,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=392451,FOLIO='48',FILE='DISK123:[20ZAD1.20ZAD19501]DM19501A.;9',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_do19501_1_49"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do19501_proposal_4__advisory_vote_on_e__pro02564"> </A>
<A NAME="toc_do19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION<BR>  (Proposal No.&nbsp;4)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and Section&nbsp;14A of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, our stockholders are entitled to vote to approve, on an advisory (nonbinding) basis, the compensation of our Named Executive Officers as disclosed in this
proxy statement in accordance with the Securities and Exchange Commission's rules. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in detail under the heading "Compensation of Executive Officers&#151;Compensation Discussion and Analysis," our executive compensation programs are designed to retain
and incentivize the high quality executives whose efforts are key to our long-term success. Under these programs, our Named Executive Officers are rewarded on the basis of individual and corporate
performance measured against established corporate and strategic goals. Please read the section of this proxy statement under the heading "Compensation of Executive Officers&#151;Compensation
Discussion and Analysis" for additional details about our executive compensation programs, including information about the fiscal year 2019 compensation of our Named Executive Officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee of our Board of Directors continually reviews the compensation programs for our Named Executive Officers to ensure they achieve the desired goals of aligning
our executive compensation structure with our stockholders' interests and current market practices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are asking our stockholders to indicate their support for our Named Executive Officer compensation as described in this proxy statement. This proposal, commonly known as a
"say-on-pay" proposal, gives our stockholders the opportunity to express their views on our Named Executive Officers' compensation. This vote is not intended to address any specific item of
compensation, but rather the overall compensation of our Named Executive Officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we are asking our
stockholders to cast a non-binding advisory vote "FOR" the following resolution at the Annual Meeting: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"RESOLVED,
that the compensation of the Named Executive Officers, as disclosed in the Company's Proxy Statement for the 2020 Annual Meeting of Stockholders pursuant to Item&nbsp;402 of
Regulation&nbsp;S-K, including the Compensation Discussion and Analysis, compensation tables and narrative disclosure is hereby APPROVED." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
say-on-pay vote is advisory, and therefore not binding on Celldex Therapeutics, the Compensation Committee or our Board of Directors. Nevertheless, our Board of Directors and our
Compensation Committee value the opinions of our stockholders, whether expressed through this vote or otherwise, and accordingly, the Board and Compensation Committee intend to consider the results of
this vote among the many factors they consider in making determinations in the future regarding executive compensation arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
approval of this Proposal No.&nbsp;4 will require the affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do19501_the_board_of_directors_recomme__the04322"> </A>
<A NAME="toc_do19501_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS<BR>  VOTE "FOR" THIS PROPOSAL NO. 4.<BR>  <BR>    STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=51,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=316160,FOLIO='49',FILE='DISK123:[20ZAD1.20ZAD19501]DO19501A.;8',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_do19501_1_50"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Proposals for 2021 Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder proposals submitted pursuant to Exchange Act Rule&nbsp;14a-8 for inclusion in Celldex's proxy statement and form of proxy for
our 2021 Annual Meeting must be received by Celldex on or before December&nbsp;30, 2020 in order to be considered for inclusion in our proxy statement and form of proxy. Such proposal must also
comply with the requirements as to form and substance established by the SEC if such proposals are to be included in the proxy statement and form of proxy. Any such proposal shall be mailed to:
Celldex Therapeutics,&nbsp;Inc., Perryville&nbsp;III Building, 53&nbsp;Frontage Road, Suite&nbsp;220, Hampton, NJ&nbsp;08827, Attn.: Secretary. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
by-laws state that the stockholder must provide timely written notice of such nomination or proposal and supporting documentation as well as be present at such meeting, either in
person or by a representative. A stockholder's notice shall be timely received by Celldex at our principal executive office not less than seventy-five (75)&nbsp;days nor more than one hundred twenty
(120)&nbsp;days prior to the anniversary date of the immediately preceding annual meeting (the "Anniversary Date"); provided, however, that in the event the annual meeting is scheduled to be held on
a date more than thirty (30)&nbsp;days before the Anniversary Date or more than sixty (60)&nbsp;days after the Anniversary Date, a stockholder's notice shall be timely if received by Celldex at
our principal executive office not later than the close of business on the later of (i)&nbsp;the seventy-fifth (75<SUP>th</SUP>) day prior to the scheduled date of such annual meeting or
(ii)&nbsp;the fifteenth (15<SUP>th</SUP>) day following the day on which such public announcement of the date of such annual meeting is first made by Celldex. Proxies solicited by our Board of
Directors will confer discretionary voting authority with respect to these proposals, subject to SEC rules and regulations governing the exercise of this authority. Any such proposal shall be mailed
to: Celldex Therapeutics,&nbsp;Inc., Perryville&nbsp;III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ&nbsp;08827, Attn.:&nbsp;Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do19501_where_you_can_find_additional_informaiton"> </A>
<A NAME="toc_do19501_3"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND ADDITIONAL INFORMAITON    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company files annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to
the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>. The SEC's website contains reports, proxy statements and other information
regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room,
located at 100&nbsp;F Street, N.E., Washington, D.C.&nbsp;20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC allows the Company to "incorporate by reference" certain information the Company files with it, which means that the Company can disclose important information to you by
referring you to those documents. The information incorporated by reference is considered to be part of this Proxy
Statement, and information that the Company files later with the SEC will automatically update and supersede previously filed information, including information contained in this document. We are
incorporating by reference the following, which include the information required by Item&nbsp;13(a) of Schedule&nbsp;14A in connection with Proposal 3:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Sections of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;7, 2019:
"Part&nbsp;II. Item&nbsp;7&#151;Management's Discussion and Analysis of Financial Condition and Results of Operations," "Part&nbsp;II. Item&nbsp;8&#151;Financial Statements and
Supplementary Data," "Part&nbsp;II. Item&nbsp;7A&#151;Quantitative and Qualitative Disclosure About Market Risk" and "Part&nbsp;II. Item&nbsp;9&#151;Changes in and Disagreements
With Accountants on Accounting and Financial Disclosure." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, all documents we file under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Proxy Statement and before the date of the Annual Meeting are
incorporated by reference into and deemed a part of this Proxy Statement from the date of filing of those documents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=52,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=540768,FOLIO='50',FILE='DISK123:[20ZAD1.20ZAD19501]DO19501A.;8',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_do19501_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
person, including any beneficial owner, to whom this Proxy Statement is delivered may request copies of reports, proxy statements or other information concerning the Company
(including the documents incorporated by reference herein) without charge, by written or telephonic request directed to our Corporate Secretary at Celldex Therapeutics,&nbsp;Inc., Perryville III
Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ 08827. A request for copies of reports, proxy statements or other information concerning the Company (including the documents incorporated by
reference herein) must set forth a good-faith representation that the requesting party was either a holder of record or a beneficial owner of our common stock on April&nbsp;21, 2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=53,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=770451,FOLIO='51',FILE='DISK123:[20ZAD1.20ZAD19501]DO19501A.;8',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_do19501_1_52"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do19501_other_matters"> </A>
<A NAME="toc_do19501_4"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this proxy statement, the Board of Directors does not intend to present at the Annual Meeting any matters other than those
described herein and does not presently know of any matters that will be presented by other parties. If any other matter requiring a vote of the stockholders should come before the meeting, it is the
intention of the persons named in the proxy to vote with respect to any such matter in accordance with the recommendation of the Board of Directors or, in the absence of such a recommendation, in
accordance with the best judgment of the proxy holder. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;SAM MARTIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Hampton,
NJ<BR>
May&nbsp;4, 2020 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=54,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=715879,FOLIO='52',FILE='DISK123:[20ZAD1.20ZAD19501]DO19501A.;8',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ma19501_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_appendix_a"> </A>
<A NAME="toc_ma19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix&nbsp;A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_celldex_therapeutics,_inc._200__cel03885"> </A>
<A NAME="toc_ma19501_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  2008 STOCK OPTION AND INCENTIVE PLAN<BR>  as amended and restated, effective as of June&nbsp;15, 2017    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_section_1._general_purpose_of_the_plan;_definitions"> </A>
<A NAME="toc_ma19501_3"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PURPOSE OF THE PLAN; DEFINITIONS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the plan is the Celldex Therapeutics,&nbsp;Inc. 2008 Stock Option and Incentive Plan (the "Plan"). The purpose of the Plan is to encourage and enable the officers,
employees, Non-Employee Directors and other key persons (including consultants and prospective employees) of Celldex Therapeutics,&nbsp;Inc. (the "Company") and its Subsidiaries upon whose judgment,
initiative and efforts the
Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company's
welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company's behalf and strengthening their desire
to remain with the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following terms shall be defined as set forth below: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Act</I></FONT><FONT SIZE=2>" means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Administrator</I></FONT><FONT SIZE=2>" means either the Board or the compensation committee of the Board or a similar committee performing the functions of the
compensation committee and which is comprised of not less than two Non-Employee Directors who are independent. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Award</I></FONT><FONT SIZE=2>" or "</FONT><FONT SIZE=2><I>Awards</I></FONT><FONT SIZE=2>," except where referring to a particular category of grant under the
Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Deferred Stock Awards, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards,
Performance Share Awards and Dividend Equivalent Rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Award Agreement</I></FONT><FONT SIZE=2>" means a written or electronic agreement setting forth the terms and provisions applicable to an Award granted under the
Plan. Each Award Agreement is subject to the terms and conditions of the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Board</I></FONT><FONT SIZE=2>" means the Board of Directors of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cash-Based Award</I></FONT><FONT SIZE=2>" means an Award entitling the recipient to receive a cash-denominated payment. "Change of Control" is defined in
Section&nbsp;20. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Code</I></FONT><FONT SIZE=2>" means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Covered Employee</I></FONT><FONT SIZE=2>" means an employee who is a "Covered Employee" within the meaning of Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Date of Grant</I></FONT><FONT SIZE=2>" means the date on which an Award under the Plan is granted by the Administrator, or such later date as the Administrator
may specify to be the effective date of an Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Deferred Stock Award</I></FONT><FONT SIZE=2>" means an Award of phantom stock units to a grantee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Disability</I></FONT><FONT SIZE=2>" means a grantee being considered "disabled" within the meaning of Section&nbsp;409A and Treasury
Regulation&nbsp;1.409A-3(i)(4), as well as any successor regulation or interpretation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=40447,FOLIO='A-1',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Dividend Equivalent Right</I></FONT><FONT SIZE=2>" means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on
the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Effective Date</I></FONT><FONT SIZE=2>" means the date on which the amended and restated Plan is approved by stockholders as set forth in Section&nbsp;22. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Act</I></FONT><FONT SIZE=2>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Fair Market Value</I></FONT><FONT SIZE=2>" of a share of Stock shall be, as applied to a specific date (i)&nbsp;the closing price of a share of Stock as of the
date of determination on the principal established stock exchange or national market system on which the Stock is then traded (or, if there is no trading in the Stock as of such date, the closing
price of a share of Stock on the most recent date preceding the date of determination on which trades of the Stock were recorded), or (ii)&nbsp;if the shares of Stock are not then traded on an
established stock exchange or national market system but are then traded in an over-the-counter market, the average of the closing bid and asked prices for the shares of Stock in such over-the-counter
market as of the date of determination (or, if there are no closing bid and asked prices for the shares of Stock as of such date, the average of the closing bid and the asked prices for the shares of
Stock on the most recent date preceding such date on which such closing bid and asked prices are available on such over-the-counter market), or (iii)&nbsp;if the shares of Stock are not then listed
on a national securities exchange or national market system or traded in an over-the-counter market, the price of a share of Stock as determined by the Administrator in its discretion in a manner
consistent with Section&nbsp;409A of the Code and Treasury Regulation&nbsp;1.409A-1(b)(5)(iv), as well as any successor regulation or interpretation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Incentive Stock Option</I></FONT><FONT SIZE=2>" means any Stock Option designated and qualified as an "incentive stock option" as defined in Section&nbsp;422
of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Non-Employee Director</I></FONT><FONT SIZE=2>" means a member of the Board who is not also an employee of the Company or any Subsidiary. "Non-Qualified Stock
Option" means any Stock Option that is not an Incentive Stock Option. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Option</I></FONT><FONT SIZE=2>" or "</FONT><FONT SIZE=2><I>Stock Option</I></FONT><FONT SIZE=2>" means any option to purchase shares of Stock granted pursuant
to Section&nbsp;5. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance-Based Award</I></FONT><FONT SIZE=2>" means any Restricted Stock Award, Deferred Stock Award, Performance Share Award or Cash-Based Award granted to a
Covered Employee that is intended to qualify as "performance-based compensation" under Section&nbsp;162(m) of the Code and the regulations promulgated thereunder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Criteria</I></FONT><FONT SIZE=2>" means the performance criteria used in performance goals governing Performance-based Awards granted to Covered
Employees which may include any or all of the following: (i)&nbsp;the Company's return on equity, assets, capital or investment, (ii)&nbsp;pre-tax or after-tax profit levels of the Company or any
Subsidiary, a division, an operating unit or a business segment of the Company, or any combination of the foregoing; (iii)&nbsp;cash flow, funds from operations, year-end cash and equivalents
balance or similar measure; (iv)&nbsp;total shareholder return; (v)&nbsp;changes in the market price of the Stock; (vi)&nbsp;sales or market share; (vii)&nbsp;earnings per share;
(viii)&nbsp;partnerships, collaborations, joint ventures, alliances and similar arrangements involving the Company; (ix)&nbsp;mergers, acquisitions and business combinations of or by the Company;
or (x)&nbsp;the Company's rights to intellectual property and scientific discoveries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Cycle</I></FONT><FONT SIZE=2>" means one or more periods of time, which may be of varying and overlapping durations, as the Administrator may select,
over which the attainment of one or more Performance </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=547688,FOLIO='A-2',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>Criteria
will be measured for the purpose of determining a grantee's right to and the payment of a Restricted Stock Award, Deferred Stock Award, Performance Share Award or Cash-Based Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Goals</I></FONT><FONT SIZE=2>" means, for a Performance Cycle, the specific goals established in writing by the Administrator for a Performance Cycle
based upon the Performance Criteria. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Share Award</I></FONT><FONT SIZE=2>" means an Award entitling the recipient to acquire shares of Stock upon the attainment of specified Performance
Goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Restricted Stock Award</I></FONT><FONT SIZE=2>" means an Award entitling the recipient to acquire, at such purchase price (which may be zero) as determined by
the Administrator, shares of Stock subject to such restrictions and conditions as the Administrator may determine at the time of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Sale Event</I></FONT><FONT SIZE=2>" shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an
unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation in which the outstanding shares of Stock are converted into or exchanged for securities of the successor entity and
the holders of the Company's outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately upon completion of
such transaction, or (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person or entity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Sale Price</I></FONT><FONT SIZE=2>" means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders,
per share of Stock pursuant to a Sale Event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Section&nbsp;409A</I></FONT><FONT SIZE=2>" means Section&nbsp;409A of the Code and the regulations and other guidance promulgated thereunder. "Stock" means
the Common Stock, par value $.001 per share, of the Company, subject to adjustments pursuant to Section&nbsp;3. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Stock Appreciation Right</I></FONT><FONT SIZE=2>" means an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the
Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation
Right shall have been exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiary</I></FONT><FONT SIZE=2>" means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent
interest, either directly or indirectly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Ten Percent Owner</I></FONT><FONT SIZE=2>" means an employee who owns or is deemed to own (by reason of the attribution rules of Section&nbsp;424(d) of the
Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Unrestricted Stock Award</I></FONT><FONT SIZE=2>" means an Award of shares of Stock free of any restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_section_2._administration_of_p__sec03872"> </A>
<A NAME="toc_ma19501_4"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS </I></FONT><FONT
SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(a)_administration_of_plan."> </A>
<A NAME="toc_ma19501_5"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administration of Plan. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Administrator. To the extent advisable or
 otherwise required by applicable law, regulation or rule, it is intended that each
member of the Administrator shall qualify as (i)&nbsp;a "non- employee director" under Rule&nbsp;16b-3, (ii)&nbsp;an "outside director" under Section&nbsp;162(m) of the Code and the
regulations thereunder and (iii)&nbsp;an "independent director" under the rules of any national securities exchange on which the shares of Stock are then listed. If it is later determined that one
or more members of the Administrator do not so qualify, actions taken by the Administrator shall be valid despite such failure to qualify. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(b)_powers_of_administrator."> </A>
<A NAME="toc_ma19501_6"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Powers of Administrator. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall have the power and authority to grant Awards
 consistent with the terms of the Plan, including the power and authority: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;to
select the individuals to whom Awards may from time to time be granted; </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=129214,FOLIO='A-3',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_4"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;to
determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock
Awards, Deferred Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, Performance Share Awards and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more
grantees; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;to
determine the number of shares of Stock to be covered by any Award; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;to
determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and
conditions may differ among individual Awards and grantees, and to approve the form of written instruments evidencing the Awards; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;to
accelerate the exercisability or vesting of all or any portion of any Award upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a
Change of Control or Sale Event; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;subject
to the provisions of Section&nbsp;5(b), to extend at any time the period in which Stock Options may be exercised; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;at
any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem
advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to
decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(c)_delegation_of_authority_to_grant_options."> </A>
<A NAME="toc_ma19501_7"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Delegation of Authority to Grant Options. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable law, the Administrator, in its
 discretion, may delegate to the Chief Executive Officer of the Company all or part of the Administrator's
authority and duties with respect to the granting of Options, to individuals who are (i)&nbsp;not subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and
(ii)&nbsp;not Covered Employees. Any such delegation by the Administrator shall include a limitation as to the amount of Options that may be granted during the period of the delegation and shall
contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not
invalidate any prior actions of the Administrator's delegate or delegates that were consistent with the terms of the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(d)_award_agreement."> </A>
<A NAME="toc_ma19501_8"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Award Agreement. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Awards under the Plan shall be evidenced by Award Agreements that set forth the terms,
conditions and limitations for each Award which may include, without
limitation, the term of an Award, the provisions applicable in the event employment or service terminates, and the Company's authority to unilaterally or bilaterally amend, modify, suspend, cancel or
rescind an Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(e)_indemnification."> </A>
<A NAME="toc_ma19501_9"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Indemnification. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither the Board nor the Administrator, nor any member of either or any delegate
 thereof, shall be liable for any act, omission, interpretation, construction or
determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and
reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys' fees) arising or resulting therefrom to the fullest extent permitted
by law and/or under the Company's articles or bylaws or any directors' and officers' liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between
such individual and the Company. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=614557,FOLIO='A-4',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_section_3._stock_issuable_unde__sec02429"> </A>
<A NAME="toc_ma19501_10"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(a)_stock_issuable."> </A>
<A NAME="toc_ma19501_11"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stock Issuable. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Stock reserved and available for issuance under the
 Plan shall be 20,000,000 shares, subject to adjustment as provided in
Section&nbsp;3(b) (the "Share Reserve"); provided that not more than 500,000 shares shall be issued in the form of Unrestricted Stock Awards, Restricted Stock Awards, Deferred Stock Awards or
Performance Share Awards. For purposes of this limitation, the shares of Stock underlying the Awards granted under the Plan that are forfeited, canceled or otherwise terminated (other than by
exercise) shall be added back to the shares of Stock available for issuance under the Plan. Shares (i)&nbsp;tendered or withheld in payment of an Option, (ii)&nbsp;tendered or withheld to satisfy
any tax withholding obligation or (iii)&nbsp;repurchased by the Company with Option proceeds, shall not revert to or be added back to the Share Reserve. Further, shares of Stock covered by a Stock
Appreciation Right, to the extent that it is exercised and settled in shares of Stock, and whether or not shares of Stock are actually issued to the grantee upon the exercise of the Stock Appreciation
Right, shall be considered issued or transferred pursuant to the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of
Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more than 2,000,000 shares of Stock may be granted to any one individual grantee during any one calendar
year period. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(b)_changes_in_stock."> </A>
<A NAME="toc_ma19501_12"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Changes in Stock. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;3(c) hereof, if, as a result of any reorganization,
 recapitalization, reclassification, stock dividend, stock split, reverse stock split
or other similar change in the Company's capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the
Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if,
as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company
or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance
under the Plan, including the maximum number of shares that may be issued in the form of Unrestricted Stock Awards, Restricted Stock Awards, Deferred Stock Awards or Performance Share Awards,
(ii)&nbsp;the number of Stock Options or Stock Appreciation Rights that can be granted to any one individual grantee in one calendar year and the maximum number of shares that may be granted under a
Performance-Based Award, (iii)&nbsp;the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iv)&nbsp;the repurchase price, if any, per share
subject to each outstanding Restricted Stock Award, and (v)&nbsp;the price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing
the aggregate exercise price (i.e.,&nbsp;the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights
remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding
Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and
conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional
shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(c)_mergers_and_other_transactions."> </A>
<A NAME="toc_ma19501_13"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Mergers and Other Transactions. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the effective time of the Sale Event, the Plan and all outstanding
 Awards granted hereunder shall terminate, unless provision is made in connection with the
Sale Event in the sole discretion of the parties thereto for the assumption or continuation </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=59,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=453255,FOLIO='A-5',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_6"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>by
the successor entity of Awards theretofore granted, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and
kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder). In the event of such termination, (i)&nbsp;the
Company shall have the option (in its sole discretion) to make or provide for a cash payment to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in
an amount equal to the difference between (A)&nbsp;the Sale Price multiplied by the number of shares of Stock subject to
outstanding Options and Stock Appreciation Rights (to the extent then exercisable (after taking into account any acceleration hereunder) at prices not in excess of the Sale Price) and (B)&nbsp;the
aggregate exercise price of all such outstanding Options and Stock Appreciation Rights; or (ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of
the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights held by such grantee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(d)_substitute_awards."> </A>
<A NAME="toc_ma19501_14"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Substitute Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may grant Awards under the Plan in substitution for stock and stock
based awards held by employees, directors or other key persons of another
corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or the acquisition by the Company or a Subsidiary of property or stock of the
employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the Administrator considers appropriate in the circumstances. Any substitute
Awards granted under the Plan shall not count against the share limitation set forth in Section&nbsp;3(a). </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_section_4._eligibility"> </A>
<A NAME="toc_ma19501_15"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;ELIGIBILITY </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grantees
under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and key persons (including consultants and prospective employees) of the
Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_section_5._stock_options"> </A>
<A NAME="toc_ma19501_16"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK OPTIONS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve. Stock Options granted under the Plan may be either Incentive Stock
Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a "subsidiary corporation" within the meaning of
Section&nbsp;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent
with the terms of the Plan, as the Administrator shall deem desirable. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(a)_exercise_price."> </A>
<A NAME="toc_ma19501_17"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price per share for the Stock covered by a Stock Option granted pursuant
 to this Section&nbsp;5 shall be determined by the Administrator at the
time of grant but shall not be less than 100&nbsp;percent of the Fair Market Value on the Date of Grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the option
price of such Incentive Stock Option shall be not less than 110&nbsp;percent of the Fair Market Value on the Date of Grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(b)_option_term."> </A>
<A NAME="toc_ma19501_18"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Option Term. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The term of each Stock Option shall be fixed by the Administrator, but no Stock Option
 shall be exercisable more than ten years after the date the Stock Option is
granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the Date of Grant. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=60,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=618832,FOLIO='A-6',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_ma19501_1_7"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(c)_exercisability;_rights_of_a_stockholder."> </A>
<A NAME="toc_ma19501_19"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercisability; Rights of a Stockholder. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Options shall become exercisable at such time or times,
 whether or not in installments, as shall be determined by the Administrator at or after the grant
date. The Administrator may accelerate the exercisability of all or any portion of any Stock Option upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of
Control or Sale Event. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ma19501_(d)_method_of_exercise."> </A>
<A NAME="toc_ma19501_20"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Method of Exercise. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Options may be exercised in whole or in part, by giving written notice of
 exercise to the Company, specifying the number of shares to be purchased. Payment
of the purchase price may be made by one or more of the following methods to the extent provided in the Option Award Agreement: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;In
cash, by certified or bank check or other instrument acceptable to the Administrator; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;Through
the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the optionee on the open market or that are beneficially owned by
the optionee and are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date. To the extent required to avoid
variable accounting treatment under applicable accounting rules, such surrendered shares shall have been owned by the optionee for at least six months; or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;By
the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company
cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker
shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Payment
instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the
exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full
purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Agreement or applicable provisions of laws (including the satisfaction of any withholding
taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation
method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for
itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless
exercise of Stock Options may be permitted through the use of such an automated system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;Annual
Limit on Incentive Stock Options. To the extent required for "incentive stock option" treatment under Section&nbsp;422 of the Code, the aggregate Fair Market
Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary
corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a
Non-Qualified Stock Option. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=61,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1034466,FOLIO='A-7',FILE='DISK123:[20ZAD1.20ZAD19501]MA19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_mc19501_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_section_6._stock_appreciation_rights"> </A>
<A NAME="toc_mc19501_1"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK APPRECIATION RIGHTS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(a)_exercise_price_of_stock_appreciation_rights."> </A>
<A NAME="toc_mc19501_2"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price of Stock Appreciation Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of a Stock Appreciation Right shall not
 be less than 100&nbsp;percent of the Fair Market Value of the Stock on the Date of Grant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(b)_grant_and_exercise_of_stock_appreciation_rights."> </A>
<A NAME="toc_mc19501_3"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant and Exercise of Stock Appreciation Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights may be granted by the
Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(c)_terms_and_conditio__mc102061"> </A>
<A NAME="toc_mc19501_4"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Terms and Conditions of Stock Appreciation Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights shall be subject to such
 terms and conditions as shall be determined from time to time by the Administrator. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_section_7._restricted_stock_awards"> </A>
<A NAME="toc_mc19501_5"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTED STOCK AWARDS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(a)_nature_of_restricted_stock_awards."> </A>
<A NAME="toc_mc19501_6"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Restricted Stock Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine the restrictions and conditions
 applicable to each Restricted Stock Award at the time of grant. Conditions may be based on
continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The grant of a Restricted Stock Award is contingent on the grantee
executing the Restricted Stock Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the Administrator, and such terms and conditions may differ among
individual Awards and grantees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(b)_rights_as_a_stockholder."> </A>
<A NAME="toc_mc19501_7"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon execution of the Restricted Stock Award Agreement and payment of any
 applicable purchase price, a grantee shall have the rights of a stockholder with respect
to the voting of the Restricted Stock, subject to such conditions contained in the Restricted Stock Award Agreement. Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated
Restricted Stock shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Stock are vested as
provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Stock shall remain in the possession of the Company until such Restricted Stock is vested as provided in
Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(c)_restrictions."> </A>
<A NAME="toc_mc19501_8"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restrictions. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered
 or disposed of except as specifically provided herein or in the
Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;18 below, in writing after the Award Agreement is
issued if a grantee's employment (or other service relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Stock that has not vested at the time of termination
shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase
price (if any) from such grantee or such grantee's legal representative simultaneously with such termination of employment (or other service relationship), and thereafter shall cease to represent any
ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of unvested Restricted Stock that are represented by physical certificates, a
grantee shall surrender such certificates to the Company upon request without consideration. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(d)_vesting_of_restricted_stock."> </A>
<A NAME="toc_mc19501_9"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Vesting of Restricted Stock. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator at the time of grant shall specify the date or dates
 and/or the attainment of pre-established performance goals, objectives and other conditions
on which the non-transferability of the Restricted Stock and the Company's right of repurchase or forfeiture shall lapse. Notwithstanding the foregoing, in the event that any such Restricted Stock
granted to employees shall have a performance-based goal, the restriction period </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=331479,FOLIO='A-8',FILE='DISK123:[20ZAD1.20ZAD19501]MC19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_mc19501_1_9"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>with
respect to such shares shall not be less than one year, and in the event any such Restricted Stock granted to employees shall have a time-based restriction, the total restriction period with
respect to such shares shall not be less than three years; provided, however, that Restricted Stock with a time-based restriction may become vested incrementally over such three-year period.
Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be
Restricted Stock and shall be deemed "vested." Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;18 below, in writing after the Award
Agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale
Event), a grantee's rights in any shares of Restricted Stock that have not vested shall automatically terminate upon the grantee's termination of employment (or other service relationship) with the
Company and its Subsidiaries and such shares shall be subject to the provisions of Section&nbsp;7(c) above. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_section_8._deferred_stock_awards"> </A>
<A NAME="toc_mc19501_10"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;DEFERRED STOCK AWARDS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(a)_nature_of_deferred_stock_awards."> </A>
<A NAME="toc_mc19501_11"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Deferred Stock Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine the restrictions and conditions
 applicable to each Deferred Stock Award at the time of grant. Conditions may be based on
continuing employment (or other service relationship) and/or achievement of pre-established performance goals and objectives. The grant of a Deferred Stock Award is contingent on the grantee executing
the Deferred Stock Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and
grantees. Notwithstanding the foregoing, in the event that any such Deferred Stock Award granted to employees shall have a performance-based goal, the restriction period with respect to such Award
shall not be less than one year, and in the event any such Deferred Stock Award granted to employees shall have a time-based restriction, the total restriction period with respect to such Award shall
not be less than three years; provided, however, that any Deferred Stock Award with a time-based restriction may become vested incrementally over such three-year period. At the end of the deferral
period, the Deferred Stock Award, to the extent vested, shall be settled in the form of shares of Stock. To the extent that a Deferred Stock Award is subject to Section&nbsp;409A, it may contain
such additional terms and conditions as the Administrator shall determine in its sole discretion in order for such Award to comply with the requirements of Section&nbsp;409A. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(b)_election_to_receive_deferr__(b)02620"> </A>
<A NAME="toc_mc19501_12"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Election to Receive Deferred Stock Awards in Lieu of Compensation. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole
 discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the
form of a Deferred Stock Award. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with
Section&nbsp;409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of
phantom stock units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The
Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the
Administrator deems appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="mc19501_(c)_rights_as_a_stockholder."> </A>
<A NAME="toc_mc19501_13"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A grantee shall have the rights as a stockholder only as to shares of Stock
acquired by the grantee upon settlement of a Deferred Stock Award; provided, however,
that the grantee may be credited with Dividend Equivalent Rights with respect to the phantom stock units underlying his Deferred Stock Award, subject to such terms and conditions as the Administrator
may determine. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=63,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=948308,FOLIO='A-9',FILE='DISK123:[20ZAD1.20ZAD19501]MC19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_me19501_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(d)_termination."> </A>
<A NAME="toc_me19501_1"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Agreement or,
 subject to Section&nbsp;18 below, in writing after the Award
Agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale
Event), a grantee's right in all Deferred Stock Awards that have not vested shall automatically terminate upon the grantee's termination of employment (or cessation of service relationship) with the
Company and its Subsidiaries for any reason. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_9._unrestricted_stock_awards"> </A>
<A NAME="toc_me19501_2"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;UNRESTRICTED STOCK AWARDS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant
or Sale of Unrestricted Stock. The Administrator may, in its sole discretion, grant (or sell at par value or such higher purchase price determined by the Administrator) an
Unrestricted Stock Award under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_10._cash-based_awards"> </A>
<A NAME="toc_me19501_3"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;CASH-BASED AWARDS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant
of Cash-Based Awards. The Administrator may, in its sole discretion, grant Cash-Based Awards to any grantee in such number or amount and upon such terms, and subject to such
conditions, as the Administrator shall determine at the time of grant. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award
pertains, the
conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated
payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be
made in cash or in shares of Stock, as the Administrator determines. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_11._performance_share_awards"> </A>
<A NAME="toc_me19501_4"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;PERFORMANCE SHARE AWARDS </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_nature_of_performance_share_awards."> </A>
<A NAME="toc_me19501_5"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Performance Share Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole discretion, grant Performance
 Share Awards independent of, or in connection with, the granting of any other Award under the
Plan. The Administrator shall determine whether and to whom Performance Share Awards shall be granted, the Performance Goals, the periods during which performance is to be measured, and such other
limitations and conditions as the Administrator shall determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_rights_as_a_stockholder."> </A>
<A NAME="toc_me19501_6"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A grantee receiving a Performance Share Award shall have the rights of a
 stockholder only as to shares actually received by the grantee under the Plan and not
with respect to shares subject to the Award but not actually received by the grantee. A grantee shall be entitled to receive shares of Stock under a Performance Share Award only upon satisfaction of
all conditions specified in the Performance Share Award agreement (or in a performance plan adopted by the Administrator). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(c)_termination."> </A>
<A NAME="toc_me19501_7"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award agreement or,
 subject to Section&nbsp;18 below, in writing after the Award
agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale
Event), a grantee's rights in all Performance Share Awards shall automatically terminate upon the grantee's termination of employment (or cessation of service relationship) with the Company and its
Subsidiaries for any reason. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_12._performanc__me102126"> </A>
<A NAME="toc_me19501_8"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_performance-based_awards."> </A>
<A NAME="toc_me19501_9"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance-Based Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any employee or other key person providing services to the Company and who is
 selected by the Administrator may be granted one or more Performance-Based Awards in
the form of a Restricted Stock Award, Deferred Stock Award, Performance Share Awards or Cash-Based Award payable upon the attainment of Performance Goals that are </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=638538,FOLIO='A-10',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_11"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>established
by the Administrator and relate to one or more of the Performance Criteria, in each case on a specified date or dates or over any period or periods determined by the Administrator. The
Administrator shall define in an objective fashion the manner of calculating the Performance Criteria it selects to use for any Performance Period. Depending on the Performance Criteria used to
establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division, business unit, or an individual. The Administrator,
in its discretion, may adjust or modify the calculation of Performance Goals for such Performance Period in order to prevent the dilution or enlargement of the rights of an individual (i)&nbsp;in
the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development, (ii)&nbsp;in recognition of, or in anticipation of, any other unusual or
nonrecurring events affecting the Company, or the financial statements of the Company, or (iii)&nbsp;in response to, or in anticipation of, changes in applicable laws, regulations, accounting
principles, or business conditions provided however, that the Administrator may not exercise such discretion in a manner that would increase the Performance-Based Award granted to a Covered Employee.
Each Performance-Based Award shall comply with the provisions set forth below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_grant_of_performance-based_awards."> </A>
<A NAME="toc_me19501_10"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant of Performance-Based Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Performance-Based Award granted to a Covered
 Employee, the Administrator shall select, within the first 90&nbsp;days of a Performance Cycle
(or, if shorter, within the maximum period allowed under Section&nbsp;162(m) of the Code) the Performance Criteria for such grant, and the Performance Goals with respect to each Performance
Criterion (including a threshold level of performance below which no amount will become payable with respect to such Award). Each Performance-Based Award will specify the amount payable, or the
formula for determining the amount payable, upon achievement of the various applicable performance targets. The Performance Criteria established by the Administrator may be (but need not be) different
for each Performance Cycle and different Performance Goals may be applicable to Performance-Based Awards to different Covered Employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(c)_payment_of_performance-based_awards."> </A>
<A NAME="toc_me19501_11"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment of Performance-Based Awards. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Following the completion of a Performance Cycle, the Administrator
 shall meet to review and certify in writing whether, and to what extent, the Performance Goals
for the Performance Cycle have been achieved and, if so, to also calculate and certify in writing the amount of the Performance-Based Awards earned for the Performance Cycle. The Administrator shall
then determine the actual size of each Covered Employee's Performance-Based Award, and, in doing so, may reduce or eliminate the amount of the Performance-Based Award for a Covered Employee if, in its
sole judgment, such reduction or elimination is appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(d)_maximum_award_payable."> </A>
<A NAME="toc_me19501_12"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Maximum Award Payable. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The maximum Performance-Based Award payable to any one Covered Employee under
 the Plan in respect of any calendar year is (i)&nbsp;250,000 shares of Stock
(subject to adjustment as provided in Section&nbsp;3(b) hereof) for a Performance-Based Award that is a Restricted Stock Award, Deferred Stock Award or Performance Share Award and
(ii)&nbsp;$1,000,000 in value for a Performance-Based Award that is a Cash-Based Award. In the case of Performance Goals based on Performance Cycles beginning and ending in different calendar years,
the number of shares of Stock or cash amount which is paid in respect of each calendar year during the Performance Cycle shall be determined by multiplying the total number of shares of Stock or cash
amount, as applicable, paid for the Performance Cycle by a fraction, of which (i)&nbsp;the numerator is the number of days during the Performance Cycle in that particular calendar year, and
(ii)&nbsp;the denominator is the total number of days during the Performance Cycle. The limitations in this Section&nbsp;12(d) shall be interpreted and applied in a manner consistent with
Section&nbsp;162(m) of the Code and the regulations thereunder. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1022043,FOLIO='A-11',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_13._dividend_equivalent_rights"> </A>
<A NAME="toc_me19501_13"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;DIVIDEND EQUIVALENT RIGHTS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_dividend_equivalent_rights."> </A>
<A NAME="toc_me19501_14"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dividend Equivalent Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A Dividend Equivalent Right may be granted hereunder to any grantee as a
component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award or
as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement. Dividend equivalents credited to the holder of a Dividend Equivalent Right
may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the
date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or
a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award may
provide that such Dividend Equivalent Right shall be settled upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be
forfeited or annulled under the same conditions as such other Award. A Dividend Equivalent Right granted as a component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award may
also contain terms and conditions different from such other Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_interest_equivalents."> </A>
<A NAME="toc_me19501_15"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Interest Equivalents. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any Award under this Plan that is settled in whole or in part in cash on a
deferred basis may provide in the grant for interest equivalents to be credited with
respect to such cash payment. Interest equivalents may be compounded and shall be paid upon such terms and conditions as may be specified by the grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(c)_termination._1"> </A>
<A NAME="toc_me19501_16"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Agreement or,
subject to Section&nbsp;18 below, in writing after the Award
Agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale
Event), a grantee's rights in all Dividend Equivalent Rights or interest equivalents granted as a component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award that has not
vested shall automatically terminate upon the grantee's termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_14._transferability_of_awards"> </A>
<A NAME="toc_me19501_17"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;14.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TRANSFERABILITY OF AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_transferability."> </A>
<A NAME="toc_me19501_18"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in Section&nbsp;14(b) below, during a grantee's lifetime, his or
 her Awards shall be exercisable only by the grantee, or by the grantee's
legal representative or guardian in the event of the grantee's incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by
the laws of descent and distribution. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and
void. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_administrator_action."> </A>
<A NAME="toc_me19501_19"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administrator Action. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;14(a), the Administrator, in its discretion, may
 provide either in the Award Agreement regarding a given Award or by subsequent
written approval that the grantee (who is an employee or director) may transfer his or her Awards (other than any Incentive Stock Options) to his or her immediate family members, to trusts for the
benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms
and conditions of this Plan and the applicable Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(c)_family_member."> </A>
<A NAME="toc_me19501_20"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Family Member. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of Section&nbsp;14(b), "family member" shall mean a grantee's child,
 stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse,
sibling, niece, nephew, mother-in-law, father-in-law, son-in- law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee's household
(other than a tenant </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1030092,FOLIO='A-12',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_13"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>of
the grantee), a trust in which these persons (or the grantee) have more than 50&nbsp;percent of the beneficial interest, a foundation in which these persons (or the grantee) control the
management of assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of the voting interests. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(d)_designation_of_beneficiary."> </A>
<A NAME="toc_me19501_21"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Designation of Beneficiary. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each grantee to whom an Award has been made under the Plan may designate a
beneficiary or beneficiaries to exercise any Award or receive any payment under any
Award payable on or after the grantee's death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If
no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee's estate. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_15._tax_withholding"> </A>
<A NAME="toc_me19501_22"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;15.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TAX WITHHOLDING</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_payment_by_grantee."> </A>
<A NAME="toc_me19501_23"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment by Grantee. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each grantee shall, no later than the date as of which the value of an Award or of
 any Stock or other amounts received thereunder first becomes includable in the
gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any
kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any
payment of any kind otherwise due to the grantee. The Company's obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding
obligations being satisfied by the grantee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_payment_in_stock."> </A>
<A NAME="toc_me19501_24"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment in Stock. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to approval by the Administrator, a grantee may elect to have the Company's
 minimum required tax withholding obligation satisfied, in whole or in part, by
authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that
would satisfy the withholding amount due. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_16._section_409a_awards."> </A>
<A NAME="toc_me19501_25"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;SECTION&nbsp;409A AWARDS.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent applicable, it is intended that the Plan and all Awards hereunder comply with the requirements of Section&nbsp;409A or an exemption thereto, and the Plan and all Award
Agreements shall be interpreted and applied by the Administrator in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section&nbsp;409A. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in the Plan or an Award Agreement to the contrary, in the event that any provision of the Plan or an Award Agreement is determined by the Administrator, in its
sole discretion, to not comply with the requirements of Section&nbsp;409A or an exemption thereto, the Administrator shall, in its sole discretion, have the authority to take such actions and to
make such interpretations or changes to the Plan or an Award Agreement as the Administrator deems necessary, regardless of whether such actions, interpretations, or changes shall adversely affect a
grantee, subject to the limitations, if any, of applicable law. To the extent that any Award is determined to constitute "nonqualified deferred compensation" within the meaning of Section&nbsp;409A
(a "</FONT><FONT SIZE=2><I>409A Award</I></FONT><FONT SIZE=2>"), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to
comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a "separation from service" (within the meaning of Section&nbsp;409A) to a grantee who is then
considered a "specified employee" (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is the earlier of (i)&nbsp;six months and one day after the
grantee's separation from service, or (ii)&nbsp;the grantee's death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or
additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any such Award may not be accelerated except to the extent permitted by Section&nbsp;409A. In no event whatsoever
shall the Company be liable </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=67,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=374128,FOLIO='A-13',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2>for
any additional tax, interest or penalties that may be imposed on any grantee by Section&nbsp;409A or any damages for failing to comply with Section&nbsp;409A. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_17._transfer,_leave_of_absence,_etc."> </A>
<A NAME="toc_me19501_26"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;17.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER, LEAVE OF ABSENCE, ETC.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the Plan, the following events shall not be deemed a termination of employment: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>(a)&nbsp;&nbsp;&nbsp;a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another;
or</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>(b)&nbsp;&nbsp;&nbsp;an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee's right to
re-employment is guaranteed either by a statute or by contract or under
the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_18._amendments_and_termination"> </A>
<A NAME="toc_me19501_27"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;18.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENTS AND TERMINATION</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or
for any other lawful purpose, but no such action shall </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>adversely affect rights under any outstanding Award without the holder's consent or (b)&nbsp;except as provided in Section&nbsp;3(b) or 3(c),
without the prior approval of the Company's stockholders, (1)&nbsp;reduce the exercise price of or otherwise reprice, including through replacement grants, any outstanding Stock Option or Stock
Appreciation Right or (2)&nbsp;cancel in exchange for, or otherwise exchange for, cash or other securities any outstanding Stock Option or Stock Appreciation Right with an exercise price at or above
the then-current Fair Market Value of the Stock</I></FONT><FONT SIZE=2>. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent
determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code or to ensure that
compensation earned under Awards qualifies as performance-based compensation under Section&nbsp;162(m) of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled
to vote at a meeting of stockholders. Nothing in this Section&nbsp;18 shall limit the Administrator's authority to take any action permitted pursuant to Section&nbsp;3(c). </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_19._status_of_plan"> </A>
<A NAME="toc_me19501_28"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;19.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STATUS OF PLAN</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights
greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator
may authorize the creation of trusts or other arrangements to meet the Company's obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such
trusts or other arrangements is consistent with the foregoing sentence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_20._change_of_control_provisions"> </A>
<A NAME="toc_me19501_29"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;20.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;CHANGE OF CONTROL PROVISIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a Change of Control as defined in this Section&nbsp;20: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Unless
provision is made in connection with the Change of Control for the assumption or continuation by the successor entity of Awards theretofore granted, or the
substitution of such Awards
with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall
agree, each outstanding Stock Option, Stock Appreciation Right and Dividend Equivalent Right shall automatically become fully exercisable. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=68,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=785176,FOLIO='A-14',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_15"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Unless
provision is made in connection with the Change of Control for the assumption or continuation by the successor entity of Awards theretofore granted, or the
substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares as such parties shall agree,
(i)&nbsp;conditions and restrictions on each outstanding Restricted Stock Award, Deferred Stock Award and Performance Share Award which relate solely to the passage of time and continued employment
will be removed. Performance or other conditions (other than conditions and restrictions relating solely to the passage of time and continued employment) will continue to apply unless otherwise
provided in the applicable Award Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;"Change
of Control" shall mean the occurrence of any one of the following events: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;any
"</FONT><FONT SIZE=2><I>Person</I></FONT><FONT SIZE=2>," as such term is used in Sections&nbsp;13(d) and 14(d) of the Act (other than the Company, any of its
Subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its Subsidiaries), together with all "affiliates"
and "associates" (as such terms are defined in Rule&nbsp;12b-2 under the Act) of such person, shall become the "beneficial owner" (as such term is defined in Rule&nbsp;13d-3 under the Act),
directly or indirectly, of securities of the Company representing 25&nbsp;percent or more of the combined voting power of the Company's then outstanding securities having the right to vote in an
election of the Company's Board of Directors ("Voting Securities") (in such case other than as a result of an acquisition of securities directly from the Company); or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;persons
who, as of the Effective Date, constitute the Company's Board of Directors (the "Incumbent Directors") cease for any reason, including, without limitation, as a
result of a tender offer, proxy contest, merger or similar transaction, to constitute at least a majority of the Board, provided that any person becoming a director of the Company subsequent to the
Effective Date shall be considered an Incumbent Director if such person's election was approved by or such person was nominated for election by either (A)&nbsp;a vote of at least a majority of the
Incumbent Directors or (B)&nbsp;a vote of at least a majority of the Incumbent Directors who are members of a nominating committee comprised, in the majority, of Incumbent Directors; but provided
further, that any such person whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of members of the Board of Directors or other
actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board, including by reason of agreement intended to avoid or settle any such actual or threatened
contest or solicitation, shall not be considered an Incumbent Director; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;the
consummation of (A)&nbsp;any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger,
would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule&nbsp;13d-3 under the Act), directly or indirectly, shares representing in the aggregate
more than 50&nbsp;percent of the voting shares of the corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), (B)&nbsp;any sale,
lease, exchange or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company; or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;the
stockholders of the Company shall approve any plan or proposal for the liquidation or dissolution of the Company. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, a "Change of Control" shall not be deemed to have occurred for purposes of the foregoing clause&nbsp;(i) solely as the result of an acquisition of
securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=69,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=317772,FOLIO='A-15',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2>number
of shares of Voting Securities beneficially owned by any person to 25&nbsp;percent or more of the combined voting power of all then outstanding Voting Securities; </FONT> <FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that if any person
referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company), then a "Change of Control" shall be
deemed to have occurred for purposes of the foregoing clause&nbsp;(i). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_21._general_provisions"> </A>
<A NAME="toc_me19501_30"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;21.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PROVISIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(a)_no_distribution."> </A>
<A NAME="toc_me19501_31"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Distribution. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may require each person acquiring Stock pursuant to an Award to
 represent to and agree with the Company in writing that such person is acquiring
the shares without a view to distribution thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(b)_delivery_of_stock."> </A>
<A NAME="toc_me19501_32"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Delivery of Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any provision of the Plan to the contrary, unless otherwise determined by the Administrator or required by any applicable law, rule or regulation, any obligation set
forth in the Plan pertaining to the delivery or issuance of stock certificates evidencing shares of Stock may be satisfied by having issuance and/or ownership of such shares recorded on the books and
records of the Company (or, as applicable, its transfer agent or stock plan administrator). Stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company
or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee's last known address on file with the Company.
Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or
by United States mail, addressed to the grantee, at the grantee's last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic
"book entry" records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any shares of Stock pursuant to the exercise of any Award, unless and
until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery of such shares is in
compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. All shares
of Stock delivered pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign
jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate to reference
restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and
representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to
require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the
discretion of the Administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(c)_stockholder_rights."> </A>
<A NAME="toc_me19501_33"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Until Stock is deemed delivered in accordance with Section&nbsp;21(b), no right to
 vote or receive dividends or any other rights of a stockholder will exist
with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(d)_other_compensation__me102232"> </A>
<A NAME="toc_me19501_34"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Compensation Arrangements; No Employment Rights. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Plan shall prevent the
Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be
either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company
or any Subsidiary. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=70,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=396539,FOLIO='A-16',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<A NAME="page_me19501_1_17"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(e)_trading_policy_restrictions."> </A>
<A NAME="toc_me19501_35"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Trading Policy Restrictions. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Option exercises and other Awards under the Plan shall be subject to such
 Company's insider trading policy and procedures, as in effect from time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_(f)_forfeiture_of_awards_under_sarbanes-oxley_act."> </A>
<A NAME="toc_me19501_36"> </A>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Forfeiture of Awards under Sarbanes-Oxley Act. </I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Company is required to prepare an accounting
 restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial
reporting requirement under the securities laws, then any grantee who is one of the individuals subject to automatic forfeiture under Section&nbsp;304 of the Sarbanes- Oxley Act of 2002 shall
reimburse the Company for the amount of any Award received by such individual under the Plan during the 12-month period following the first public issuance or filing with the United States Securities
and Exchange Commission, as the case may be, of the financial document embodying such financial reporting requirement. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_22._effective_date_of_plan"> </A>
<A NAME="toc_me19501_37"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;22.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;EFFECTIVE DATE OF PLAN</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
amended and restated Plan shall become effective upon approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present. No grants of
Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the
date the amended and restated Plan is approved by the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="me19501_section_23._governing_law"> </A>
<A NAME="toc_me19501_38"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;23.</FONT><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING LAW</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law
principles. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ADOPTION
AND APPROVAL OF PLAN (AS AMENDED AND RESTATED):<BR>
Date Amended and Restated Plan Adopted by Board: April&nbsp;17, 2015<BR>
Date Amended and Restated Plan Adopted by Stockholders/Effective Date: June&nbsp;10, 2015<BR>
Date Amendment Adopted by Board: March&nbsp;1, 2017<BR>
Date Amendment Adopted by Stockholders/Effective Date: June&nbsp;15, 2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=71,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=937006,FOLIO='A-17',FILE='DISK123:[20ZAD1.20ZAD19501]ME19501A.;7',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_mg19501_1_18"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="mg19501_amendment_to_celldex_therapeut__ame04206"> </A>
<A NAME="toc_mg19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AMENDMENT TO<BR>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  2008 STOCK OPTION AND INCENTIVE PLAN<BR>  as amended and restated effective June&nbsp;15, 2017    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;The
Celldex Therapeutics,&nbsp;Inc. 2008 Stock Option and Incentive Plan (the "Plan") is hereby amended by the Board of Directors of Celldex Therapeutics,&nbsp;Inc.
(the "Company"), subject to approval of the Company's stockholders, to among other things, increase the aggregate number of shares authorized for issuance under the Plan by 900,000 shares of common
stock, par value $0.01 per share, of the Company, as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3(a)
of the Plan is hereby amended and restated in its entirety as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"(a)&nbsp;Stock
Issuable.&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,233,333 shares, subject to adjustment
as provided in Section&nbsp;3(b) (the "Share Reserve"); provided that not more than 100,000 shares shall be issued in the form of Unrestricted Stock Awards, Restricted Stock Awards, Deferred Stock
Awards or Performance Share Awards. For purposes of this limitation, the shares of Stock underlying the Awards granted under the Plan that are forfeited, canceled or otherwise terminated (other than
by exercise) shall be added back to the shares
of Stock available for issuance under the Plan. Shares (i)&nbsp;tendered or withheld in payment of an Option, (ii)&nbsp;tendered or withheld to satisfy any tax withholding obligation or
(iii)&nbsp;repurchased by the Company with Option proceeds, shall not revert to or be added back to the Share Reserve. Further, shares of Stock covered by a Stock Appreciation Right, to the extent
that it is exercised and settled in shares of Stock, and whether or not shares of Stock are actually issued to the grantee upon the exercise of the Stock Appreciation Right, shall be considered issued
or transferred pursuant to the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award; provided, however, that Stock
Options or Stock Appreciation Rights with respect to no more 500,000 shares of Stock may be granted to any one individual grantee during any one calendar year period. The shares available for issuance
under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company." </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;21
of the Plan is hereby amended as follows to add a new subsection&nbsp;(g): </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"(g)&nbsp;</FONT><FONT
SIZE=2><I>Dividends</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in this Plan to the contrary, the Company shall not pay dividends with
respect to any unvested Award (including, without limitation, Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Deferred Stock Awards, Restricted Stock Awards,
Unrestricted Stock Awards, and Performance Share Awards). A Restricted Stock Award may provide that any dividends which would otherwise be payable on Restricted Stock shall accrue on such shares of
Restricted Stock and shall be payable only upon vesting of the shares subject to the Restricted Stock Award to which they relate." </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;Except
as amended herein, the Plan is confirmed in all other respects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Date
Amendment Adopted by the Board: March&nbsp;14, 2019 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Date
Amendment Adopted by Stockholders/Effective Date: June&nbsp;19, 2019 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=72,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=568915,FOLIO='A-18',FILE='DISK123:[20ZAD1.20ZAD19501]MG19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_mi19501_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A NAME="mi19501_appendix_b"> </A>
<A NAME="toc_mi19501_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix&nbsp;B    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="mi19501_amendment_to_celldex_therapeut__ame04206"> </A>
<A NAME="toc_mi19501_2"> </A></FONT> <FONT SIZE=2><B>  AMENDMENT TO<BR>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  2008 STOCK OPTION AND INCENTIVE PLAN<BR>  as amended and restated effective June&nbsp;15, 2017    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;The
Celldex Therapeutics,&nbsp;Inc. 2008 Stock Option and Incentive Plan (the "Plan") is hereby amended by the Board of Directors of Celldex Therapeutics,&nbsp;Inc.
(the "Company"), subject to approval of the Company's stockholders, to among other things, increase the aggregate number of shares authorized for issuance under the Plan by 1,900,000 shares of common
stock, par value $0.001 per share, of the Company, as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3(a)
of the Plan is hereby amended and restated in its entirety as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"(a)&nbsp;Stock
Issuable.&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 4,133,333 shares, subject to adjustment
as provided in Section&nbsp;3(b) (the "Share Reserve"); provided that not more than 100,000 shares shall be issued in the form of Unrestricted Stock Awards, Restricted Stock Awards, Deferred Stock
Awards or Performance Share Awards. For purposes of this limitation, the shares of Stock underlying the Awards granted under the Plan that are forfeited, canceled or otherwise terminated (other than
by exercise) shall be added back to the shares of Stock available for issuance under the Plan. Shares (i)&nbsp;tendered or withheld in payment of an Option, (ii)&nbsp;tendered or withheld to
satisfy any tax withholding obligation or (iii)&nbsp;repurchased by the Company with Option proceeds, shall not revert to or be added back to the Share Reserve. Further, shares of Stock covered by a
Stock Appreciation Right, to the extent that it is exercised and settled in shares of Stock, and whether or not shares of Stock are actually issued to the grantee upon the exercise of the Stock
Appreciation Right, shall be considered issued or transferred pursuant to the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or
types of Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more 500,000 shares of Stock may be granted to any one individual grantee during any one calendar
year period. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company." </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;Except
as amended herein, the Plan is confirmed in all other respects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Approved
by the Board of Directors on March&nbsp;19, 2020. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Approved
by Stockholders on [&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT FACE="SYMBOL" SIZE=2>&middot;</FONT><FONT FACE="times" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;], 2020 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=73,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=636850,FOLIO='B-1',FILE='DISK123:[20ZAD1.20ZAD19501]MI19501A.;6',USER='CHE109864',CD='27-APR-2020;14:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information. Vote by 11:59 P.M.   ET on June 17, 2020. Have your proxy card in hand when you access the web   site and follow the instructions to obtain your records and to create an   electronic voting instruction form. During The Meeting - Go to   www.virtualshareholdermeeting.com/CLDX2020 CELLDEX THERAPEUTICS, INC.   PERRYVILLE III BUILDING 53 FRONTAGE ROAD, SUITE 220 HAMPTON, NJ 08827 You may   attend the meeting via the Internet and vote during the meeting. Have the   information that is printed in the box marked by the arrow available and   follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone   telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on June   17, 2020. Have your proxy card in hand when you call and then follow the   instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it   in the postage-paid envelope we have provided or return it to Vote   Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE,   MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR   RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY   WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority to   vote for any individual nominee(s), mark &#147;For All Except&#148; and write the   number(s) of the AllAll The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 01) Karen L. Shoos 06) Harry H. Penner, Jr. 02) Anthony S. Marucci   03) Keith L. Brownlie 04) Herbert J. Conrad 05) James J. Marino The Board of   Directors recommends you vote FOR proposals 2, 3 and 4. For 0 0 0 Against 0 0   0 Abstain 0 0 0 2. To ratify the appointment of PricewaterhouseCoopers LLP as   our independent registered public accounting firm for the year ending   December 31, 2020. To approve an amendment to our 2008 Stock Option and   Incentive Plan including an increase in the number of the shares reserved for   issuance thereunder by 1,900,000 shares to 4,133,333 shares. To approve, on   an advisory basis, the compensation of the Company's Named Executive Officers   as disclosed in this proxy statement. 3. 4. NOTE: In their discretion, upon   such other business as may properly come before the annual meeting or any   adjournment or postponement. Please sign exactly as your name(s) appear(s)   hereon. When signing as attorney, executor, administrator, or other   fiduciary, please give full title as such. Joint owners should each sign   personally. All holders must sign. If a corporation or partnership, please   sign in full corporate or partnership name, by authorized officer. Signature   [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date 0000465447_1   R1.0.1.18 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1165" height="1510" src="g19952bii001.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=74,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=853477,FOLIO='',FILE="DISK124:[20ZAD2.20ZAD19502]1995-2-BI_ZAD19502.CHC",USER="DSLOAN",CD='Apr 25 11:49 2020' -->

<div style="page-break-before:always;"></div>
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice &amp; Proxy Statement and Annual Report on Form 10-K are available   at www.proxyvote.com CELLDEX THERAPEUTICS, INC. Annual Meeting of   Stockholders June 18, 2020 9:00 a.m. This proxy is solicited by the Board of   Directors The undersigned hereby appoints Sam Martin and Anthony S. Marucci,   and each of them, as the true and lawful attorneys, agents and proxies of the   undersigned, with full power of substitution, and hereby authorizes them to   represent and to vote, as designated on the reverse side, all shares of   common stock of Celldex Therapeutics, Inc. held of record by the undersigned   on April 21, 2020 at the Annual Meeting of Stockholders to be held virtually   via the Internet at www.virtualshareholdermeeting.com/CLDX2020, on June 18,   2020 at 9:00 a.m. local time, or at any adjournment or postponement thereof.   This proxy, when properly executed, will be voted in the manner directed   herein. If no such direction is made, this proxy will be voted in accordance   with the Board of Directors' recommendations. Continued and to be signed on   reverse side 0000465447_2 R1.0.1.18 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1166" height="1511" src="g19952bii002.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=75,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=801269,FOLIO='',FILE="DISK124:[20ZAD2.20ZAD19502]1995-2-BI_ZAD19502.CHC",USER="DSLOAN",CD='Apr 25 11:49 2020' -->

<BR>
<P><br><A NAME="20ZAD19501_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ca19501_1">ABOUT THE MEETING</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ce19501_1">PROPOSAL 1: TO ELECT SIX DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY ELECTED AND QUALIFIED</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ce19501_2">(Proposal No. 1)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da19501_1">Compensation Discussion and Analysis</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_1">Summary Compensation Table</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_2">Grants of Plan-Based Awards</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_3">Outstanding Equity Awards at Fiscal Year-End</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_4">Option Exercises and Stock Vested</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_5">Employment Agreements</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_6">Pension Benefits</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc19501_7">Nonqualified Deferred Compensation</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de19501_1">Potential Payments Upon Termination of Employment or Change in Control</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de19501_2">CEO Pay Ratio</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de19501_3">Director Compensation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de19501_4">Compensation Committee Interlocks and Insider Participation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de19501_5">Risk Considerations</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg19501_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di19501_1">REPORT OF THE AUDIT COMMITTEE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk19501_1">THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" THE ELECTION OF THE DIRECTOR NOMINEES.</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm19501_1">PROPOSAL 2: RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2020 (Proposal No. 2)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm19501_2">THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" THE RATIFICATION OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm19501_3">PROPOSAL 3: APPROVE THE AMENDMENT TO THE 2008 STOCK OPTION AND INCENTIVE PLAN (Proposal No. 3)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dm19501_4">THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" APPROVAL OF THE AMENDMENT TO OUR 2008 STOCK OPTION AND INCENTIVE PLAN.</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do19501_1">PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION (Proposal No. 4)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do19501_2">THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" THIS PROPOSAL NO. 4. STOCKHOLDER PROPOSALS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do19501_3">WHERE YOU CAN FIND ADDITIONAL INFORMAITON</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do19501_4">OTHER MATTERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_1">Appendix A</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_2">CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated, effective as of June 15, 2017</A></FONT><BR>
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_3">Section 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_4">Section 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_5">(a)  Administration of Plan.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_6">(b)  Powers of Administrator.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_7">(c)  Delegation of Authority to Grant Options.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_8">(d)  Award Agreement.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_9">(e)  Indemnification.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_10">Section 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_11">(a)  Stock Issuable.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_12">(b)  Changes in Stock.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_13">(c)  Mergers and Other Transactions.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_14">(d)  Substitute Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_15">Section 4. ELIGIBILITY</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_16">Section 5. STOCK OPTIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_17">(a)  Exercise Price.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_18">(b)  Option Term.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_19">(c)  Exercisability; Rights of a Stockholder.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ma19501_20">(d)  Method of Exercise.</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_1">Section 6. STOCK APPRECIATION RIGHTS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_2">(a)  Exercise Price of Stock Appreciation Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_3">(b)  Grant and Exercise of Stock Appreciation Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_4">(c)  Terms and Conditions of Stock Appreciation Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_5">Section 7. RESTRICTED STOCK AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_6">(a)  Nature of Restricted Stock Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_7">(b)  Rights as a Stockholder.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_8">(c)  Restrictions.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_9">(d)  Vesting of Restricted Stock.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_10">Section 8. DEFERRED STOCK AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_11">(a)  Nature of Deferred Stock Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_12">(b)  Election to Receive Deferred Stock Awards in Lieu of Compensation.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mc19501_13">(c)  Rights as a Stockholder.</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_1">(d)  Termination.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_2">Section 9. UNRESTRICTED STOCK AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_3">Section 10. CASH-BASED AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_4">Section 11. PERFORMANCE SHARE AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_5">(a)  Nature of Performance Share Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_6">(b)  Rights as a Stockholder.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_7">(c)  Termination.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_8">Section 12. PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_9">(a)  Performance-Based Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_10">(b)  Grant of Performance-Based Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_11">(c)  Payment of Performance-Based Awards.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_12">(d)  Maximum Award Payable.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_13">Section 13. DIVIDEND EQUIVALENT RIGHTS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_14">(a)  Dividend Equivalent Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_15">(b)  Interest Equivalents.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_16">(c)  Termination.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_17">Section 14. TRANSFERABILITY OF AWARDS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_18">(a)  Transferability.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_19">(b)  Administrator Action.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_20">(c)  Family Member.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_21">(d)  Designation of Beneficiary.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_22">Section 15. TAX WITHHOLDING</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_23">(a)  Payment by Grantee.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_24">(b)  Payment in Stock.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_25">Section 16. SECTION 409A AWARDS.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_26">Section 17. TRANSFER, LEAVE OF ABSENCE, ETC.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_27">Section 18. AMENDMENTS AND TERMINATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_28">Section 19. STATUS OF PLAN</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_29">Section 20. CHANGE OF CONTROL PROVISIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_30">Section 21. GENERAL PROVISIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_31">(a)  No Distribution.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_32">(b)  Delivery of Stock.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_33">(c)  Stockholder Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_34">(d)  Other Compensation Arrangements; No Employment Rights.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_35">(e)  Trading Policy Restrictions.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_36">(f)  Forfeiture of Awards under Sarbanes-Oxley Act.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_37">Section 22. EFFECTIVE DATE OF PLAN</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_me19501_38">Section 23. GOVERNING LAW</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mg19501_1">AMENDMENT TO CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated effective June 15, 2017</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mi19501_1">Appendix B</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_mi19501_2">AMENDMENT TO CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated effective June 15, 2017</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=DSLOAN,SEQ=,EFW="2241464",CP="CELLDEX THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g19952bii001.jpg
<DESCRIPTION>G19952BII001.JPG
<TEXT>
begin 644 g19952bii001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 7F!(T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $K%C\56<ND6^H+%<[9[D6BPE
M1Y@DWE"",XX()//05MUQ-KX:U*+QVS-&HT&*=]0A8.,^>Z!2NW.< EVZ8^:A
M;Z@]OZ_K<VI_%5M#)<%;2\FM+5BEQ>1JIBB8?>!RP8X[E5('X&F:GXJ_LW4+
M:U_L?4;G[6^RVEA:#9*=N[C=*". >H'2LU=+U73=)U+1+6P-PEY+.T-WYJ".
M-922?,!(?(+'[H.<#D=KE]H5PMWX62U0RP:;,?.<L 540L@/)R>2.E-?Y?\
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MW84'/08I+S'I?RT_X)F:SXEU>+3KM;:P@BN;>V$\T@N=WE!B=FT%,.<*20<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2-[%]1,CH0%O'0H5)['G..M7++Q)K5]8QS7&OVNFR0M#;A9X4VW<Y57D#<9
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M6@^'+3P]%*EJSNTI7>[I&G"C"@*BJH 'H*UJ* (/L=MYD\GV>'?< +,VP9D
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MV5M-(T9A9Y(E8E#U4DC[I].E6J* ,\>'](%NT TJQ$+,K-']G3:2HPI(QC(
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M1)=2-<7*VQ0VLJ/&2I8%D*[@,#N/?H#2P^+]+;RDEGVRN$)\N*5T0,2%)?8
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M110 4444 %%%% !1110 4444 %%%% !7FOBOQ#J$6NZY;6?]H>68+>PAE@D
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ML=L@XIKS_K2W]>8=;_UO<P-=6^N=5M;/3]7NY=4V0L([=BD-NH.7EEQPVX9
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M?GK^!0M_$M\]T]C#9I/J!E<>7)<A8D5$C+8<1YQF0  J2>Y Z-7QI+-F:#3
M;6.."29WN-KKYC%<!0I#$$>H!]:U&\+:4T(C,,PP_F>8MS*)=VT*?W@;=R%
M//..:E7P_IBPR1):*D<B1QLBL0-L9R@ !XQGM1H2D[&=XDU;4;#4((;(0B%[
M.YF=V;YE9%7:0-I!P3TR,_AS!!XKNXK61+RQA6[2""5/]* 602DJ"QVC:<J<
MA0WMGI6[?Z19ZF\3W<3.T0=5*R,G### [2,@CL?0>E0W/AS3;L'S8'W%(X]R
M3.C*(R2F&4@@@L>1SS27]?B6[?U\C'TWQ1?:KJVF1Q6L4,$OVE;E6D;(:,J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*'2]/UBTBM!I]RD+;)%=G8R$9RXPL2@'.YLY/''&7;^OZ] .MHI*6D 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLLDM[<Q(WVDHJ1Q-C)^3KC\_49XB3QW(?M&[35)6%9X?+N"PD4NJ8+; H/S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$L42R8;/ ^5@1WQWXJ#1I[6#Q0H2WADO+-;J2^NH+B.0S<_+NPV0<<?/MQC
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BLS7KC4+/39;G3?LI:%&D<7 8@@#.!@]:Q;/Q!K=S_ &;;
M^7IWVO4;<W2$!]D40"YW#.2<NH&,=Z%J!UM%9F@:LVLZ9Y\L0AGCED@F16R
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MM))$"WEP1,Q)2/CG Z9 'TK?HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3BEV84D?(HR<D ?C73T4 <_KVL>(=/ODBT;PS_:MN8PS3?;XX-K9.5VL,G@
MY]_:LS_A)_&G_0@_^5F'_"NSHH Y*R\1>+I[ZWBNO!/V:W>15EF_M:%_+4GE
MMH&3@<X'6M/Q#J>M:;]G_L30/[7\S=YO^F);^5C&/O#G.3TZ8]ZVJ* .,_X2
M?QI_T(/_ )68?\*/^$G\:?\ 0@_^5F'_  KLZ* ,S7K_ %33[%)=&TC^U;@R
M!6A^TK!M7!RVYN#R ,>_M7/_ /"3^-/^A!_\K,/^%=G10!QG_"3^-/\ H0?_
M "LP_P"%=!=W^J0^'EO+;2//U,QQL=/^TJN&.-R^8?E^7)Y[X]ZTZ* .,_X2
M?QI_T(/_ )68?\*/^$G\:?\ 0@_^5F'_  KLZ* *6D75[>:7#/J=A_9]V^[S
M+;SEEV88@?.O!R #^-<S_P )/XT_Z$'_ ,K,/^%=G10!QG_"3^-/^A!_\K,/
M^%;/A[4]:U+[1_;>@?V1Y>WRO],2X\W.<_='&,#KUS[5M44 <E>^(O%T%]<1
M6O@G[3;I(RQ3?VM"GF*#PVTC(R.<'I4/_"3^-/\ H0?_ "LP_P"%=G10!S^@
MZQXAU"^>+6?#/]E6XC++-]OCGW-D87:HR."3GV]Z@U?7?$]GJDT&F>$?[0M$
MV^7<_P!IQ1;\J"?D89&"2/PKIZ* .,_X2?QI_P!"#_Y68?\ "KFD:[XGO-4A
M@U/PC_9]H^[S+G^TXI=F%)'R*,G) 'XUT]% '/Z]K'B'3[Y(M&\,_P!JVYC#
M--]OC@VMDY7:PR> #GW]JS/^$G\:?]"#_P"5F'_"NSHH Y*R\1>+I[ZWBNO!
M/V:W>15EF_M:%_+4GEMH&3@<X'6M/Q#J>M:;]G_L30/[7\S=YO\ IB6_E8QC
M[PYSD].F/>MJB@#C/^$G\:?]"#_Y68?\*/\ A)_&G_0@_P#E9A_PKLZ* *6K
MW5[9Z7-/IEA_:%VFWR[;SEBWY8 _.W P"3^%<S_PD_C3_H0?_*S#_A79T4 <
M9_PD_C3_ *$'_P K,/\ A706E_JDWAYKRYTCR-3$<C#3_M*MEAG:OF#Y?FP.
M>V?:M.B@#C/^$G\:?]"#_P"5F'_"C_A)_&G_ $(/_E9A_P *[.B@#,T&_P!4
MU"Q>76=(_LJX$A58?M*S[EP,-N7@<DC'M[US_P#PD_C3_H0?_*S#_A79T4 <
M9_PD_C3_ *$'_P K,/\ A6SX>U/6M2^T?VWH']D>7M\K_3$N/-SG/W1QC Z]
M<^U;5% ')7OB+Q=!?7$5KX)^TVZ2,L4W]K0IYB@\-M(R,CG!Z5#_ ,)/XT_Z
M$'_RLP_X5V=% '/Z#K'B'4+YXM9\,_V5;B,LLWV^.?<V1A=JC(X).?;WHU[6
M/$.GWR1:-X9_M6W,89IOM\<&ULG*[6&3P <^_M7044 <9_PD_C3_ *$'_P K
M,/\ A4UEXB\73WUO%=>"?LUN\BK+-_:T+^6I/+;0,G YP.M=;10!B^(=3UK3
M?L_]B:!_:_F;O-_TQ+?RL8Q]X<YR>G3'O6-_PD_C3_H0?_*S#_A79T4 <9_P
MD_C3_H0?_*S#_A70:]?ZII]BDNC:1_:MP9 K0_:5@VK@Y;<W!Y &/?VK3HH
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M[5IT4 <9_P )/XT_Z$'_ ,K,/^%'_"3^-/\ H0?_ "LP_P"%=G10!2^U7O\
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M=.:OVFKZY/X?T_3QJ&H);ZKJWV>TOICBY-IC.[=_>..#7H&L^'!K&N:/J#7
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MK=%N;BXBU&1O.FC4@L'4@9P-V,CCBNQ\$ZLVKWFOSK=/<6WVX?9RSE@J&)"
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ML:N,%F&[YC^(JXW@"W.O:#JR76VXTJ 0/B+_ (^%"[1W^7&2>_6A>?\ 6_\
MP/O\@?\ G^2_X)Q'@R?^TY+2>_UKQH]VUV1MADD:T.), $[2-N.O/K5J3^UW
M7Q=KMMX@U2*?2+Z40VS3[K9D4!MIC/MD<$5TVA>#->\/6\=I9^)XOL22M(8C
MIJDD,VXC=O\ <\U%+\.KR:YU2,^(7CTK5+IKBYM(K10[@]4\PL2!P.@I>G;_
M "_X);:N_7\-3K]*O?[2TBSO=NW[1"DNWTW*#C]:MTR&%+>".&)0L<:A54=
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M_P!]4?V+;>LG_?5 $_\ :%K_ ,]TH_M"U_Y[I4']BVWK)_WU1_8MMZR?]]4
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M/_:%K_SW2C^T+7_GNE0?V+;>LG_?5']BVWK)_P!]4 3_ -H6O_/=*/[0M?\
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M?^>Z5!_8MMZR?]]4?V+;>LG_ 'U0!/\ VA:_\]TH_M"U_P">Z5!_8MMZR?\
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MWU1_8MMZR?\ ?5 $_P#:%K_SW2C^T+7_ )[I4']BVWK)_P!]4?V+;>LG_?5
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M4(C\P$2;#D%?85T.A:JNN:-;:@L30^<I)C8Y*$$@C/?D'FBP&A1110 4444
M%%%% !1110!YCXPT7Q!XCU[5)].M+<06,"06[W1='+@B4M#A2"<A1D\<4R:'
M4-4NKJ^.G7D9N;[2IMC0,"-N-_;^$YSZ5ZC13B[6\O\ ._X@]0HHHI %%%%
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MG.[!F);IC('RCMWKJ:&K"O<****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%<QX]T37->T.&V\.:E_9]VERLCR^>\64"L"N4!/4J<=.*X#_
M (5Q\2O^AO\ _*G<_P#Q- 'LU%>,_P#"N/B5_P!#?_Y4[G_XFC_A7'Q*_P"A
MO_\ *G<__$T >S45XS_PKCXE?]#?_P"5.Y_^)H_X5Q\2O^AO_P#*G<__ !-
M'LU%>,_\*X^)7_0W_P#E3N?_ (FN;MK[Q5H/Q.TW0]5\0WUPT=_;),$O97C=
M79&Q\V,C#8.1ZT ?15%%% !6-?\ _(:M_JG\ZV:QK_\ Y#5O]4_G0!LT444
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MM_JG\Z -FBBB@ HHHH **** "BBB@#(O/^0Y!_P'^=:]9%Y_R'(/^ _SK7H
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M_>\/GN-8@Y_!JZ>A:J_]=/\ ,'H[>7^?^04444 %%%% !1110 4444 %%%%
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M>9LS\N['&[&,XXS4/_%RO^I1_P#)F@#LZ*XS_BY7_4H_^3-'_%RO^I1_\F:
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MISC'R@9QZDY[5TU9UYI/VO7-.U'SMOV)95\O;G?O '7/&,>AJU%%<+=SR27
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MD^K.EM'=0LJ11RL&9E*G[B<$9!XXJ>W\11P>']*NYDO+M[[:D>V)!([E2PR
M=HZ'O@>N.:L:/HLUC-/=7]XMW>S1I$9$B\I%1<[55<G'+$DY.:9;^'O(T[1[
M7[3N_LV19-WEX\S",N,9X^]GOTILE;?UV_S"Y\31VL<1?3[]I6B,TL*HF^",
M'!9_FQ^"DD]@:?+XCMTNUAAMKNYC&SS9X$#)%O\ N[N=QSD'Y0< Y.*I^(O"
M$.O7T=V18^:(O);[78K<C;G.4W$;6&3SR.>0:G/A^XAO"]AJ'V6VF\O[1&(0
M7;8 !L8$!,@ 'Y3QTQ27F##3->N;W6=3M)],N+>"S<*)W:/;]T-SAR><Y''3
MK@\4V/Q=:/!+,]K>11+;/=0LZ+_I$2XRR8;/<<-M/(XJRFD31:O=W*7,?V2\
MP9X&A)<L$" J^X # '&T_6LY/"4K6C6USJ(ECBLI+*TQ!M,2. "7^8[VPHY&
MT>U'3^OZ[#5K^1<?Q-##IDM]/8WL,2%!&)%0&;>0%V_-@9)'WBN.^*T;"\^W
MVBSFWGMR208IU 92#[$@_4$@]C4%_IKWFC&RCG6-MJJ'>(2(V,<,AZJ<8(R.
M#U%,T#1QH>F"T#QM\[/B*/RXUR<[43)VJ/3)IZ:D]$:=%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %9\OA_2)]1%_-I5C)>AE<7#VZ&0,N-IW8S
MD8&/3 K0HH **** "L:__P"0U;_5/YULUC7_ /R&K?ZI_.@#9HHHH **** "
MBBB@ HHHH R+S_D.0?\  ?YUKUD7G_(<@_X#_.M>@ HHHH **** "BBL+Q5X
MHA\*V]C<7,6^&YNTMG;?M\H,#\W3G&.G% &[16+9>*+*6WNIKZ:WL8X;R2T5
MIIU D*G&03CD^E79]:TRUE,5QJ-G%(%#E))U4A3T.">E %VBLQ=:@EU[^S()
MK25TB:28+=+YL9^7 ,?7!#9SVX]:GM=7TZ^F:&TO[2>55#E(IE9@IZ' /3WH
M N453@U?3KF":>WO[66& D2R),K+&1UW$' Q[TC:UIBZ<-0;4;,61Z7)G7RS
MV^]G% %VBHX9XKF%)H)$EB<;E=&#*P]01UJ2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>Q%#T3_KS&NAVT,T=Q"DL,B212*&1T.58'H01U%/K(\)?\BAH_?_ $*'_P!
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M:-%%% !1110 4444 %%%% !6-?\ _(:M_JG\ZV:QK_\ Y#5O]4_G0!LT444
M%%%% !1110 4444 9%Y_R'(/^ _SK7K(O/\ D.0?\!_G6O0 4444 <Y=ZE;)
MXA$S:7;R+;2I:/?L1YL3R8PJC;DK\RY.X=>AJ;3M5>]U7SDTH+:S[X4O5;+M
MY9/WQM^52=VT[C]!FJ=YH][)J-U;);%K6\OH+UKG>H6,1[,J1G=DF,8P".>2
M,56T'PY<:9JUJ$L/LYMWE,]\)%/VN-MVQ.#NXR#A@ -O&<TUM_7;_.X/R-SP
M\5-I<[O^/C[5+]H_W]W\MNW'MBIM6NH[469EMTG\RZCC7=CY&;C<.#R*K:"A
M-YK-P/\ 53WQV>^V-$/_ (\K?E2^)=)&M6=K:R6R7,'VN)YHY,%2@/.0>OTI
M?R_+] ?7YE1[CP](MS-J]KI=LD%\R+)=>6 \H ^<%@/F(_'BM)[K1M+\HR36
M%IB-8XBSI'A"?E5?8D< >E<J_AR_TXO!I>GF&T,]QL%IY"LBN$V_?R%0X;.T
M;N!Q6GHFA3PRZ4U_:(?L^D+:R%RK;7RN5]^GTIQV7R_+^OO$^O\ 77^F:<SZ
M NL1S3MI@U/F-)',?G=,E03\W0YQZ&K%O_9NZU^S?9-QC9K;R]N2AQN*8_AY
M7...E4]/TKRM:UBYN+:/;<31-$Y"DL%C4?A@@UF>$;&5-3U%Y"K6UBYLK)E.
M1Y>[>?RW*G_;.DOZ_KU&]-3:\03P0:/(;NTBO('>.)X90"K!W5>000<9ST[5
M5TJTTH2:KIEKI%E;6T4BQRQQ0H$FW1JWS* !T;'.:E\4::^K:%+9I"L_F2Q;
MHVQAE$BELYXZ U3TO2'\.+KC:5I<0C>19;2VB98UE(B4$9Z+E@1DT+K_ %V'
MT.B    & .@%<EXAU..#5YYIO#]E?0Z5"D\EU+(OG1*V[_5J4/(VY^\*ZU22
MH+#!(Y'I7.3^&(M2\3WMYJ"3M:M% L:+<LL<A4N2'16PV,C[PI]2>AJ+/I#7
MRV:R6/VP'[2(,IY@)'^LV]<\GGWJ"TN?#J75[-9S:4MP4\R[>)HP^W^](1SC
MW-847A_4D\2EI/MKVWV]KQ9!);B$ C 'W?-W8^7&<8[]JANO#.H-H-O;0V:^
M<NFWD#J'0?O)-I49SW(//3UI+I_7]=BDKRLSH[$>'SIUU'IXTO["I87*P>7Y
M0/\ %O X^N:DLKS0[+2HI+"XTZ#3CGRV@=%AXR3@CCL2?H:PM7\.W]U_:*VB
M&)9+>S$?EL@+F*1F90&R <8'S#'/IFF67A^]<VTUU;W+EM46ZD6\> NJB(KN
M(B 0'..%R>^?1VU$MOZ['7V]Q#=P)/;2QS0N,I)&P96'J".M251N[DZ<;..W
MM5=)[@1,%8+L!!);&.>1T]\U>I 4KK4/LVI6-IY>[[47&_=C;M7=T[T^WU2P
MN[AH+:]MIIE4.T<<JLP4]"0#G%8]O'J]]KMJ^H6*01V+3$3I(I2?=\J[5R6'
MR]=V.>F:M^&]+_LW2(8YK:.*X5I2< $_,Y;J/7@T"->BJ]E-<3VJO=6WV:4E
M@8O,#X ) .1ZC!_&K% PHHHH **** "J0T;31!<0C3[0171W3IY"[93ZL,?-
M^-7:* ,H^'-/@TVZL],M+73TNEVRFV@5-PZ'[N.<$@'MFM-$6-%1  JC  ["
MG44 1?98,S'R8\S_ .M^0?O.,?-Z\<<U&NFV2(42SMU0LKE1$H&Y<;3TZC:N
M#VP/2K-% %4Z98M?&]:RMC=LGEF<Q+YA7^[NQG'M3A8V@4*+6 *(O) \L8$?
M]W_=]NE6** *MOI=C:6\<%M96T,,3;XXXXE54;U  P#SUJK?Z(EZ]M&#%%9Q
MS_:985A&99 VY3NSQ\W)X.:U**/, JHVEV#Z@M^UC;->*-JW!B4R >@;&:MT
M4 1I!%%+))'$BR2D&1E4 N0,#)[\<42P17"A9HTD4,' =00&!R#SW!&:DHH
MJ7.DZ?>1RQW5C:SI*XDD62%6#L  &((Y( '/M3X;"TMRA@M8(S'NV%(P-NXY
M;&.F3R?6K%% %2ZTG3[Z=)[NQM9YHP5226%690>H!(R*=_9ME]O^W?8[?[9M
MV?:/*7S-OINQG'M5FB@"M!IME;7<UU;V=O%<S_ZV5(E5Y/\ >8#)_&I8H8H
MPAC2,,Q<A% RQ.2?J34E% !1110 4444 %%%% !4<T$5S"\,\:2Q.-K(ZAE8
M>A!ZU)10!3ET?3IM/6PET^T>R7&VW:%3&,=,+C%)/IJ33V39"0VC%UB5< MM
MVK^ !/&/3TJ[10 57^P6FU!]E@PDAF4>6/E<DDL/1LD\]>35BB@"K::98V$D
MLEE96UN\S;I6AB5#(?5B!R?K4@M+=;=X!!$(7W;HP@VMN)+9'0Y).?7-344
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M/L]2A$-_:P7408,$FC#KD=#@]Z9=:787QA-W96TYA.8C+$K>7_NY''X5;HH
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M@ HHHH 3K4=M:P6<"P6L,<$*?=CB0*H^@'%2T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFY^PPR6NH2W0C,BC+><RJ6*E<CKMR1GM2RZW<W6B6US=7-S!-=)/-&CW\EN
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MV@N;*3S(B2N2I4@C@@J0""/0BK59NB:7)I=K*+B<7%S<3-/-(J;%+MZ+DX
M ZFN5\>:M)9W<RPW4D$\%IYT(-Z\(9LMRD:C]\>.0QV@8]32ZI"74[RBN);4
M)(_'BQM>R3&2156W2Z=&C4QCGR""CQYR?,&"#QGC%=5J\ES#H][)8KNNT@=H
M5QG+[3C]:3T5P6KL7**X'^T-ME?/I&IW=W:QV\4L\K7#RF*7S!O&XDE3MSN0
M<#'09J:;4VU6XNS8ZE,;5]5MHHY;>8[3&T:[@IZ8.3R._/6BVMOZWL%]&_ZV
MN=Q4,UU%!-!%(Q#SN4C 4G) +=1TX!ZTVRM%L;5($EGE5,X::0R/C/=CR?QK
M)UB,P^)-#GCFN4::=X9$%PXC=1%(W,>=N<@'.,\4^H=#>J"2\@BO(;5WQ/,K
M/&N#R%QNYZ?Q"N29[A=6N+L7EV7364MDC,[>4(V1,KLSM/))R1D=JS;"\:34
M[2:WO)[G6ET^[:XMI)F<13_)\NT\)SP  ,C!]Z72_P#6UP6KM_6[7Z'HU%>6
MQZO=_P!CW4G]J$0 VOGR6^HS7#QN9E#Y9D7RR5)S&#QZ#O>OM4GCLL6=Z9-$
M-_L6[GU&2)6C\H''VD!FV^9D;L]1C-.P+4]$J"[O(+&W\ZY?9'N5-V">68*.
MGN17#PO>ZA!:+=ZA<C;IEQ.#;7,J!RLBB-BV%+87N0 ?0@U5U._%W$IU2_GC
MO&DL6M+<3,JS(3$6;RP<-\Q;)(.,#IW$M;?UNU^@D]?Z\O\ ,])HK@%U+46\
M8R1/=11SB[9/(-]*6-O@X/V<)MQC!\S=UXSVJ;PVDTXTJ*>]OYEU+2&FN-]W
M(27!C *G=E#AS]W'YTEJK_ULW^A3T_KY';1RI-&LD3JZ-R&4Y!_&GUS'@'[%
M%X<AMK:Y:6XA4+<Q/<M*T+]-I#,=G3[O'TJWXF$LCZ3!'<SP+/>B.0PR%"R>
M6Y(R.>P]QVYH>XNYN45P7BR>ZTJZMK1+UHK5+5F@EN=2E@9YMW RJ,96 QA&
MZYZ&HM8U&5+E_MVI7-KJ*S6:VT$,[QK+&QC\P[.-P+%P21Q@#C/(M0.\%U$;
MQK4,?.5!(5VG&TD@'/3J#Q4I.!D]*P;6-K;Q?J,<<]R8Y+..;9).\BJY>0$J
MK$A>@X&!Q6'X6F.I0ZC8S7MQ>;H 7FAOI6^;)R"IPT$GJ@.!Z"ETN-JS^X[F
M.1)HUDB=71QE64Y!'J#3J\[MKQ+/X=Z>FE7F[8T,>H&34)%^S_+\ZM)\S0C(
M P -N>W6K-G+=W]EHL,E_+Y%Q?S1;[6[D?S(1&[ >:55FY4?..>.O>K:U:70
MGIK_ %_5CNZ@N[R"QB62Y?8CR)$#@G+,P51QZDBN&\575_INHI:17OE116BF
MSDN-0EB:2;<P/"HWGL,+\A]>ASD-UFZ275=FH7TT=^NIV@M[03,J/#NC)81Y
MP1NW?,1D$8R.E**NUZ_K8;T_KR/0J*@O6*6-PRDAA&Q!'4<5YY8:I(VA)-IV
MIWET!I\4U](]P\C12AX_4G82N_*C' SCGE+7^O7_ "!Z?UZ?YGHEQ=PVAA$[
M[3-((DX)RQS@<?0U7U'5[32G@6\:9!.XC1E@D=0Q( #,JD+DD#YB*XS4]5M-
M2DN9GU)_[-75K<+<13$*B>2,E7!X&<Y(/J<U<FF>;PB#YTMQ;C5(%MII6+-)
M%]H3:=QY8=<$]0 <FG%7>O=?I_F.VJ_KO_D=?-=103012,0\[E(P%)R0"W4=
M. >M35@ZQ&8?$FASQS7*--.\,B"X<1NHBD;F/.W.0#G&>*H+>1'Q-,EYJ-Y'
MJ"W:I;VD<IVO!M7GR_NLO+9?!(Z9&,46$]#K:*KW\QM]/N90)"8XF8>6,MP.
MP[FO/-/U>Z:*_%K?226QAMI))(KZ2[,:F4K*P=@-K!.H7A>U):NP[:7/2Z*X
MJ:]M5TV'[+JUX^BF^V7%XURQ"1^63\L^=VS?M!;=QDC-17-_;>7;"YUC4(=-
M\B5K2X:=HFGE#X4;@07XQM!SN')!H>G]>5Q'=45P-[KMU9VMW'J5W);7\]A:
M/%%O*DR9/F;!['&<=.,U:B,XU2&Y-[>,TNL2VK(;A_+\K8YVA,XZ@$'&1ZXI
MM:V_KM^HD[J_];-_H=BDJ2@F-U<*2IVG.".H^M,MKJ*[1VA8L$=HVRI&&4X(
MY]QUKF/"-KI]N=5TY;N<W9N9_,@>^E>1(RYVL 6)7((^88)ZY)JN&G7PX+=+
MV\4#6OLXD-P[2>7]HV[=Y);IQUI+6WG;\;#EHF^W_!_R.UHKAI+D6Z+:ZAJ-
MW;Z7%J$T+W#7;JX 0&-6ESNQDGJ>< <YQ6]X.G>Y\*V4LD\MPS!OWLQ)=AO.
M"<]\4+57%?6Q>OM6M-.E@BN&E\V<D1I%"\K'&,G" D 9&2>!FIQ=1&\:U#'S
ME02%=IQM)(!STZ@\5SNI:9!/X_TN9Y+H/]DG?"7<J+E6BQ\H8#'/(Q@]\XJU
M91FW\97\237+126D<QCDN'D57+N"5#$A> .!@<4=%\RFM#>HKAE@G7P=)J)U
M+43=2MY98W3X"^?M&!G ('&1R>^:L^!;BYDEOHKBZN+A52-E,\K2$'=(O!)]
M$7\L]230B;G84444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R-8\4Z3H,T<%_<L)Y%W+%%$\K[?7:@) ]S6O7+Z6,_$C7CW%G:@'\9* Z%K
M3?&FB:K?)9V]S(EQ)GRTGMY(2^.NW>HR?85O5S'C7[WA\]QK$'/X-73T+57_
M *Z?Y@]';R_S_P @HHHH *KW]_:Z792W=].D%O$,O(YP!5BN7\>C.DZ>#R#J
MEID>O[U:%JTN[0!_PL;P\.6GO%7N[6$X4#U)V<"NCMKF&\MH[BVE26&50R.A
MR&!Z$&I&Y4@^E<U\.O\ D1=.]A)_Z,:@#IJ*** "BBB@##U3QEHNCWK6=U<R
M-<J SQP023% >F[8IQGWI^D>+-(URY:VL;ES<*N\Q30O$Y7U < D>XJAX0'_
M !-O%![_ -J'G_ME'2ZYQX\\,'OMNAG_ ( *%TOU7Z7!]3IZ*** "L:__P"0
MU;_5/YULUC7_ /R&K?ZI_.@#9HHHH **** "BBB@ HHHH R+S_D.0?\  ?YU
MKUD7G_(<@_X#_.M>@ HHHH **** "J&MZS::!I-QJ%]*D<4*%@&<+O.,A1GN
M<<"K]9OB.TFO_#6IVMLF^>>UDCC7(&YBI &3Q0.-FU<@L/$=K+HT.H:A=Z9;
M1S-M1XKY9(F/H'(4$]1C':KUUJMA9;?M=]:P;L;?-F5<YX'4]^U96J6=W%J%
ME>PV!OTCM9+=H%=%*EMOS?.0,?*0><\\ U#I'AZ6TO-.^VPQ3+;:7]E>0X8;
MMPRHSSC IZ7_ *\_\OQ)Z?U_7_#'2Y&,YX]:Q;?Q;I5_:ZC+IMW;W<EBKL\<
M<RDL%&<C!/RGIFMKI7.+:7R1:[8_892MV9I8;@21^6VY  N-VX'.>HQ[U+OK
M;L4MUZFII^N:?J-BUS!>VKK&H,^R96$)QDAB.F/?%6;2]MM0MEN+*XAN('^[
M)"X=3]".*Y'4O#-_/!)':1&$?8;2,>6R LT4A9D&<C..!D%>?K6QX6L+JSAO
M9;Q;M9+J?S,73PF3[JKDB)0@Z=!GZU;M=D]%_70M7$-D=6^VW-[AK*+<87D4
M)"#G]X1U!(R,DXP#[U9GU*RMIX(;B\MXI;@XA1Y55I/]T$\_A7.^*;&2YU_3
M8;<KMOP;:\7/)A4B3./3AE_[:57\1^']2O=:NGM_MKV]Y!%#_H\ENJIM))WF
M12X'.04R<]NAI+H-G4C5+ ZB; 7MM]M"[OL_FKYF/7;G.*(=4L+BZ-M!>VTE
MP%W&))5+@9QG .<9KESI.KR>)K>5K:9;:'4#.65H1"4*,H8 ?O"_(W;N/2MK
MPWI1T[3W6XMTCG-U<2Y !.'E8@Y'JI%"VN#T-:65(8FDE=4C0;F9C@*/4FJ9
MUW2ELDO&U.R%H^=LYN$\ML=<-G!JMXITZYU709K:S9EFWQR *5!8*X8J-P*Y
M(&.01Z\5B:7H%\-1L[RZ@NC_ *<]Q)]KD@,BCR"@8B(! 2<<+GU)I+6X/0U=
M6U/2]($FMO>0-*]HRP1M<*JSA<N GJ3[9^E.MKRSBU[RX9X&O-019IH&N4\R
M)53Y2$^\0:YV;0-5M]*N8ETO[8UU826BQB6,"!M\C G<P^4AEZ9/RCCTZ:6Q
MN&U#1)1'\ELKB4[A\N8\#Z\^E"_K\0?3^NQ<AU;3[B\:TAO[62Z4$F%)E+@
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MU'N4E>5G '\'   ]:ZRBA ]0HHHH *QK_P#Y#5O]4_G6S6-?_P#(:M_JG\Z
M-FBBB@ HHHH **** "BBB@#(O/\ D.0?\!_G6O61>?\ (<@_X#_.M>@ HHHH
M **S)?$>EPZRFE27:K>OC$>UL9(R 6QM!(!(!.36G0 4450U?6K/0[47-^TR
MPY.6CMY)<8&22$4X''4\4 7Z*IZ;JEMJ]K]ILS,8LXS+ \1_)P#CGKBKE !1
M110 4444 0_98/M9NO(B^T%/+\W8-^W.=N[KC/:IJ** "BBB@ HHHH ****
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MD9=(P<$_,S!5''J2!0!/116?J>N6&CF,7TQ0R D!8V<[1C+$*#A1D9)X&>M
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M HHHH **9+(L,3R2'"(I9CC/ HAE2XACEC.4D4,I((R#R.#0 ^BBB@ HHHH
M**** "BH9KJ*":"*1B'G<I& I.2 6ZCIP#UJ:@ HHJK<:C:6UJMQ+.ODM(L0
M=?F!9F" <9_B(% %JBBB@ HHHH **AO+N&PLYKJY?9! ADD;!.U0,DX'-2JP
M=0R\@C(H 6BBB@ HHJE)JUI'JB:>6E:Z90VU(7=5!S@LP!5<X.-Q&<4 7:*0
MG R>E5YM0M8((9GF7RIG2.-U^8,6.%QCU)Z]* +-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%9&L>*=)T&:."_N6$\B[EBBB>5]OKM0
M$@>YH UZ*P=-\::)JM\EG;W,B7$F?+2>WDA+XZ[=ZC)]A6]0 4444 %%%5[^
M_M=+LI;N^G2"WB&7D<X H L45R__  L;P\.6GO%7N[6$X4#U)V<"NCMKF&\M
MH[BVE26&50R.AR&!Z$&@"6BBB@ HHHH **P]4\9:+H]ZUG=7,C7*@,\<$$DQ
M0'INV*<9]Z?I'BS2-<N6MK&Y<W"KO,4T+Q.5]0' )'N*%J#T-FBBB@ K&O\
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ME*^>&52Y$?23YB0<@[1SQUKHM<U>ZTI-]O8?:8TB>::1Y?+5$7&0#@Y8YX'
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M[D4L!W'7' -4U8E.YU%%>>K?ZHB6T,=Q>21:NSV=M,7;*!925D![$Q%CN[[
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M19EL[JWFE.;28S H4 ^0+N PS$Y7MVJW<Z[ MWIL,$H(O6!5S;RLDB%6("R
M;0W&<$],\5"=.U"\U.SO[M+6%XK6>&2.*9I "[)MPQ5<C"'/ Z]Z9!H5S%I7
MAZU9X=^FM&9B"<-MB9#MXYY(ZXIZ?UZO_@#_ ,F7SKM@-4_L[SF^TYVX\I]F
M[&[;OQMW8YVYSCM3#I]II_AV6RDDD%I' ZNYY8*0<G@=>3VK.DT&^_X2L:A
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MW^J?SK9K&O\ _D-6_P!4_G0!LT444 %%%% !1110 4444 9%Y_R'(/\ @/\
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M0VKOB>96>-<'D+C=ST_B% $]%0VUU%=H[0L6".T;94C#*<$<^XZU-0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.M_-EVV*&VB,;M(A0;78Y+#'!-<_XEU.RL_$'AR*ZNH8I&NW*J[@$@Q.H_\
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MEE=;(7BJNH27!:1'!*L2 $)'RLB\#-=CX6NI-2TV35'>4QWTK30(Y/R1<*F
M>F0H;'JQK1O[3[?926WVB:W$@P9(2 X'?!(/7I4MO!':V\<$"!(HE"(HZ  8
M HOI_7]=A?U_7XG-^++NVM]3TE-0U":QLI/.\UH[EH Q"C;N92".??KQWJII
M\5WJ]YI\-]>ZA$ITXRE8YFB9F$F$=L8.=IY'0YY!KJ9K".>_MKMF<26P<( 1
M@[@ <_E5JDM!O8XJ6]D77V07UQ_:HOTC2S\YMIM<C+>7G!&W)WXSGC/:J.EZ
MI<-\VF7US>ZGYEX+BWEN'<(BF3R_D)POS! " ,@GKCCT.JNG:?%IEF+:%G9
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M]C\MO-SGS-^1MV]MN-V<\]*LT4[C"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6-?_P#(:M_JG\ZV:QK_ /Y#5O\ 5/YT ;-%%% !1110
M 4444 %%%% &1>?\AR#_ (#_ #K7K(O/^0Y!_P !_G6O0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8U__ ,AJW^J?SK9K
M&O\ _D-6_P!4_G0!LT444 %%%% !1110 4444 9%Y_R'(/\ @/\ .M>LB\_Y
M#D'_  '^=:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5C7_\ R&K?ZI_.MFL:_P#^0U;_ %3^= &S1110 4444 %%%% !
M1110!D7G_(<@_P" _P ZUZR+S_D.0?\  ?YUKT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6-?_P#(:M_JG\ZV:QK_ /Y#
M5O\ 5/YT ;-%%% !1110 4444 %%%% &1>?\AR#_ (#_ #K7K(O/^0Y!_P !
M_G6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %8U__ ,AJW^J?SK9K&O\ _D-6_P!4_G0!LT444 %%%% !1110 4444 9%
MY_R'(/\ @/\ .M>LB\_Y#D'_  '^=:] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:_P#^0U;_
M %3^=;-8U_\ \AJW^J?SH V:*** "BBB@ HHHH HZM8RWUO']EF2&YAD$L3R
M1[T##(^9<@D8)Z$5DVWAJ[MR(6O87MGNA>38@V.T@(8A<' 4L ><G&1D]:U]
M5TN'5[(VTY=5W*X9&P00<_B/:J_]C:992Q31V)WB10I0,VT^IYZ>]"T8/4;>
M?\AR#_@/\ZUZR+S_ )#D'_ ?YUKT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C7_\ R&K?
MZI_.MFL:_P#^0U;_ %3^= &S1110 4444 %%%% %>^L8-1MC!<J60D$%6*LI
M'0A@00?<5G_V%#;W$$^;V]>-QM6>[9EC_P!O:3@D?B?2K6KVDEY8,D5Y)9NK
M!_-0XX!Y!]B.*KK86UI)#+)JEWAG 02W7RN3T&#USZ4(&)>?\AR#_@/\ZUZR
M+S_D.0?\!_G6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %8U__P AJW^J?SK9K&O_ /D-6_U3^= &S1110 4444 %%%%
M&1XCT^ZU&QACLXK6=DG61X;IRL<BC/!(5N^#T[5C:'H.K:=J/G3Z5HH5I21(
MEY*[P1G^",-$  /0$"NPHH6@/4R+S_D.0?\  ?YUKUD7G_(<@_X#_.M>@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU 50JC  P!2Z7&+17 6]K='QG#<IITL+_:YUGD6SD#F,H^W=<$X=20I  PO
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M0$+'&40 ,A'R@L&(4@8XXK=T&>:P\-:-%=6UV\SHD+CRR6B.T\OGD 8QGW%
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MM**** "BBB@ HHHH *QK_P#Y#5O]4_G6S6-?_P#(:M_JG\Z -FBBB@ HHHH
M**** &/(D>/,=5W':-QQD^E,NT:2SG1!EFC8 >IQ6;XCM;6ZM[07[6HM([D/
M*+E@$8;6&.>">15"UN=-M]5AMM*\0Q@/\WV.243HRY (0DY4\\ ''^S2MS:#
MORZEA(WAN]/CD&'2*-6'H1UK?K(O/^0Y!_P'^=:]4W=W)2LK!1112&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %92>)--DNI
M;>.69Y(@Y^6VE(?9]X(=N'(]%)-:M<I8>'-3B\0V]]=RPND,DQ+_ &F5V=7!
MVXC(V1XX&%Z]<T 7;+Q;:WGA^?51;7JQP[MT9M)MQP2!@;,MTY(! []*GM_$
MUE+HMOJ4HN(8YL!8VMI?,9B,[53;N;OR <XS4>E:9?6VE7.F70MA!B189HI&
M9F#ECEE*@+C(Z$Y]JJII6K_V?IC-'8"\TQQY2"=S',OEE#N;9E#R3P&QCO1W
M^0M=/G_P#0F\2Z7!;6\[7+%+G=Y(2)W9ROW@% )W#GC&>#QP:;)XITF*=(GN
M7WLJ/Q!(0JO]TL0N%!QU;%5;#P_<VTVGS2R0L\,]Q<3A<X#2Y.%XY )QDXI=
M3T"YO9=7:-X0+V&"./<3P4+$YX]_>F#;Z%^77].AU'["\[>>"%($3E0Q&0I<
M#:&(Y"YR?2I+;5[*\:U6WGWFZA,\.%/S(,9/3C[PZX-<]+X2G/B&2ZRCVDEV
MEV6>]N%*E0OR^2"(VY4$,?R.*?X-LQ]JU.^CF$UFTQAL67IY.XN<>V]V'T44
M+5?U_6_Y#?\ 7]>AT=]8V^HVCVUTF^)\$@,5((.001@@@@$$<BJ9?3?#%@J_
MO(XWD. !)/+*YY/]YW;@GN>*L:=-=S).;V-$99W6/8",Q@_*3GOC\/3BL[Q-
MHD^KK9RVIS+:2EQ&;J6V#@J5(\R/YEZ^A].]("R_B72HXT=KL!9(Q*GR-\ZE
M@O'')W$#:.<D<4^ZU[3[*^CL[B=EF?;TC<JNXX7<P&U<G@;B,]JY\^$+X1Z:
M8GM$?3"UQ I=W#SLY+!F?<VW:2,Y));.!@"I-6\)W-]KDUS&4>WNS$TN^^N(
M_+V8'$2$+)D ?>(P?7I3$;AU_3AJ1L#.?M .W_5/LW8SMWXV[L<[<Y]J1=?T
M]X(98Y9)%GMC=1".%V9XQC)"@9S\R\8SSTJG;:7J=K?20Q-:?V=)<O<F1B3-
M\V24VXQU/WMW3C'>JN@Z!J>GWE@;PV?V>PLGLXS%(S/("R$,05 '"<C)^I[)
M:K^NS_6Q3_K^O0NZ;XJLK_0%U619[:$XRLL$@;)Z!05!?.1C:#D\"IF\2Z6E
ME%=M<,L4LAA0&%]_F $["F-P;@\$9K-M]#U2+0[:R(LA+ITL;VK^:Q6<+G[X
MV#9D'MNP>>>E20Z!>-)!<W#6ZSMJ/VZ=$8E%'E&,*I(!/\/) [T^O]>7_!^X
M3_K\?^!]YJ6L-CJ%Q#J\*N\AC,<;OO7:N>?D;&TYZ\ ]JOU3OYKN)[06D:.K
MSA9MP)VQX.2,=#D#KQ^.*N4@,U/$.FR:B;)9V\X%ER8G$99>642$;21@Y .1
M@UFIXTL)-1E"RD6$5KYSRM;R*Q)<*"N1\RG/! (/K5&7PGJ=WK"S74\1A6>9
MO,%S*6*.CJ (B-B%=PZ9W8R33F\.:S=@K=G3T$=K';1F*1SOVR*VXY48R%Z#
M.#W-"Z?UT?\ P EY?UJBY>ZYH>LZ5-<*\UQ':.LA5;><X?G:615W,H(.>" 0
M<\CB_+K]G965E+>S$R74>]!!!)(9,*"=JJ"W?..N*S='\-7>GP:BDLD!-U;B
M)-C'@[I#SQT^<?K5Z'1YXY=&9FBQ8V[128)Y)15XXZ<'TH[V_K<2N[7\Q9O$
M%NUQID=K,"M\P9)&MY621"K'"N!M#<9PQZ \58EURPAU-;!YF%P2%XB<H&/(
M4OC:&/8$Y-9]KH%S!I6@VS/"7TZ57E()PP".OR\>K#KBH[W0;^;Q/'?VK00Q
M[T9YDGD1RH^\C1@;),XX8D$9XZ4^OS&_+L7-)\26^KWU_:Q07<;6<A0M+;2H
MK *ISEE !^;IG.!GH:6W\4Z3=023PW3&&./S3(87"E>GRDC#<\8&3GCK26%A
M?66LZB^VW>RO)?/\SS&$B-L5-NS;@CY<YW=^E0Q:-?6_@R+2X)HDO(X53>&(
M4D'D;L9&>1G&1G-+I]P^H7OC"PM=&GU&)+J987$;1"UE616X.&4IN48(.2,<
MCU%6[CQ!86EM!/.\Z"<$I&;67S,#J3'MW #N2!CO6+:>%KY-(UFWE>".6_97
MB'VB2<(0BC#.XW-RO7WZ5>N;+6);FUU*.&P6]2&2WD@:X<QA692&#[,DC:.-
MHSGJ.M#_ *^[_,1+?:YHIEMXKB<R/A+F+RHY'PI)"OE <+U!/3GGK6U6%HGA
M^31[N)O-22**PBM0>C%D9B3CL/F'>M%IKL:PD(C0V1@9F?!W"3< !GIC&??B
MGIL@?^1+'#!8QS.H$:,S2R,S=SU))_R *SX_%&DR6MQ<_:BD5N TC2PO'A2<
M!L, 2I_O#CWJ[JEBNIZ5=V3.46YA>(L.HW C/ZUS\_A_5-1M[HWILHYVM5M8
MEB=F0@-N+,2H(SC[H!QZG-) ]K_U_6YLP2Z?KODW,:R.;28M&9(WB*/M(SM8
M GY6/;'.:BU._P!*TJ_ANKUG6Z,31H4CDD(CR"Q*J#A00,L1@>M:U8NK:=J#
MZB+S3/LKO);FVD2X=E"@G(8$ Y(Y^7C/J*&^P;[_ -:A-XGM8=?M=+$5U(UQ
M"95FCMY'3JH'S!2,?-RV<#OC(J/3?%%M=:C/87+[+E;J2","%PC;>0-^-N[
M)QG/M3%T2\TZXTB33O(G6RM#9R">1HR4.SYP0K9/R=#CKU%*N@7(EA;?#A-4
M>]/)^XRL .G7YA_C3TO]_P">GX!T_KL_U+D7B/3)IYXDN&+0*SL3$X5@OWBK
M$8?'?:3BC1]0TR_>Y?3&9M["5V,;JKY& RE@ 00.J\<5@:;X-NK*5D=HVBAA
MFC@E:^N)2V\$#]VQV1\'G;G/;%=5IMLUGI=I;.5+PPI&Q7ID #BDOZ_K[@>Y
MF>+M2BTO1&N)('F=9$,2B"250^1M+!!T!YYQD@#KBD_MN2"#3([B4&XNY%7S
M#I]Q$C GI@Y\MO0.U7=<L)-2TJ6UA9%=V0@N2!PP)Z?2C5K"6_6S$3(/)NHY
MFW$\JIR<>]"W^:![/T*.O^)X-)Q!"V^\,D*[3$[(H=U7YF VJ2"2 2,^]:$>
MLV,IA"3Y,T\EO'\C<R)NW#IVV-STXK%U70=3FN[M;(V9MKVY@N)6F=@\9C*9
M"@*0<A!W&#ZTV#P[J4>I6RNUI]@M[Z>Z#B1O-<2K)QMVX&#)ZG(]*:V&[6-:
M#Q)IMR\R032R-$C286WD/F*."8_E_>#/'R9IEEK]N^A_VG=3KY/F.@*02*>'
M*JOEL-^_@ C')S@5%H.G:GIR6]I=-:?8[.#R(FB):2;& &;(&S '0$Y)ZU V
MA:A'X;>RMY8A<&[DG^69XPZ-,S[?,4;D.#C(&0>E#L(NMXHTI+2*Y:XD"2R-
M$BF"3S"X!)39MW;N#QC-2?\ "0:;Y$TQN"J00"YDW1L"(SG!P1D_=/'7BL?2
M_#%[:26;S/;_ +G4);M@LKO\K1,@&YADD$]3UZ^U)XCLUU'Q1I-M;S+YAR;R
M(=3;@AP3_P #0+_P)J+;"[_UU.J4AE!'0C-)(ZQ1L[G"J"2?055EFO%UBWAC
MC0V30R-*Y!W*X*[0#TP06]^*DOO^0?<_]<F_D:F3M&Y25W8H6FNVVN6T@T:Z
M43&,21O<6LFTJ>C!3L+K[@_C3=.UU?\ A&;;4]4=$9U&_P F-B&;. %0;F)/
M8#)K.\(:??/9Z7?W_P!F18=-2"!8'8[U8(2S9 VGY0,#/?FGW/ABYF\+V-@)
M$-S9RB4!;B2%7()X\Q,,O#=0.O8U4ERNR_K7_(F#YE?^MC1D\3Z7%9PW)GE9
M)BP58[>1Y/E^]E%4LN.^0,=Z?<>(],MC;B2Y)%P@D1DC=U"'HS,H(53ZM@5@
M'PKJ:64$4+0@,TKSQ?;[@ ,^,-YO+R8 .5.T-GMBB;PIJ8L=)AMWMDN+2TCM
MS<I<2Q/$R]6&T8E4_P!QL#\Z$-G1/KNGIJ8T]IS]H)"X$;% Q&0I?&T,1SM)
MS[4RWT33=,NI;^*(QOAB6>5V6,$Y;:I)5 2,G:!FL23PE<-XADN<I):RW:79
M9KVX4JRA?E\E2(VY4$,>GH<5T.M6Z7FAWUO(75);=T8H,L 5(X'<TKVC?J-:
MRMT*MKXHTR]%Q]FDN)&MXQ*Z"TEW["2 0NW+ X., YIVG:W!<6%C--.A>]=D
MB*1.@9AN.,,,J<*>N.0:Q/"=[-JNOWEVSV<L4=E! );.0R1E@SD@L0/FY!*_
MPY R:NS>'KP^$18030QZA"YFMY<DHL@D+KGC..<'CN:;T)6K&ZU<^'+](9]1
M>609DB7R1,"RJV) PCY:,$<[LK711-&\*-"5,94%2O0CMBN3U'PA.8].^PL)
M&M;4VKJ][/;9S@[]T7+<@Y4\'/45TVG6@T_3;:T7&V")8QMSC@8XR2?S)HZ!
MU,5O$4T_C'^R+8-'%#&KS-)83MYA);A9.%0 +]XY!)P.16FNK6]W'"EE<H)K
MN)WMF>)F4[< DCC@$CC(S38=.EC\27>H%D\F:UBA503N#*TA.>.GSC]:R](T
M+4K/4;$W)M/LMA%-%&T;L7D#LI!(*@+C;C&3]:7D4]RSI5]J>I:!-*9K.._C
MGFA\S[.QB/ER,N=F_/(7^]WJYX?OY=4\/Z??7 19KBW21P@(4$C)P"3Q^--T
M;39M.T^>"9D9Y+F>4%"2,/(S#MUPPS3] L)=*T"PL9V1I;>!(G*$E20,'&<<
M4]-?E^H.VMN[-"BBBD(**** "L:__P"0U;_5/YULUC7_ /R&K?ZI_.@#9HHH
MH **** "BBB@"AK,.FW&GM'JY@%LS#F9PH#=B#V/H1S7/Z8=,B\3QC^U=-NB
M+<I %V>:<NO4C@GTQ@^W>N@U>"PN[:.TU*)9([B4(BD'[_)!!'((QG/:N=T[
M[-;^)PTC>=;H&M(;@VFW][N!VEP-I(*D;L#GCKU(_%_784OA_KN;5Y_R'(/^
M _SK7K(O/^0Y!_P'^=:] PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YSP^^KRZIK:WE_;3117/EQ(MLRE#Y<9&"9#\
MO/3')R<C.*Z.J4>DVD6IR:A&DB7$H^?;,X1C@#)3.TG  SC/'6A;@8EG)?\
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MC9T/&-HZ>E"!%^HYIXK:%I9Y$CC499W. /QJ,6-N-0:^$?\ I+1"$OD_<!)
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ML+GP_JL5[/\ 9'BN'6V\JWWQB/>PY5&+#K@D#'&3]=C7Y473U@>VM[G[5(L
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M ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\
M;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\
MW]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_
M /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_
M ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\
M;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\
MW]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_
M /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_
M ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\
M;M__ -"QJ_\ W]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\
MW]M/_C]']NW_ /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]']NW_
M /T+&K_]_;3_ ./UM44 8O\ ;M__ -"QJ_\ W]M/_C]0S^*+FVFMHIO#>KJ]
MS(8HAOM3N8(SX_UW'RHQY]*Z"L77?^0OX<_["+_^DMQ0 ?V[?_\ 0L:O_P!_
M;3_X_1_;M_\ ]"QJ_P#W]M/_ (_6U10!B_V[?_\ 0L:O_P!_;3_X_1_;M_\
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M3U*J!FI** ,B\_Y#D'_ ?YUKUD7G_(<@_P" _P ZUZ "BBB@#%UW_D+^'/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MQ="_Y"_B/_L(I_Z2V];58NA?\A?Q'_V$4_\ 26WK:H **** "BBB@ HHHH Q
M?%?_ ""(/^PC8_\ I5%6U6+XK_Y!$'_81L?_ $JBK:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L:_P#^0U;_ %3^=;-8U_\
M\AJW^J?SH V:*** "BBB@ HHHH **** ,B\_Y#D'_ ?YUKUD7G_(<@_X#_.M
M>@ HHHH Q==_Y"_AS_L(O_Z2W%;5<YXPO)=-_L:_CT^^OUM;\O)#90F63:;>
M9,[?3+"L_P#X6/\ ]2AXN_\ !9_]E0!V=%<9_P +'_ZE#Q=_X+/_ +*C_A8_
M_4H>+O\ P6?_ &5 '9T5QG_"Q_\ J4/%W_@L_P#LJ/\ A8__ %*'B[_P6?\
MV5 '9T5QG_"Q_P#J4/%W_@L_^RH_X6/_ -2AXN_\%G_V5 '9T5QG_"Q_^I0\
M7?\ @L_^RH_X6/\ ]2AXN_\ !9_]E0!V=%<9_P +'_ZE#Q=_X+/_ +*C_A8_
M_4H>+O\ P6?_ &5 '9T5QG_"Q_\ J4/%W_@L_P#LJ/\ A8__ %*'B[_P6?\
MV5 '9T5QG_"Q_P#J4/%W_@L_^RH_X6/_ -2AXN_\%G_V5 '9T5QG_"Q_^I0\
M7?\ @L_^RH_X6/\ ]2AXN_\ !9_]E0!V=%<9_P +'_ZE#Q=_X+/_ +*C_A8_
M_4H>+O\ P6?_ &5 '9T5QG_"Q_\ J4/%W_@L_P#LJ/\ A8__ %*'B[_P6?\
MV5 '9T5QG_"Q_P#J4/%W_@L_^RH_X6/_ -2AXN_\%G_V5 '9T5QG_"Q_^I0\
M7?\ @L_^RH_X6/\ ]2AXN_\ !9_]E0!V=%<9_P +'_ZE#Q=_X+/_ +*C_A8_
M_4H>+O\ P6?_ &5 '9T5QG_"Q_\ J4/%W_@L_P#LJ/\ A8__ %*'B[_P6?\
MV5 '9T5QG_"Q_P#J4/%W_@L_^RH_X6/_ -2AXN_\%G_V5 '9T5QG_"Q_^I0\
M7?\ @L_^RH_X6/\ ]2AXN_\ !9_]E0!V=8NN_P#(7\.?]A%__26XK&_X6/\
M]2AXN_\ !9_]E6?J7CB6\OM)FC\)>*PMG=M/(&TTY*F&6/CYNN9!^&: /0Z*
MXS_A8_\ U*'B[_P6?_94?\+'_P"I0\7?^"S_ .RH [.BN,_X6/\ ]2AXN_\
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M*@#LZ*XS_A8__4H>+O\ P6?_ &5'_"Q_^I0\7?\ @L_^RH [.BN,_P"%C_\
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M:U%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g19952bii002.jpg
<DESCRIPTION>G19952BII002.JPG
<TEXT>
begin 644 g19952bii002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 7G!(X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZ_Y&1IWCW7D\%R^*-7L=.6Q\@>1#;L_FR2E]H)SD*I_$U5N[CQ#-XW\'?\
M"16NGQ,TL[QO92.1S']U@PX(]02#750>"[;_ (0)/"]Y.T\*P^49E38<YR&
MR<$''K6?9^ ]176=(U'5/$L^H/IC/Y<;VJ(I4KM ^4YSZL<Y]JK3F$K\OG9_
MD8EGXHN="\)7][I6G68F;7Y+;R29-LFY\$Y+$AC^0]*W]*\4:U#XJN='\1VE
MC%BS-]#)9N[ (&P58L!D^X IO_"O?^)+)I_]I??U;^TO,\CI\V[9C=^OZ5L3
M^'1-XM76VG# 6+69MRG#9;=G=G\,8J>G]?R_YC2W_KK_ )'&7/Q \4)X4E\2
MQZ9I:Z9-(JVJL[F5%+[=SC@$'M@C''!KO->>]7P[>OIIA6[$#-&92P4''MST
MS7CC:+XAN-,E\,+I^O10_:5-O;O"AM(%W[B3<<%QC.!@ >YKW":!9[22!R=K
MH4)'H1BB:O!V_K1 G::O_6IXWY^K/\._"4]_]GN&.L0/;>6[;Y%^;_6%OXBV
M>1Q79VWC+5--U+6+/Q-:62&QLC?QO9.S*8\D;3NQELCKP/:FVWP[N8M$TS3)
M]<,\.FZA'=VY-HJE43/[OAN>2?F/Y5L7GA."_P#$-[J-U-O@O-/^P26^S'R[
MB2V[/OTQ52>]O/\ )6_$%LK]+?GK^!QOAGXN2:MXAL[*\_LUHK]]D:6HF$MN
MQ' D+J%;)X^6O0/$.KQZ#X?OM2F("VT+. >[=A^)P*Q=!\&ZAI%Y;?:/$M]>
M6%DNVUL]BQ!1C $C+S)@=,U?\6>&SXITZ"Q:Z$%NMPDTZ^5O\Y5.=G48R<<\
M].E3))JR".CNSSGP'=67A[Q-I AU2WNY->M6^W+%<+(8[G.\%@#QPQ7ZUV%W
MXUN-)G\30ZG% 'TR);BTV*5\^-AA<Y)R=WRDC%3Z[\.](U*RC72K6RTB]AF2
M:*[M[- RE3G!QMR#]:?XD\#6_B36=+U">Y:(V9 GC5.+E P8*W/ ##/>F]?+
M?[O^!MZ M-?ZO_P?S,_7/%NMZ/HFE/+_ &):7UW#YD\M],8X8S@'8J F1CSV
MR!CWK)N?%W_"3?#_ $[4[NPM9)#JL,#)ND$>X/C>N"K>X!S[YKI_$7@Z;6->
MLM8L-6DTZ[MXS"S"W28-&3D@!N%;WYJE'\._+\/_ -E#5&9%U,:@LCP9;&[=
ML/S<G_:X^E"WN^_ZK]!-:67]:/\ 4IZ=>/I_COQU=QQ+*\,%LZHTBQAB(SP6
M8@*/<TSPK\0K_5O%:Z-?MHUP)H&F233)'<0X_A<MPQ_W>/SK7O\ P%%J5UXC
MDN+YQ'K<<*%4CP8?+& <Y^;)[8%1:1X%O-/UC3=2O-=:]FLHI(-IM$B0HPX"
MA3\I'4D[L^U+_+]/\RIZ[?UM_P $X_PEKOB/P_X%;4K33[";1[6YF:<22L)Y
M%W\E !M 'OG.*Z>>_@NOB)F.UBS-X?:9;@E_,VE_NXW;<=_NY]ZKVWPMNX-*
M.DGQ1=G2YI6DNK9+=%$H)SA6R64>O)SZ"NA?PDG_  E U:*Y$<:Z:=/6W$><
M#=D-NS^&,?C1NOE^C7YCO[S?];I_D<1X;G2+P_\ #U&M89GDGE"/(7!B.&Y7
M:P'Y@U)X;U/Q=!#XPN\Z;<2VMQ(=A\UR95P=B#(_=[<XYSFNFT_P%]ALO#=O
M_:._^Q)7DW>1CSMV>/O?+U]ZEM-!G\+ZCK>K1W=S>6-V7N6TV&U5I#(<9*MG
M+' P%XZTY/63]?T(@K12?E^HV+Q?+J>H^';;24@<:C ;NZ+@GRH0!TP1@ECC
MG/0U=\6^(YM MK..QM1=:A?W"VUM&[;4W'G+'T %8/PR\.2Z:-1U.YM;FU%U
M*4L[>Y&)(+<,6"D?P\L>/:NC\3>&H?$ME#$]Q+:W%M,L]O<0XW12#H>>"/:B
M5M/Z_K3\077^OG]_X&):>)/$2ZA=Z!JEOI<>M&S-U9S0/(;:3G&&!^88-9?P
M8TR9-#NM7NDMS+?R']\DDC22;68'>&.WKTV]NM='H7A&>PU.;5=8U:75M4DA
M^SK.\*Q+''G.%1>![FKGA+P]_P (MX=@TO[3]I\IG;S?+V9W,6Z9/KZT*ROW
M_P"#_P ,-ZJWG^G^9YOXBM-&NOB7KO\ ;7AS5]:"Q6_EC3XW?RODYW;67KQC
M.>AK4L-0UOP1\-[F]-HX;[<!96=ZQ9XH'=55&(.0>N/3]*[73] ^P^)]6UC[
M3O\ [02%?*V8\ORP1USSG/H*7Q/H/_"2:1]A^T?9_P!]'+OV;_N.&QC(ZXQ2
MCHDO3\QSU;?];&%?^)?$>FII^FS6>F2Z]J<T@MTC>0011J =SD\DC/.,9[4_
M3O$FOW,NJZ)=6VG1>(;.!9X6C+O;3J>G!(8<\<GWK4\3>%U\0&SN(+V6PU&Q
M<O:W42ABA(P05/# ]Q6?:>"KVUM-2F.O2RZYJ$:Q2:E);C]V@Z!(P0%X]^O-
M'1_UZ?\ !%V_KKJ5O#'C'5O%EVRV5K;VT%I;[;UIT8L+KG]VH##Y01DGGTJ*
M+QW?W'A:PDAM[8:]=7WV!K=E8QI(K8<D YP%&>O<5?T7P%#X9U>WO-%NV@@\
MCR;RW:/?]J(Z/G(VMDGGFL?PKHLFI_$#4/$4FFW^GV*Y,$%\GEL9V 620+D\
M84<]\U2M?^N_Z_Y"V7]=OTW^\Z/Q]G_A -<SU^QR?RKSS2YI+3P+-X165O/N
M[BWB@S][R;A0[$?3]Y^5>J:_I7]N:!?:9YWD_:X6B\S;NVY&,XR,_G6+#X"M
M8_$>D:PUP6FTVR%IM\O D(7 ?KQ@%N.>HYXJ5UOUM^K_ .!\P=]+=+_I_P $
MYCPEJ]QX<^$UK+8K9^9]JEB$E[.(HHQYC?,QR"W3HO)JM<^.M8\0^!_$J02:
M<+K3@HDN[-Y1')&V<F//S!AC&3P:Z%_AH?\ A&;#38=7:*ZL+M[J"Z^S*R[F
M8G!C8D'KZ_X5/#\/B(=>CNM7FN3K4"1S2-"JNKJ"-PQ@8Y^[@8QUHEJG?^MO
M^"5HGIW_ %,?4_'6H>$?"FA07QTQ=2O8LK*WFFWBC4#!8*"Y)!48'?-)#\4[
MJZ\$WNIVD%G/J%E<Q0.$$GDS!V W+NVL,\]>F.];<W@:\GTO2P^OR+K&E[A;
M:C':HN%(QM,><$8P.O:I;CP5<7GAM]-O=<NKNYEN8[F2ZG3<,JP;:J @(O'0
M=,]ZIM.3]?U_R(LU%6[&=J-SJ:ZUX6'B"STQ[N6_E\LV[2XA79D8)89;J#D$
M>@JCXM^)6I^'M6NEC71!:VLBQ_99;AGNYP<?,H3(0<]&YX]Q79:SX?\ [7U?
M1[[[3Y7]FSM-L\O=YF5QC.1C]:YF]^%SW/\ ;$$.O3P6&IR-,UN+9&(E)SDO
M]XJ"!\N1TZU*_K\/^"7I_7S'17;)\4M2NXX7E8:#'*L2_>8[R0H]^U5O"7Q"
MU77=8MX+M=%:&Y+ P6\[)<VI&>'23&[T^4>]='#X2*>()]4DOW)FTY;!EB0Q
MLN#G>K!L@^W;UK,M?A]=G5[*YU;Q#<:E;6$@EMHI+:-9 PX!>4?,_P"/6FK7
M2Z?\%D:V??\ X"+'Q1FU&#P'?R:8\,>%_?M(6#"/H=A'\6<=>,9K"T:ZU7PU
MI>D>&-#T_3/[7NX7NW9I93;1)G[QR2Y)XX'&?:NW\2Z+_P )%X=O=+\_[/\
M:DV>;LW;>0<XR,]/6LS6?!SZ@^GWFGZI+INJV$7DQ74<2N&4@ AD;@CCUI+2
M_P#7?];%O6W]=O\ @F)>?$'4[#PWKC7-G:)KFC21)+&I9X) Y&&7D'!!/&>.
M*Z[0)=9FLGEUZ.QBF=]T4=H7(6,@8#%NK=<X&*Y^7X=K-X<U*QFU26;4-3DC
MENK^2($NR$$ (" !Q@#/&:[-1M4#T%/2W]>7ZB_X)Y?IUQK\OBSQO'>2V3VD
M4&V10TA*#RV,8C!X''WL]^E'AKQ)KFA^&O"S2V%D=&NC%9Y$K&XW,<!\8VA>
MO')^E=.W@V=?$>K:E;ZLT=MJL'EW%J;=6RP38K!\Y&,YQ^M#>"=WAK0](^W_
M /(*N(9_-\G_ %OEDG&-W&<^IHCI:_\ =_6X/5OY_DK'*^(OB_)IFOWMK9_V
M:+>PD,;Q7'G>=<$=?+**47G(^8UZ5IM_%JFF6M]!GRKF)94SUPPS_6N8O? E
MV=4O)]'\17FE6NH2>;>6\,2DNW0E'ZQD]R,UU,ML_P#9SVUO,T<GE&-)7RY4
MXP&/.2>_7FDM(>8/66FQXSXBU:RO?$.K^)TU.V2]T>[AAL;<W"J\L<9_>X4G
M)#;CV[&O0/$7BV^M#X>.A6]K=C5Y-H$[%1M*;@0PZ=>>#3M'^'&@Z=H,6GW>
MGV-].J,LEW+:)YDA))+9.2.O'-1:;X"EL;7P]!+JQG&BSO(C&#!D5@0%^]QC
M/7GZ4UHN7T_X(/5W]?\ @%>R\8:U':^)[?5[2Q34M%@\]6MRYAD#(67AOF[<
M]/PJMI_C7Q)O\.W>J:=IJ:;K+)"OD2.94=AD,<\!3_=Y/O6[<^#_ +1>^([C
M[;M_MJV2WV^5GR=J%<YS\W7..*1_!V_2O#EE]MQ_8LT4N_RO]=L4KC&[Y<Y]
MZ%;KY?\ !"6VGG^2M^-R"U\5WDUMXKDDCME_L:21(,*<,%CW#?SSSZ8JGJ?C
M34K?PIHE_!_9%O<:C"LDD]_/Y<$1V@D!0=[9SQC..]2:A\/[BYU#5WL]?N+.
MQU8$W-HL"-N<KC(<\@>H&,^M%W\/I9(=!:RUE[2\TBW%NL_V9)!(F #\C$A3
MQUYQ26WW?D[_ (V&_P#/_@'-W_BN7Q?X"M+RXCA26'6X(&:#=Y<F&!W+NY .
M>AYKT#QC_P B7K7_ %XS?^@&L)/ASY>DSV U5W635%U+S)(<OD$$J<, <D=>
M.O2NIUG3_P"UM%O=/\SROM4#P^9MW;=P(SC(SUI2UBTOZT7ZA!VFF_ZU?Z'D
M/A^[FTOP!>>'5E)GU!;8V>>I6Z4!L?[I#U=\/>)8_ 7PV<H$DD.JS6L)F)VC
M!^\^T$X &>!FNNM_A[;0ZIX=OWNB\NBVOV?B+'GX7"MU^7!)..>M-'P[B/A]
M].?4)!.M^^H6]U%&%:&0MD<$G.,X]_:KD]6U_2NK?A<E+9?U>SO^-C*\._%9
M+W3=7DU#[)/-IMO]H\RQ$BQS+TP!( P(.!SZU5\-?%:ZUK6XM-E.E227JO\
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MA,6LBR,]U'*NUNJ"%\GCM[^]):V^7X@^O_;WX&]K.K0:'I4^H72R/#" 66,
ML<D#C)'K3-0UJWT^XM;;RY;BZNCB."$ OM[N<D *.Y)]N20*YSQM+JTG@?5Q
M?6=C;@(GEF&[>;)WKU!C3 _$TNG1W'A;Q )-9N!=C6-B?;C'M\J8#B+VC/\
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M!@5Z$.E95Z"I;.^K6W:WF^XT]6A:***YAA1110 4444 %%%% !1110 4444
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M8;.VM[46T%O%';@$")$ 0 ]1@<5%8:78:5&T>G65M:(YW,L$2Q@GU( %6Z*
M*M]IMEJD(AU"SM[N('(2>)9%SZX(J2"SMK7?]GMXH=^-WEH%W8&!G'7@8J:B
M@"!;&U2S-HEM"ML0081& F#U&WI4-IHVFV 06>GVEN$#!!% J;0WWL8'&<#-
M7:* *\.GVEMY?D6L$7E1^5'LC"[$Z[1CH.!Q4$&A:5:NSV^F64+,XD8QVZ*2
MXZ-P.OO5^B@"DVBZ8]TERVG69N(V+I*8%WJQZD'&03ZU9%O"LTDJQ1B60!7<
M*-S 9P">^,G\ZDHH J66DZ?IKRO86-K:M*=TAAA5"Y]3@<T^]L;34;<V]]:P
M7,#')CFC#J?P/%6** *D6E6$$3QPV-K'&\8B95A4!D&<*1CD#)X]S3TLXK>Q
M^R62K:1JA2/R$51%Z%1@KQ],>U6**=^H&"?##LMPIUJ^(N?]>#;VG[WC'S?N
M>>..>U.E\-S36IMI=<U![<KM,306A0CTQY.,5N45M]9J>7W+_(5D89\.3FX2
M<Z[J!F12BR>1:;E4XR ?)R!P./:E'AV<7#3C7=0$SJ$:3R+3<RCH"?)SCD\>
M];=%'UB?E]R_R"R.?/A0FR6S.KWIM5QB#[-:;!@Y'R^3CKS50^!A-?W-S=ZO
M<W#3.DB^9:VK%65< _-$1GZ ?CUKJZ*J.,K1O9K7R7^0<J,1O#L[3I.VNZ@9
MHU*I(8+3<H/4 ^3D X'Y5#/X3^U7,5S<:M>2SQ?ZN62VLV9/H3#D5T-%)8FH
MMK?<O\@Y48B^'9UN'N%UW41.ZA6D$-IN8#H"?)S@9/YU2NO!]S/;I9IKUVFG
ML29K?[+;#?SG@K& O/)X.:ZBBB.*J1=U;[E_D'*C$F\/7%S \,^O:C+$XVLC
MPVK*P]"##S1-X=N+B!H)]=U&2%AM:-X;0J1Z$&'%;=%)8B:[?<O\@L8-OX7>
MTM?LUMK-]#;X(\J.WM%3GKP(<5"_@N&2Q2RDU&X:TC.4@:TLS&OT7R,"NDHI
M_6JJ=[K[E_D'*C"D\,R2Q1Q2:U?O'$P>-&M[0A&'0@>3P1VID_A/[5<Q7-QJ
M]Y+/#_JY9+:S9D^A,.17044+%5%M;[E_D'*CG[OPG]O>-[S5[RX:([HS+;6;
ME#ZC,/%2GP[<-.DYUW43,BE4D,-IN4'&0#Y/ .!^5;=%'UFI:VGW+_(+(P3X
M7=H9(3K-\8I6+R(;>TVNQ.22/)Y.><UMPHT4*(TCRLJ@&1P-S'U. !D^P I]
M%9SJRG\7Y)?D%K!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH YC5_\ A./[4F_L3_A'/L'R^5]L\_S?
MNC.[;QUSC';%4_\ BY7_ %*/_DS79T4 <QI'_"<?VI#_ &W_ ,(Y]@^;S?L?
MG^;]TXV[N.N,Y[9J[XA_X27_ $?_ (1G^R/XO/\ [1\WVV[=G_ LY]JVJ* .
M,_XN5_U*/_DS1_Q<K_J4?_)FNSHH S->_MS["G_".?V=]K\P;_M^_P O9@YQ
MLYW9V^V,US__ !<K_J4?_)FNSHH XS_BY7_4H_\ DS707?\ ;G_"/+]C_L[^
MVO+CW>;O^S;^-^,?-M^]COTS6G10!QG_ !<K_J4?_)FC_BY7_4H_^3-=G10!
MF6G]N?\ "/-]L_L[^VO+DV^5O^S;^=F<_-M^[GOUQ7/_ /%RO^I1_P#)FNSH
MH XS_BY7_4H_^3-=!H/]N?87_P"$C_L[[7YAV?8-_E[,#&=_.[.[VQBM.B@#
MC/\ BY7_ %*/_DS1_P 7*_ZE'_R9KLZ* ,7P]_PDO^D?\)-_9'\/D?V=YOON
MW;_^ XQ[U2U?_A./[4F_L3_A'/L'R^5]L\_S?NC.[;QUSC';%=/10!QG_%RO
M^I1_\F:N:1_PG']J0_VW_P (Y]@^;S?L?G^;]TXV[N.N,Y[9KIZ* .?U[_A+
MOMR?\(Y_87V3RQO^W^=YF_)SC9QMQM]\YK,_XN5_U*/_ ),UV=% ')67_"P?
MMUO]N_X1;[)YB^?Y/VCS-F?FVYXW8SC/&:T_$/\ PDO^C_\ ",_V1_%Y_P#:
M/F^VW;L_X%G/M6U10!QG_%RO^I1_\F:/^+E?]2C_ .3-=G10!F:]_;GV%/\
MA'/[.^U^8-_V_?Y>S!SC9SNSM]L9KG_^+E?]2C_Y,UV=% '&?\7*_P"I1_\
M)FN@N_[<_P"$>7['_9W]M>7'N\W?]FW\;\8^;;]['?IFM.B@#C/^+E?]2C_Y
M,T?\7*_ZE'_R9KLZ* *6D?VG_9</]M_8_M_S>;]CW>5]XXV[N>F,Y[YKF?\
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M ,F:[.B@#,N_[<_X1Y?L?]G?VUY<>[S=_P!FW\;\8^;;]['?IFN?_P"+E?\
M4H_^3-=G10!QG_%RO^I1_P#)FN@M/[<_X1YOMG]G?VUY<FWRM_V;?SLSGYMO
MW<]^N*TZ* .,_P"+E?\ 4H_^3-'_ !<K_J4?_)FNSHH S-!_MS["_P#PD?\
M9WVOS#L^P;_+V8&,[^=V=WMC%8M[_P +!^W7'V'_ (1;[)YC>1YWVCS-F?EW
M8XW8QG'&:ZVB@#C/^+E?]2C_ .3-:>@_\)=]N?\ X2/^POLGEG9]@\[S-^1C
M._C;C=[YQ7044 <QJ_\ PG']J3?V)_PCGV#Y?*^V>?YOW1G=MXZYQCMBJ?\
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MN^W)_P (Y_87V3RQO^W^=YF_)SC9QMQM]\YKH** .,_XN5_U*/\ Y,U-9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2RI#$
MTDKJD: LS,<!0.I)KG)/B-X3BD9&UZR)4X.U]P_,<&N ^,>J:AJOB?2_"5C*
M8XKGRV<9P)'=]J[O88S^/L*V;;X$>'([:-;FZU"68*-[K(JACWP-IP/Q- '2
M?\+*\)?]!VT_,_X4?\+*\)?]!VT_,_X5@?\ "B_"_P#SUU+_ +_K_P#$T?\
M"B_"_P#SUU+_ +_K_P#$T ;_ /PLKPE_T';3\S_A1_PLKPE_T';3\S_A6!_P
MHOPO_P ]=2_[_K_\31_PHOPO_P ]=2_[_K_\30!O_P#"RO"7_0=M/S/^%'_"
MRO"7_0=M/S/^%8'_  HOPO\ \]=2_P"_Z_\ Q-'_  HOPO\ \]=2_P"_Z_\
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M_0=M/S/^%'_"RO"7_0=M/S/^%8'_  HOPO\ \]=2_P"_Z_\ Q-'_  HOPO\
M\]=2_P"_Z_\ Q- &_P#\+*\)?]!VT_,_X4?\+*\)?]!VT_,_X5@?\*+\+_\
M/74O^_Z__$T?\*+\+_\ /74O^_Z__$T ;_\ PLKPE_T';3\S_A1_PLKPE_T'
M;3\S_A6!_P *+\+_ //74O\ O^O_ ,31_P *+\+_ //74O\ O^O_ ,30!O\
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M'_"B_"__ #UU+_O^O_Q- &__ ,+*\)?]!VT_,_X4?\+*\)?]!VT_,_X5@?\
M"B_"_P#SUU+_ +_K_P#$T?\ "B_"_P#SUU+_ +_K_P#$T ;_ /PLKPE_T';3
M\S_A1_PLKPE_T';3\S_A6!_PHOPO_P ]=2_[_K_\31_PHOPO_P ]=2_[_K_\
M30!O_P#"RO"7_0=M/S/^%'_"RO"7_0=M/S/^%8'_  HOPO\ \]=2_P"_Z_\
MQ-'_  HOPO\ \]=2_P"_Z_\ Q- &_P#\+*\)?]!VT_,_X4?\+*\)?]!VT_,_
MX5@?\*+\+_\ /74O^_Z__$T?\*+\+_\ /74O^_Z__$T ;_\ PLKPE_T';3\S
M_A1_PLKPE_T';3\S_A6!_P *+\+_ //74O\ O^O_ ,31_P *+\+_ //74O\
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M_P ]=2_[_K_\30!O_P#"RO"7_0=M/S/^%'_"RO"7_0=M/S/^%8'_  HOPO\
M\]=2_P"_Z_\ Q-'_  HOPO\ \]=2_P"_Z_\ Q- &_P#\+*\)?]!VT_,_X4?\
M+*\)?]!VT_,_X5@?\*+\+_\ /74O^_Z__$T?\*+\+_\ /74O^_Z__$T ;_\
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MX4?\+*\)?]!VT_,_X5@?\*+\+_\ /74O^_Z__$T?\*+\+_\ /74O^_Z__$T
M;_\ PLKPE_T';3\S_A1_PLKPE_T';3\S_A6!_P *+\+_ //74O\ O^O_ ,31
M_P *+\+_ //74O\ O^O_ ,30!O\ _"RO"7_0=M/S/^%'_"RO"7_0=M/S/^%8
M'_"B_"__ #UU+_O^O_Q-'_"B_"__ #UU+_O^O_Q- &__ ,+*\)?]!VT_,_X4
M?\+*\)?]!VT_,_X5@?\ "B_"_P#SUU+_ +_K_P#$T?\ "B_"_P#SUU+_ +_K
M_P#$T ;_ /PLKPE_T';3\S_A6_8:C9ZK:K<Z?=0W4#<"2%PZY],CO7 ?\*+\
M+_\ /;4O^_R__$UQVC07GPQ^+=OHT-T\]A?R1QE3QO20[4)']Y6[^QZ T >\
MT444 %%%% !1110 4444 >+^-_\ DO6@?6V_]&-7M%>+^-_^2]:!];;_ -&-
M7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C,%4LQ  Y)/:N;M_B)X6NM5_LZ'6K9KDG:!\P1CZ!R
M-I//8TSXE?:?^%>ZQ]CSYGD_-CKLR-__ ([FEG_X18>#K$ZA]@_L8+%Y7F8\
MO/&W'X_US0AO8FUWQYX=\,WRV>L:A]GN&02!/(D?Y22 <JI'8TMAXZ\/:GI-
M[J=GJ'F6=D,W$GDR#9WZ%<G\ :Y76#K9^+A/AK^S/M!T==WV[?Y>SS#TV<YS
MBM+Q-_;O_"LM>_X2/^S?M/D/L^P>9LV8'7?SG.?TI/2#EZ_F%KR2]/R.T@FC
MN;>.>%MT<BAT;&,@C(JMIFL66L+<-83^:+:=K>7Y&7;(O4<@9Z]1Q2:'_P @
M'3_^O:/_ -!%<Q\-/^/?Q#_V&[G^8JVO>:[?YHB+O%/O_DS7\0>-=!\+W$4&
MM7_V:29=Z+Y,CY&<?PJ:LZ+XFTCQ%9O=:3?1W,4?W]H(9?JI (_$5A7_ /R5
M_2?^P9-_Z$*KRA!\6[G[&!M.C'[7LZ;]_P N[WQ^.*B^E_7\+_Y%VU]+?C;_
M #)_^%N^"Q_S&?\ R5F_^(K>C\2Z5+JUOIJW6+RX@%Q#&T;KYB=<@D8/TSGV
MKSWX>_\ "<?\(78?V-_PCGV#Y_+^U^?YOWVSG;QUSTK1^+.V6TTFWL4D?Q*T
MX-A]G;#KC[YS_=Q_3T-5)<K$M3MM.UW3]6N[RVL+CSI+*3RY]J-M1O3<1@GZ
M$XK,USQ_X<\.:@;'5M1^SW(4/L\B1^#T.54BJ7POFT^3P5;1V"-'+"Q2\20_
MO!/_ ![O<G],4_XI?\DXU?\ W$_]#6E)<HX>\[$]K\1?#%[IUU?V^I[[6T*+
M,_V>4;"YPO!7)R?2MC4M9L=(6V:^G\H74RV\/R,VZ1ONC@''U/%<E\3L_P#"
MK9MN-W^CXST^^E8?BO\ X2[S?#O_  D/]A?9/[7M]GV#SO,W9.,[^,8S^E4D
MF[>=OR)6U_)L[37/'_ASPYJ!L=6U'[/<A0^SR)'X/0Y52*(/'_ARYT*XUF'4
M=VGVT@CEF\B0;6.,#;MR>HZ"N9O_ /A(/^%L:E_PC?\ 9?G?V=#YO]H>9MV[
MC]W9SG/K4GC_ /MO_A5E_P#V]_9WVWSXL?8M_E[?,3'W^<]:F.J7]=;#ZV_K
M:YNZ7\2?"FLW\=E8ZO&]Q(<(CQ21[CZ LH&?:M/7_$NE>&+2.YUF[%M#(_EH
MVQGRV,XPH)[5P.H2:_J?B71]#\8OIEI;-,ES;36,+E9W3GR][M\I_#FG>+M9
MAO?B(EK-I&J:K9:7:NLD=A;>=B:5<?,,@#"_K0]E;S_#^K O,]$NM7L;/1WU
M6>X L4B\XS*"PV8SG !)K$TOXD^%-9OX[*QU>-[B0X1'BDCW'T!90,^U<7IF
MK27?P7UW3;E)HKK2XGMVCG39(J=4W+V../PK9A\.>*O$<&DQ:]/HD.FVKQ7*
M_8DE,S;<%5R_ SW(IV][RT_$5]//7\#>UGXB>&?#^I26&J:EY%U& 6C\B5L9
M&1RJD=*GM/&^@7VD_P!IVU_OL_M"VWF>3(/WAQA<%<]QSC%<BW_"1_\ "TO$
M?_"-?V3O\BV\[^T/,QC;QMV?CUJ[XTDU2'P+;R^(38BZCU&W:5K+?Y002C!^
M;GIUI1UM?K;\QRT;M_6ESLM0UBRTN6TBO9O*>\F$$ V,=[GD#@<=.IXKGKOX
MI^$+&\FM;G5]D\#M'(OV:8[6!P1D)CK5?QW(DNL>$$C969M51U .<J%.3]*?
MXX_Y&'PA_P!A/_V0T+IZV_+_ #$W:_I?\_\ (U[7QGH5[!I\UO?;X]1E:&U/
MDR#S''4<KQ^.*;KOC?P]X;N%@U?4XH)F (C"L[ =B0H) ^M8WCK_ )&KP;_V
M$&_]!IGP^\@WOBC[9Y?]I_VG+]HWXW^5QL]]N.G:A:W^?Z?YC>G]>O\ D=7_
M &[IG]D'5?M]N=/"[OM <;,?6J.@^-= \33/#H^I1W$J#)C*LC8]0& )'/45
MS?B6W\)WOP_FM+'4;:PTZ2Z"K/;QF2-9]V?F '0D<DX[<U4MKK4-.\=Z%%XJ
ML=,NKR97BL;_ $^5U95V\[X^A!SUQ@4UJ_Z[">B/3*RY_$FEVUY?6LUUMGL(
M/M-POEN=D?7=G&#]!DUJ5Y?KG_(W^-_^P"/_ $$U#=OQ_(J*N_N_%I'=)XIT
M>3PZVNI>JVF*I<SJC' !P?EQNSGMC-2WVO:9IFE+J5]>106;*&623C<",C Z
MDX[8S7B-P;CPE\/C;L7DTGQ!8))$<9\FZPI8?1@,_A[5W5P8O^$O\%?VCL^Q
M_8&\CS/N>?M7'7C..E6UJTOZWO\ D1>R3?\ 6W^>IUN@^+=$\3JYT;4(KDQ_
M>0 JX'KM8 X]\5L5C@Z$/%9_X]!KIM_;S?*S_*MBD4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B7Q
M _Y+KX>_ZZV?_HZO;:\2^('_ "77P]_UUL__ $=0![;1110 4444 %%%% !1
M110!XOXW_P"2]:!];;_T8U>T5XOXW_Y+UH'UMO\ T8U>T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3(>%4@C*Y/<BH+3QRNJ:3X?O;&YLD^WW26]PLT<WW]N62/ ^\#W;Y?>A7O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!FZ[>ZE86 ETC2O[4N"X4P?:5@PO.6W-QZ<>]<UX;\<:[XAOFC
M'A/R+6&Y:VN;C^THV\EE^]\NT%L>U=O7%?#3_CV\1?\ 8;N?YBA=?2_Y ]OZ
M\S4\/>,+/6M/CN+EH+&66XD@BADN 6D*,1\N<9SCH!5PZQ(/% TGR(?*-K]H
M\[[4F_.[&WROO8_VNG:O*&T73I/A#J^I/9PM?QWDA2X* R)B8#"MU Z\#UKJ
M+]!-\3I$99Y _AMP5@(\QLO_  Y(^;TIK:_]?#<JV_\ 75+]3M[36M,O[F2W
ML]1L[B>+_6113J[)]0#D5-=WEM86S7%[<0V\"8W2S.$5<G R3QUKQ?PFUE:>
M)M%M=*BAU">&4K(C:;)9W=HA'+2NIV/CH<YS^-=[\6<?\*WU/(R/W7 _ZZ+0
M]$F*.LN4Z>VU6PO;F6WM;ZUGGA_UD<4RLR?4 Y'XTVWUK3+N=8+;4;.:9PQ6
M..=69@IPQ !SP>#7F^F?V-?>/- _X1+3FM7L8Y/[3VVK0;%*859,@;FS]:D\
M+Z LGPXUB\TJUC&M7+7:I<*H$I^<C:&ZCIT]:3T5Q+6WR/1;?5].N[N2UMK^
MUFN8O]9#',K.GU4'(H_MC3MET_\ :%ILM#BX;SEQ"?\ ;Y^7\:\DL_[&OE\,
MV/A739+?Q!9W,+7C"T:.2% O[SS7(&<_4U)XQ:&^\6WNHV%G+<:)8M$FN^4V
M$N&5L@8_BV#K^5.VMOZ]?072_P#7IZGK-MJ=C>3&&UO+::5460I'*K,%;[K8
M!Z'L:?;7MM>^;]EN89_*<QR>4X;8XZJ<="/2N!\8ZFF@7NF>,M*7[1:S6K6;
M^4,AU9=T)_[Z&/QKJ?!NC-H7ABTMIN;IP9KEN[2N=S9_$X_"BV_]?UI^8=OZ
M_K4GT[6C>7&II<1V\$=C-Y8D6Z23<,9W,!_JS[-S5K3]6T_5HV?3;ZUO$0X9
MK>99 #Z$@FO-I;2*]TOQ[!<)?/$VI#=]BC#R# 4YVDC<!W'IFF?#BXM9/%SC
M2X[*]M_LA26_L[*6R"$'A7C^XS'KD#/7G%*.OW+\K_U_2'+3[_U/3[V_M--M
MS<7UU!;0 X,DT@11^)XI;>]MKRU6YM;B&:W89$L;AD(]<CBN)^*5O9R6VF7%
M^\\,=O.SB<V0N[9./^6T><X/0$ XKE;:.[U+X=^((M'L%:U-U'();".6%+R/
M(,GEQ.3MP!@A< ^E"UO_ %V!Z6/7++5;#4C(+"^M;HQ';(()E?8?0X/%<[:^
M-Y+O29KV+3X5,6IG3RDMZD8(#8WAF &?]GJ:YG27T75/'.AS>"++[/%:)*NI
M21VK0H%V@"-\@;FS]:S/^9+N?^QK_P#:HII:K^NJ1+>G]=F_T/6KW5].TZ6*
M.^O[6VDE.(UFF5"Y]@3S56^ULV6N65BT=OY%Q%)(\[W:(T809XC/+#U(X'>O
M/]5DT+3/&^OMXVL3<+>K$-.9[9IMZ!<%(R =K9^G/>M*6.WD\;^#8X[.>"V;
M3[E5MKKYG5-H&ULD]O4FDM;?UT8Y.W]>:.F\,^+].\4V]U+9RQC[/*T;(95+
M;0<!R > ><?2M2QU2PU,.=/O;:Z$;;7,$JOM/H<'@UX]9VJ2?#_Q5I6C6PCU
MF&[<W$45N5D,'F<+G'S#:&PN>GUJ3P7IHN=8NI]!UB2ZD2PEB<PZ*EE$KD?*
MCLI&7#8/W3TZT=+^7Z7'_G^IZ)XA\9V.BV3RVLEM?SQ7$4$L$=RH:/>VW+8R
M1]"*U-<U/^QM"OM1\KSOLL#S>7NV[MHSC.#C\J\2GD\/#P9I=G#IC1>(;2[A
M6\<VC*\;;^=\A&.>PS7K_CC_ )$;7/\ KRE_]!-*6D6_ZV01UFEZ?FR70O$M
MCK=E9NL]M%>7-LEP;,3JTB*P!Z<''/7%7H]4L)K*2\BO;9[6/=OF652B[?O9
M;.!CO7C>G?V->6?A"R\/::\/B"*:">XD6U:-Q%CYW=R &4]CDBM;6K6ZL_$>
MH>#[5'%MXANH[I'7I'&<FX'_ ([_ ./5<E[UEW?Z?AO]PEM=_P!?U^IZ?)J%
MI'IS7[7$/V01^;YV\;-N,YW=,>]<H?B392^"_P#A(+*W6?$ZPO:F=0\>Y]HW
M8!P<<XKJ;FQMY-*DLF@C>W,1C\EE!4KC&,=,5XQ;MI[_  3DM+>-8[V&]BCO
M@(C&X?SN-QP,G;CUQ26K^[\P=U&_K^1[3;ZC9W<\T%M=V\TT!Q+''(&:,_[0
M!R/QIL6K:?/?2645]:R7<8R\"S*9%^JYR*XBZT6UTGXC6*:):P6<L^DW(_=(
M$#."NTMCJ<]S7!>&-*+ZOI-JVIW$>M6]V'GM(M$030X;):2XRI9".Y)Z]#1'
M5I?UNU^@/1/^NESVWQ%J_P#8'A^]U/R?/^RQ&3RM^W=CMG!Q^5<N?'VM6$=O
M=Z[X2DL-,F=$-TFH1S;-YPI*  XYK6^(G_)/];_Z]6KRV>]T2:QLQH/B?7M:
MUF*2)X--N_,F@9P1D%60# &><\8I1UE;T&]OO/:[_5+#2XEEU&]MK2-CA6GE
M6,$^F214TEU!%;&YDGB2W5=QE9P%"^N>F*\V\02Z7IGC^XO_ !M9B739;*-+
M*26W:>&-_P"-< '#$\YQTK(E^T:7\-#]KTW.FSZN7MTNXY"MI;%LJSQJ02 0
M3M/'(SFCI?\ K>W_  1]?Z[7_P" >KP:WIES8R7MOJ5G+:1 F2=)U:-,=<L#
M@4L>LZ;,D[Q:A:.EL 9F6=2(@1D%N>./6O&M-1(;#QT(I(FBGTM)H?*LOLB.
MN&&Y8CR!GC/?KWKH?$OA^TTWX=Z*UEIZBQ2:UGU-((OFGB ^8O@9;DY.:=OT
M_'_(E/6WK^2_S.QA\6VUWXKMM(LQ%<P3V37:W<4X9>&V[0 ,'ZYK<GN(;6%Y
MKB5(HD&6>1@JJ/4D]*\P\-3Z%=_%F&X\-6BV]E)I3'<EL8$D;>.54@9],X[5
MM?$N'=_8ES>V\MSHMO=[]0BC0O\ +CY691U4'K2>B7G_ )L?5_UT.J_MS3&T
MN34H[^UDLHP2TZ3*4&/]K.*QO!'C%_&5I<W8T]+6WC<+$PNTE9^OWE7E#P.#
MZUR_A^WTW5_$6MWF@64:^&)M.$<BFV,<,\X).51@!P.O'6M[X46MO;_#W3)(
M8(HY)D+2LB &0[B,L1U./6FEN_3]?\A-ZI?UT_S&7/C;7)/$&IZ;HOA7^T5T
MYU22;^T4AR67</E9?Y$U;7QND_A:[U2VL@MU9R^3/9W=REN8WW $,[?*.#D'
MO7-6'C+0_"WCWQ:FM7OV9I[B$QCRG?<!&,_=4^O>L[7H9IO 'C#6)()H(-3O
M8I+=)E*N8U9%#%3TS1'6WHOT_P""4M96\_PU/49]<TRS8I>:C9V\@569);A%
M*AN >3T)X![U)<:MI]I=16MS?6L-Q-_JXI)E5W^@)R?PKBHM'L-5^+$[:A:0
MW(@TB%HUF0.%8N><'OQUKA?$^FD^*==BUK4'MKFZN";2%=%6[DN8\#;Y4AP5
M(&!@$?6EU7S_ #L2M4_E^5SW"_U2QTJ)9=1O;:TC8[0\\JQ@GTR2*R?$7C+3
M?#8T[[5-$WV^=8D/FJH53UD))^Z/7W%<3JJ6.B^*M/N?'$37>EC24@AGN;4R
M(LX/S;D&X!R/K]:B\4P:&GA;PW?Q:1-::3;:HN];R NR0$L6X)8A&./E^G%.
MVJ]?UL/_ "_2YZ==ZSIMA%%+>:A:6\<V/+>694#YZ8)//X5)<:C9VBQ-<W=O
M"LQVQF20*'.,X&3SP,\5YEJ$^@Z=XUU"]\6V8FTNZM8%TJ22T:6%4V\HJA3M
M;//;\*I1:-+-X=\(V.KVTBVLVMLT-M<#YE@(8HC ^W8]C0E?^O.WWB;M_7E?
M[CU*7Q!H\%E%>2ZK81VLQQ'.UR@1S[-G!Z=JO12I-&LD3J\;#*LIR"/8UYC\
M0[#1],U73)I@FG6]O T<9FTL75A@G.PHO*/GG(%='\,Y&?PA&/L*VD2S2"$)
MY@25,Y#JKDLH.3Q0M4V-Z-'74444@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\2^('_)=?#W_76S_P#1U>VUXE\0/^2Z^'O^NMG_ .CJ
M /;:*** "BBB@ HHHH **** /%_&_P#R7K0/K;?^C&KVBO%_&_\ R7K0/K;?
M^C&KVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LSQ#H-MXET2?2[UYD@GV[FA(###!A@D$=1Z5IT4 G8:BA$51T
M48&:=110 4444 86K^$[/7-7M+Z^N;YX[8JRV8GQ;NRDD,R8Y()]>U;M%%'D
M'F%%%% !1110 4444 %%%% !1110 4444 %85AX3L['Q#<:TUS?7=Y,&5/M4
M_F+;JQR5C&/E'YUNT4>8>04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5XE\0/^2Z^'O\ KK9_^CJ]MKQ+X@?\EU\/?]=;/_T=
M0![;1110 4444 %%%% !1110!XOXW_Y+UH'UMO\ T8U>T5XOXW_Y+UH'UMO_
M $8U>T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7B7Q _Y+KX>_ZZV?\ Z.KVVO$OB!_R77P]_P!=;/\ ]'4 >VT444 %
M%%% !1110 4444 >+^-_^2]:!];;_P!&-7M%>+^-_P#DO6@?6V_]&-7M% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XE\
M0/\ DNOA[_KK9_\ HZO;:\2^('_)=?#W_76S_P#1U 'MM%%% !1110 4444
M%%%% 'B_C?\ Y+UH'UMO_1C5[17B_C?_ )+UH'UMO_1C5[10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)?$#_DNOA[_K
MK9_^CJ]MKQ+X@?\ )=?#W_76S_\ 1U 'MM%%% !1110 4444 %%%% 'B_C?_
M )+UH'UMO_1C5[17B_C?_DO6@?6V_P#1C5[10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>)?$#_DNOA[_ *ZV?_HZO;:\
M2^('_)=?#W_76S_]'4 >VT444 %%%% !1110 4444 >+^-_^2]:!];;_ -&-
M7M%>+^-_^2]:!];;_P!&-7M% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5XE\0/^2Z^'O^NMG_ .CJ]MKQ+X@?\EU\/?\
M76S_ /1U 'MM%%% !1110 4444 %%%% 'B_C?_DO6@?6V_\ 1C5[17B_C?\
MY+UH'UMO_1C5[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>)?$#_ )+KX>_ZZV?_ *.KVVO$OB!_R77P]_UUL_\ T=0!
M[;1110 4444 %%%% !1110!XOXW_ .2]:!];;_T8U>T5XOXW_P"2]:!];;_T
M8U>T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7B7Q _Y+KX>_ZZV?_HZO;:\2^('_ "77P]_UUL__ $=0![;1110 4444
M %%%% !1110!XOXW_P"2]:!];;_T8U>T5XOXW_Y+UH'UMO\ T8U>T4 %%%%
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M#TNOZW.RO[^VTNPFO;V58K>!"\CGL!6)H_C:RU?4%LVL=4L)),_9VOK4PK<
M<_(3UXYP<'':G^.-&N=>\*7=E9,XN"4D0(^QF*L&P&[$XX/8UQ6@Z//?^(;$
ME/')%G.)9&UFZ40(0#RORGS.XXQP>HI1U>H2T5T=7J'Q!T^PO988].UB]A@<
MI/=VEFTD$)'WMS^W?&:MZQXRT[28;1DBO-0FO(_-@M[& RRR)Q\V.,#D=37
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M".]9WB?Q1K;>!+ZYBT6[T^_BD2*56G4"-3@[TD'#CD#CGGVI =[17'RZK/\
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MY7/6Z*YG2/%MS<ZQ)INM:--I$YA:X@,DZ2K+&I ))7A2,C(Y^M4T\>7;XO\
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M$%G%I1EL)+&WMHYQ,R;SEG9@ #T7 %=9=:;:WMS:7%Q%OEM',D#;B-C%2I.
M>>">M2W%S!9P-/=31PPI]Z21@JCZDTN@7U_KO<X::T\6ZYI\?A_4M)L[2T7R
MUGU%+L.)44@G9'C<"<=^E=!?Z)<7'B*SN87061(>[C(Y=H\F+'XMS_NK6REU
M!)<O;I/$T\:AGC#@LH.<$CJ <'\JEIW%8YS1_#DMLVIK>R!XI=UO:XZI;G+
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M7]O8Z);Z?<WES!(+.&[:4HJ.I.Z1VVEL9^[@?6O2Z*J^M_ZWN3;1+^NQQ?Q
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M2UJ[T^3[58?9?+LT9%@.[.%!^\.2<D@^U3)7O\_R'M;^NO\ D9&D>*M0\/>
M-"CNVTH7M\@2S>:<Q0I$$!WRLW<=P.I(Q6IHOC[,5_%K-QI%Q<6=JUV9M)N/
M.B>,=1@\JPXX/7-5_P#A!-3NO#.G6E^='EOM(8K9F2%I8)HMH4"56Y!/J.A
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M'8G!]:;TM;S_ #T_ %Y^7Y:_B2^*/&EQINH0:7I\FD6EZ\ N))=6NO*BB4G
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M;V8XD0@=0W..AZ=*.G]>5Q?U^#+GA3QA/J>J-I6IW.BW-V8C-'-I%R98F4$
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M%%%%(84444 %%%% !7B7Q _Y+KX>_P"NMG_Z.KVVO$OB!_R77P]_UUL__1U
M'MM%%% !1110 4444 %%%% 'B_C?_DO6@?6V_P#1C5[17B_C?_DO6@?6V_\
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MZUP\8.<$29('X@TO7^M&_P! :[?UJE^IVNIZG::/9-=W\OE0*RJ7VEN6(4<
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M"WAT69B%P=6C$9ESM!V/R<<U#::SK'AW7+ZPU_48]4A33WU".:.V$#(%;!3
M)!'H>M">FOG^"N-K56\OSL=O56#4;6YO[FRBEW7%J$,R;2-NX97G&#D#M7DU
MO\4WC>/4IO%-I/O*F31ETV15121D+,1DL!W/!-=)>:S+H^M^*KRS1)+AQ8Q0
M!_N[W!52<=@3FG9BN=I=ZG:6-S:07,NR6\D,4"[2=[8)QP.. >M6Z\[OK#Q!
M9>)/#/\ ;6JV^IQ/J#,KI;"!HF\I_EP"0R]>3SQWSQZ)1;0.H4444@"BBB@
MHHHH *\2^('_ "77P]_UUL__ $=7MM>)?$#_ )+KX>_ZZV?_ *.H ]MHHHH
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MWVIA6X Y.P]^.><&HM3^(6F:7?SV[V>J3PVS;;F[M[1G@MSW#-[>P--MO?\
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M. ", G<[!1U(XR:T*-_Z\O\ )AM_7]=CG[WPM]L\,Z?I'VO9]C:W;S?+SO\
M*(/3/&=OKQ[UR'B?4;/1O%5XL7B'5- ENV4S0C3_ #TO3M W0M@[6QA2?4#B
MO3Z*&VV"LE8YOX?:?/IG@JPM[E)4D^>3;-]\!G9AN]\$9K2UW18=>TTVLTLL
M+*ZRQ31'#Q2*<JP^E:5%.3N[@M#F-'\)WT&J0ZCKVNS:Q<VP9;8&W2".+<,$
M[5ZMCC)]:U- T;^P[*:W\_SO,N9;C=LVXWN6QC)Z9QFFZOXCT_1;JQM;N7_2
M;Z988(4P68DXW8S]T=S3=?\ $EKX>BB,T%W=3SDB&ULX3++)CDX4=@.I-*^G
MX!;6WS+]_8P:G83V5VGF6\Z&.1?4$8-<G_P@^LM']AE\8W\FCE?+-N;>/SBF
M,;3-U_'%=%HFNVNOV37%JLT;(WERP3QF.6%\9VLIZ'D5I46L%SG[WPP[:MI-
M]IE]]A_L^,V[1>2)%EA.W*<GY?NCD5F3> [Y9)K6P\2WEGHD[,TE@D",PW$E
M@DI^902>F/6M'6_&EGHM_P#8EL=3U&Z50\L>GVIF,2G."QX Z?6I+CQGI4/A
M^'5XWFN(+AO+AC@B+2R/S\@3KNX/!Z8HOI?^M0M;0JZGX-D::WNO#NJRZ+=P
M6ZVH=(5F1XEZ*R-P2.<'WI\?A&4'29+C5[F[GL+IKJ26X&XS,RE=H&0$49X
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M^[@<<9YZ8ZUE>#/]9X@_["\W\EI^B^";+1[];Z6]U/4[Q 5BGU&Y,S1 ]0O
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MQDA@NW&.^>N:\^TBYFU3P=X>TW4KUOL-UJ,]K<S13,!(B[RD8<G=M)  YR0
M*TH-&T[0/'<UCI4KB%-$F/V9IC)Y&77H6)(!ZXS0]/Q_*X+_ "_.QW]C-<7%
MC!+>6WV6X= TD'F!_+;NNX<''K5BO,-/M8-;LO"&B:I-(FF3:29C"DIC%S(
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M>/\ -(F-K=>VT<=.*LOIEH^JQZDT6;R.)H4DW'A"02,9QU [5;HH_K] ,_\
ML+3?(O86M(WBOI#+<I)EUD8@ D@Y[ =/2J>A>#-!\,S23:/IL=O+(,-)N9VQ
MZ L20/85N44; 9NB:2FCV]Q$@51-<R3[5)(&YL]3S[_4\<5%KWA31?$\<::S
M81W/E_<8EE9?HRD''MFM>B@#*_X1G2!I4.F)8QQV4,BRI%'E '5MP/!!)R,\
M]>]:M%%%P.=O? 'AG4=7;4[S2()KM^69BVUCZE,[2?<BIY/!^B2VFG6TECNB
MTQP]I^]?=$1R,-G)'3@G' K;HH6@$%[96^HV<MI>0I-;S+M>-QD,*PM-^'GA
MC1YH9M/TJ.&:"7S8Y1(Y<-C'WBV<8/3I[5TE%"TU HPZ-8V]E=6D4&V"Z>1Y
MDWL=Q?[YSG(SD]*PO$>D7MSIEKX:TK34&DS1K#/=-<8-O&I'RA3EF)48!S]:
MZNB@!D4:PQ)'& J(H50.P%8FL>!_#VOZC'?ZIID5Q<Q@ .69<@= P! ;\<UO
M44=;AY&.GA/1$T:721IT)T^5S(UN<E Q.3M!/R\],8QVK+NO"MEX<TJ27POH
M*S7RP-;11+<^7E';+$LYP<=<G)XQ7644/4%H<W:^#[&[\&Z;HNOVD-V+6!$8
M9/RL%P2K#!'U&*T-,\-Z1HVF/IVGZ?!#:2 B2,#/F9&#N)R6X]:U**;=VWW!
M:6\CGK#P'X<TMU>QTN*%UG%P&5VR'&<<YZ#)^7I[5J6>CV5A;W,%M#LBN9'E
ME7>QW,_WCR>,^U7:*0&;)X>TR70XM'>VS81!%2+S&X"$%><YX('>IX=+M+>>
M\FBAVR7I#3G<3O(7:._' QQBK=%#UW#8S!X=TQ='M]*%M_H-NR-%%YC?*4;<
MO.<G! ZFJNN^"M \2W"3ZOID5Q,G DW,C8]"5()'L:W:* ,_^P]. L EHB+I
M[;K54RJQ':5X X/!/6I/[*L_[4DU'R0;N2$6[2%CS&"3MQG'4GM5RBC<#.T7
M0=.\/6LEMI-L+>"20RE [,-QZXR3CIT'%4];\%Z!XCNH[G5M,BN)X\!9,LI(
M'8[2,CV.:W:* ,_^PM.$MA(MHB'3]WV4)E5BRNTX4<=/6KLJEHG4=2I I]%#
MU0+0XOPO\/\ 2[;3M*N]6TB#^V+:%59V.[# \' .TD<<\GWK:U_PAH?BCRCK
M.GQW+1?<?<R,!Z;E(./:MJBFW<#*N/#.CW.B#1Y=.MSIP&! %VJON,<@^XYJ
M/1?"6B>'K6:WTK3HH(YQB7DLSCT+,22.3QFMFBD!QEYX$L8[W1K.QTU#H\3W
M+7,32%E7S$QT8YY/IT]JW](\,Z1H.GO8Z980P6TF?,3!;?\ [Q.2?QK4HH P
M-(\"^'-"U![[3-*A@N6S^\RS;<_W020O7MBM.WTJSM([M((=JW<C2SC<3O9A
M@GD\=.U7** ,:Z\(Z)>Z'!H]UI\<MA;J%BC<L3& ,<-G<#[YS26G@_0[#1)]
M(M-/CBL;@%9HU9LR ^K9W'\ZVJ* *=QI-G=7%E/-#NEL6+6[;F&PE=IZ'G@]
M\T#2K(7EU=>0IFNT6.<L20ZKG (/'<]N]7** .?TKP)X;T34VU#3M)AANB20
MX+-MS_=!)"_@!6I;Z59VD=VD$.U;N1I9QN)WLPP3R>.G:KE% &++X0T2>UTV
MVDL08M,8-:?O'!B(Z8;.3T'4GI6I=VL%]:2VMU&LL$R%)$;HRGJ*FHH>NX;&
M1IOA;2=):S:QM3&;.)X8"97;8C'+#DG/([U931=/2:_E^S(S:AC[4')82X7:
M,@\=..*O44/4%H8&C^!O#N@7[WNEZ7%!<OG]YN9MN>NW<2%_#%:=AI5GID<\
M=G#Y:3S//("Q;<['+'DGKZ=*N44 <[:> /#-CK']J6NCV\=YG<&!;:I]0F=H
M/N!4NM^"] \1W4=SJVF17$\> LF64D#L=I&1['-;M% %"31-/D@LX#:HL5E(
MLMNB918V4$# &/4\=*?;Z39VFI7>H00[;J\"">3<QW[1A>"<# ]*N44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5XE\0/^2Z^'O^NMG_ .CJ]MKQ+X@?\EU\/?\ 76S_ /1U 'MM%%% !111
M0 4444 %%%% 'B_C?_DO6@?6V_\ 1C5[17B_C?\ Y+UH'UMO_1C5[10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/[, <)^)X[XJ6'XC,?#^N7EUI#VVH:,0+BR:<,.>F) ,<_2AZ*X;G;45Y_\
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M:1@0<,G.WD=<]Q]:P/"GAC3&U33(QX"U&UOK5E:ZO;FYECBC=>=T?S$29(Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+X@?\ )=?#W_76
MS_\ 1U>VUXE\0/\ DNOA[_KK9_\ HZ@#VVBBB@ HHHH **** "BBB@#Q?QO_
M ,EZT#ZVW_HQJ]HKQ?QO_P EZT#ZVW_HQJ]HH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O$OB!_R77P]_UUL__1U>VUXE
M\0/^2Z^'O^NMG_Z.H ]MHHHH **** "BBB@ HJ"\O;?3[<SW<RQ1 @;F/<\
M?6JD?B'3);N*VBNT>28 H5!*'(R!N V@D=B<T >4^-_^2]:!];;_ -&-7M%>
M+^-_^2]:!];;_P!&-7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5XE\0/^2Z^'O^NMG_ .CJ]MKQ+X@?\EU\/?\ 76S_
M /1U 'MM%%% !1110 4444 4=6L9;ZWC^RS)#<PR"6)Y(]Z!AD?,N02,$]"*
MR;;PU=VY$+7L+VSW0O)L0;':0$,0N#@*6 /.3C(R>M:^JZ7#J]D;:<NJ[E<,
MC8((.?Q'M5?^QM,LI8IH[$[Q(H4H&;:?4\]/>A:,'J>6>-_^2]:!];;_ -&-
M7M%>+^-_^2]:!];;_P!&-7M% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5XE\0/^2Z^'O^NMG_ .CJ]MKQ+X@?\EU\/?\
M76S_ /1U 'MM%%% !1110 4444 4M5EOH;(OIL,4TX9<I(2!MSSCW YJ.$:Q
MYR><]AY6?FV*^['MDU-J-_\ 8(4987GEED$<42$ LQ]SP!@$_A6=+J5_') -
M2L3:0O.B"6WN1)R3A0X*@X)('&>OXT(&>9^-_P#DO6@?6V_]&-7M%>+^-_\
MDO6@?6V_]&-7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5XE\0/^2Z^'O^NMG_Z.KVVO$OB!_P EU\/?]=;/_P!'4 >V
MT444 %%%% !1110!7OK&#4;8P7*ED)!!5BK*1T(8$$'W%9_]A0V]Q!/F]O7C
M<;5GNV98_P#;VDX)'XGTJUJ]I)>6#)%>26;JP?S4.. >0?8CBJZV%M:20RR:
MI=X9P$$MU\KD]!@]<^E"!GEOC?\ Y+UH'UMO_1C5[17B_C?_ )+UH'UMO_1C
M5[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>)?$#_DNOA[_KK9_^CJ]MKQ+X@?\ )=?#W_76S_\ 1U 'MM%%% !1110
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M7BWC5@_QX\/LI!4_9B".A^<U[30 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KQ+X@?\EU\/?]=;/_ -'5[;7B7Q _Y+KX>_ZZV?\ Z.H ]MHH
MHH **** "BBB@!",C!Z4R*WAA),44:$]2J@9J2B@#Q?QO_R7K0/K;?\ HQJ]
MHKQ?QO\ \EZT#ZVW_HQJ]HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *.H ]MHHHH **** "BBB@ HHHH \7\;_P#)>M ^MM_Z,:O:*\7\;_\ )>M
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M'SN6[C'0<5VM%.^MQ6TL8GC'1KCQ#X3O],M'B2>YC"HTI(4'(/) )[>E<O\
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M<E_$^O:KI_V2!"@@LH3FX/0-(SC*GV7BNHHIIV_KY ]0HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5XE\0/\ DNOA[_KK9_\ HZO;
M:\2^('_)=?#W_76S_P#1U 'MM%%% !1110 4444 %%%% 'B_C?\ Y+UH'UMO
M_1C5[17BOCV1;?XZZ!)*=B9M?F/ QYA&?I7M5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
